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ABSTRACT 
 
The potential use of the macrolide antimicrobial tilmicosin in the horse was 
assessed by initially reviewing bacterial isolates from equine infections.  This 
demonstrated that respiratory disease due to Gram positive organisms was the most 
common bacterial infection documented at WCVM.  Furthermore, 45% of Streptococcus 
zooepidemicus isolates were resistant to the commonly used potentiated sulphonamides.   
 It was necessary to first develop and validate a robust HPLC analytical technique 
to detect tilmicosin in a variety of equine tissues.  The methodology was fully validated 
in plasma and lung with LODs of 13 ng/mL and 181 ng/g respectively. 
In a preliminary trial, we administered tilmicosin to recently weaned foals at a 
dose of 4 mg/kg PO sid or 10 mg/kg SC q 72 hrs.  The oral dose did not result in 
detectable tissue concentrations of tilmicosin.  The pharmacokinetics of the injectable 
dose were similar to previous reports in other species.  The injectable preparation 
resulted in severe swelling at the site of injection associated with edema and tissue 
necrosis.  Otherwise, tilmicosin was well tolerated by the foals and no foals developed 
severe colitis.  However, a semi-quantitative fecal bacteriological technique 
demonstrated marked changes in the normal fecal flora, with profound overgrowth of the 
Enterbacteriacae and almost complete removal of the normal β-hemolytic streptococci 
population.  No known pathogens were isolated from the feces. 
 In a subsequent study, we investigated the administration of higher doses of oral 
tilmicosin to unweaned foals to simulate treatment of R. equi.  A dose of 40 mg/kg PO 
sid resulted in detectable plasma concentrations of tilmicosin.  Foals were treated at this 
dose regimen for 2 weeks and sequentially euthanized.    Tissue analysis demonstrated 
  iii
concentrations of tilmicosin in tissues similar to those seen with the 10 mg/kg sc dose 
with a Cmax of 4 µg/g in lung and a MRT which was shorter at 8.8 hrs.  The MIC50 of R. 
equi to tilmicosin was 4 µg/g.  Based on pharmacodynamic studies it appears that oral 
tilmicosin has the potential to be of use in the treatment of R. equi pneumonia in foals.   
No adverse clinical effects were noted in the foals; however, the fecal flora was again 
changed by tilmicosin administration.   
The fecal flora of the unweaned foals was different from that of the older animals 
with almost no β-haemolytic streptococci and a predominantly Gram negative flora.  
Disruption of the fecal flora did result in overgrowth of Cl. perfringens which was not 
associated with disease. 
In a final study, we compared the effects of tilmicosin and ceftiofur on the fecal 
flora of adult horses.  The fecal flora of the horses receiving tilmicosin was severely 
disrupted in the same manner as the weaned foals with the added effect of overgrowth of 
Cl. perfringens.   Ceftiofur which is widely regarded as being associated with 
antimicrobial associated diarrhea had very little effect on the fecal flora. 
It is concluded that oral tilmicosin shows potential for the treatment of R. equi 
pneumonia in young foals.  However, care should be taken due to possibility of 
developing colitis. The drug’s use should be avoided in older horses due to the very real 
risk of developing acute bacterial colitis.  The injectable preparation should not be used 
in horses due to the severity of the reaction at the injection site. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1.  Introduction 
The initial idea for this PhD thesis was based upon three clinical observations: 
Firstly, the impression that oral trimethoprim potentiated sulphonamide (TMS) 
antimicrobials are commonly prescribed to treat a wide variety of equine bacterial 
infections.  The decision to use this medication is commonly made based upon the ease 
of administration rather than a particular belief that either the spectrum of activity, 
pharmacokinetics, or pharmacodynamic are particularly suited to the case.  Secondly, 
Streptococcus equi subsp. zooepidemicus (S. zooepidemicus) is commonly isolated from 
infections affecting many equine body systems and that a high proportion of these 
isolates are reported resistant to TMS by our bacteriology laboratory.  Finally, the horse 
meat export industry is relatively large in Canada.  In 2005 48,715 horses were 
slaughtered; 11.7 million kilograms of meat were produced most of which was exported.  
The export industry is valued at approximately $60 million dollars per year.  Most of 
this product is exported to either Europe or Japan (Wiecek 2006).  Currently, there are 
no pharmaceuticals licensed for use in the horse as a food animal in Canada.  The nature 
of the equine feedlot industry is not dissimilar from the bovine feedlot industry and 
respiratory disease in groups of recently mixed horses is extremely common.  These 
disease outbreaks are typically treated with a variety of injectable antimicrobials 
2 
(Dowling-unpublished data).  The use of these antimicrobials is extra-label since the 
animals are destined for human consumption and no withdrawal intervals exist as the 
depletion of tissue residues has not been studied in the horse.  Estimation of appropriate 
withdrawal intervals is complicated by the lack of maximum residue limits (MRLs) set 
by Health Canada. 
We hypothesized that a macrolide antimicrobial may have potential as an oral 
antimicrobial for use against equine infections caused by Gram positive organisms.  
Macrolides typically have a high oral bioavailability, high volume of distribution, 
partition well into pulmonary tissue (making them particularly effective for the 
treatment of respiratory disease) and have a good safety profile in most species.  Their 
use has generally been avoided in the horse because of unsubstantiated reports that 
describe a possible association with severe diarrhea (Prescott 2000). 
Of the several macrolides available, tilmicosin was chosen in particular for a 
number of reasons.  Firstly, tilmicosin is a veterinary product with no potential of being 
used in the human field.  Many of the other macrolide antimicrobials that have been 
investigated for use in horses are human products.  Consequently, treatment is extremely 
expensive.  Additionally, there are increasing concerns about using human products in 
the veterinary field due to concerns about the development of antimicrobial resistance 
and the possible transfer of resistance to human pathogens.   
Secondly, tilmicosin is already licensed for use in several food producing species 
and is available in both an injectable and oral (feed additive) formulation so it has 
potential for use in the horse as a food producing species.  Although the use of injectable 
tilmicosin is discouraged in horses due to concerns about diarrhea and cardiac toxicity 
3 
(Prescott 2000)(U.S. Product label), there is little evidence to support this view.  Pigs are 
also very susceptible to cardiac toxicity following injectable tilmicosin (Jordan, Byrd et 
al. 1993) but tolerate the oral formulation very well.   
We hypothesized that the use of the medicated feed mix in horses would be free of 
the adverse reactions seen with the injectable formulation. Finally, there is one report of 
the use of a compounded tilmicosin product to successfully treat refractory Rhodococcus 
equi pneumonia in two foals (Fenger 2000).  In our initial plan for investigating 
tilmicosin use in horses, we did not focus on R equi as the disease is extremely rare in 
our geographical area (typically one or two cases per year diagnosed at the WCVM). 
 
1.2.  Literature review 
The goals of this literature review are four fold: 
1. To review the basic chemistry and  pharmacology, pharmacokinetics and 
pharmacodynamics of the macrolide class of antimicrobials with particular 
reference to tilmicosin; 
2. To specifically review what is known about the use of macrolide antimicrobials 
in horses; 
3. To review the toxicology of macrolide antimicrobials with particular reference to 
the syndrome of antimicrobial associated diarrhea (AAD) and the known cardiac 
toxicity of tilmicosin; and 
4. To review what is published on analytical techniques for tilmicosin in animal 
tissue matrices. 
 
4 
1.2.1.  Basic Macrolide Chemistry and Pharmacology 
The chemistry and basic pharmacology of the macrolide antimicrobials has been 
extensively reviewed (Prescott 2000; Chambers 2001; Papich and Riviere 2001).  The 
macrolide antibiotics are a group of chemically related compounds.  The original 
member of the group, erythromycin was isolated from the soil borne bacteria 
Streptomyces erythreus in 1952 by McGuire and co-workers.  The other members of the 
group were derived from related bacteria (e.g. tylosin) or by chemical modification of 
the original compounds (e.g. tilmicosin, azithromycin, tulathromycin and 
clarithromycin).  The basic chemical structure of the group is highly complex.  It is 
classed as being a macrocyclic lactone, with between 12 and 20 carbon atoms in the 
lactone ring structure depending on the compound (Figures 1.1, 1.2).  The group 
consists of erythromycin, tylosin, tilmicosin, roxithromycin, dirithromycin, 
azithromycin, clarithromycin, spiramycin, tulathromycin, oleandomycin, carbomycin 
and flurithromycin.  The group of drugs may be further subdivided into tylonides such 
as tylosin, tilmicosin; azalides such as azithromycin and triamilides such as 
tulathromycin.  Erythromycin, clarithromycin and azithromycin are licensed for human 
use and are the focus of most research publications for this class of drugs 
This group of antibiotics is closely associated in activity to the lincosamides and 
to chloramphenicol and related compounds.  However the chemical morphology of these 
other compounds differs greatly. 
1.2.1.1.  Drug characteristics 
Macrolides are all weak bases with pKa’s ranging from 6-9.  Some of the drugs are 
poorly absorbed from the gastrointestinal tract (most notably erythromycin which is also 
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very unstable in gastric acid).  A number of different formulations of erythromycin have 
been developed in order to overcome this problem.  These include the estolate and 
ethylsuccinate esters which are absorbed before being hydrolyzed to release the active 
erythromycin base, but these esters are highly susceptible to degradation by stomach  
acid.  An alternative is the formation of a stearate or phosphate salt which dissociates in 
the intestines releasing the free drug which is then absorbed.  These formulations are 
also highly susceptible to degradation by stomach acid and it is necessary to provide an 
enteric coating to protect the drug from the gastric acid until it enters the intestines.  The 
estolate is reported as being preferred for oral administration  (Chambers 2001).  
Various formulations are also available for IM and IV administration.  The glucoptate 
and lactobionate forms are used for IV administration as they are soluble in an aqueous 
solution. 
Clarithromycin is more rapidly absorbed in the upper intestines and is stable in 
stomach acid.  Unfortunately, it has a very high first pass metabolism by the liver and 
bioavailability is in the region of 50%.  Azithromycin is also rapidly absorbed and has a 
much higher bioavailability. 
1.2.1.2.  Mechanism of action 
Macrolides exert their action by reversibly binding to a specific site on the 
prokaryote 50S ribosomal subunit.  This binding site is closely related (but not identical) 
to the binding site of chloramphenicol and is thought to be the same binding site as that 
of the lincosamides.  Concurrent use of antibiotics from these different groups may 
result in an overall decrease in activity as the drugs act as antagonists at the other sites.  
The presence of the macrolides on the ribosome prevents the translocation of the tRNA 
8 
disrupting protein synthesis.  The drugs are selective for the prokaryotic 50S ribosome 
and do not bind to the mammalian ribosome.  Macrolides are capable of binding 
mitochondrial ribosomes but in contrast to chloramphenicol they cannot enter the 
mitochondria, and consequently, are free of many of the adverse reactions associated 
with chloramphenicol. 
The drugs are generally regarded as being bacteriostatic.  However, in some 
circumstances they may be bactericidal especially against streptococci.  The bactericidal 
action is time dependant and is more pronounced in an alkali environment with optimum 
activity seen at pH 8 (Chambers 2001). 
1.2.1.3.  Mechanisms of resistance 
Resistance to the macrolides occurs by several different mechanisms and has been 
well reviewed (Chambers 2001).  These mechanisms are generally regarded as being 
plasmid mediated although they may also occur as a result of one step chromosomal 
mutations.  Such mutations may result in high levels of resistance but are typically 
unstable. 
i. The first mechanism involves a decrease in the intracellular accumulation of the 
drug.  This is achieved by decreasing the permeability of the bacterial cell wall to the 
drug.  This mechanism is described for Staphylococcus epidermidis.  This mechanism is 
also the explanation of the inherent resistance of Gram negative organisms to many of 
the macrolide antibiotics.  Gram positive organisms typically accumulate 100 times 
more erythromycin than Gram negative organisms.  Acquired efflux mechanisms are the 
products of the genes mrsA and mefA seen in staphylococci and mefE in streptococci. 
9 
ii. The second mechanism of resistance is associated with alteration of the 
ribosomal binding site to reduce the affinity of the antimicrobial.  This is achieved by 
methylation of the binding site on the 50S ribosome.  This greatly reduces the affinity of 
the site for the drug and results in cross resistance for other macrolides and 
lincosamides.  This mechanism of resistance is seen in both Gram positive and negative 
organisms.  This mechanism is mediated by the genes ermA, ermB and ermC.  Such 
resistance also confers resistance to the lincosamide antimicrobials.  A chromosomal 
modification of the 50S ribosomal protein is described in Bacillus subtilis and 
Campylobacter spp. 
ii. The final mechanism of resistance is described in Enterobacteriaceae 
and involves the production of an esterase which hydrolyses the drug, thereby 
inactivating it. 
Most mechanisms of resistance will confer a degree of cross-resistance to other 
macrolides and related antimicrobials.  However, the 16 membered ring structures (such 
as tilmicosin) are commonly unaffected by these acquired resistance mechanisms 
(Giguere 2006). 
1.2.1.4.  Pharmacokinetic properties 
A large number of studies have been conducted on the pharmacokinetics of 
macrolide antimicrobials in numerous species.  The section below gives an overview of 
comparative pharmacokinetics between the drugs.  The pharmacokinetics of the 
individual drugs in the horse are also discussed in the next section. 
The oral absorption of the drug (especially for erythromycin) is dependant on its 
being protected during passage through the stomach.  The kinetics of absorption are also 
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highly dependant on the presence of food within the upper intestines (it should be noted 
that crushing tablets to aid administration is contra-indicated as this removes the enteric 
coating and allows the drug to become degraded in the stomach).  Tylosin, azithromycin 
and clarithromycin are well absorbed from the gastrointestinal tract and do not require 
enteric coating.  Tylosin is formulated as both a phosphate and tartrate.  Differences are 
observed in the absorption kinetics of these two preparations with the tatrate being more 
readily absorbed (Prescott 2000).   To our knowledge the oral bioavailability of 
tilmicosin has never been determined.  Azithromycin has a very high bioavailability in 
dogs (97%) (Papich and Riviere 2001). 
All macrolide drugs have a high volume of distribution.  They typically reach high 
concentrations in tissues which are traditionally regarded as difficult to treat such as the 
prostate and middle ear. The basic nature of the drugs also results in accumulation in 
certain types of cell.  Azithromycin accumulates in fibroblasts resulting in an extremely 
prolonged elimination half-life.  The extremely high concentrations of drug found in 
certain tissues and their extreme persistence contrasted with the low plasma 
concentrations and short plasma elimination half-life would lead one to question the 
validity of any discussion of plasma kinetics.  Erythromycin, tylosin, azithromycin, 
tulathromycin and tilmicosin all accumulate in lung tissue and phagocytes at 
concentrations many times those seen in plasma.  Tilmicosin, and tulathromycin in 
particular, persist in lung tissue for at least 72 hours following a single dose in cattle 
(Papich and Riviere 2001).   
The macrolide drugs are mainly excreted by the liver with a small proportion of 
the drug excreted unchanged in urine.  For erythromycin, much of the drug is excreted 
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unchanged in the bile where concentrations may reach 250 µg/mL (Chambers 2001).  
Clarithromycin is metabolized by the liver to several metabolites, the most significant of 
which is the 14-hydroxy metabolite, which maintains the activity of the parent 
compound.  A significant amount of clarithromycin and its metabolites are excreted in 
urine.  Azithromycin undergoes some hepatic metabolism and the parent drug and 
metabolites are mainly excreted in the bile.  Enterohepatic circulation does not appear to 
be a significant factor with any of the macrolides. 
1.2.1.5.  Drug interactions 
Drug interactions have been most widely studied for erythromycin. It is known 
that phenobarbital will induce the cytochrome p450 enzyme responsible for the 
degradation of erythromycin (CYP3A4) and consequently increase the clearance of the 
drug potentially resulting in therapeutic failure.  However, erythromycin is also a potent 
inhibitor of this enzyme.  Inhibition of this enzyme may interfere with the elimination of 
other drugs with a low therapeutic index, including theophylline, cyclosporine, digoxin 
and warfarin.  Clarithromycin appears to have similar interactions to erythromycin while 
azithromycin is free of many of these problems.  There is no information available on 
drug interactions with tilmicosin (Papich and Riviere 2001; Giguere 2006). 
1.2.1.6.  Adverse effects 
The main adverse effect reported following macrolides use in animals is 
gastrointestinal disturbance.  In humans, use of the estolate ester of erythromycin is also 
associated with a reversible cholestatic hepatitis which is only seen during long term 
therapy and may be very severe.  Diarrhea and vomiting are much more common and 
may occur for two main reasons: 
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i. Macrolides may seriously disrupt normal intestinal flora resulting in the potential 
overgrowth of pathogenic bacteria and development of clinical gastrointestinal disease 
(Job and Jacobs 1997). 
ii. Erythromycin appears to also have a separate prokinetic effect on the 
gastrointestinal tract.  This effect appears to be specific for erythromycin and involves 
the increased activation of motolin receptors (Peeters, Matthijs et al. 1989). 
1.2.1.7.  Clinical uses and pharmacokinetics 
Erythromycin is generally used for the treatment of infections caused by Gram 
positive organisms, especially; Staphylococcus spp., Streptococcus spp., 
Corynebacterium spp., Clostridium spp., Listeria spp., Bacillus spp., Erysipelothrix 
spp., some Gram negative organisms Haemophilus spp., Brucella spp., Fusobacterium 
spp., Pasteurella spp., Borrelia spp., Campylobacter spp. and also for Mycoplasma spp..  
In human medicine, it is largely seen as an alternative to penicillin for individuals with a 
penicillin allergy; it is also widely used for the treatment of respiratory infections 
(Papich and Riviere 2001).  It’s main veterinary uses are in the treatment of pyoderma, 
respiratory disease and diarrhea due to Campylobacter spp. It has been used in a great 
variety of species including cattle, swine, poultry, and dogs.  Until recently, it was the 
treatment of choice in combination with rifampicin for the treatment of R. equi 
pneumonia in horses (Lakritz and Wilson 2002).  Its use has also been recommended for 
other refractory infections in horses including Potomac Horse Fever (Palmer and 
Benson 1992) and Lawsonia intercellularis (Lavoie, Drolet et al. 2000).  The MICs of 
macrolide antimicrobials against a variety of veterinary pathogens are shown in Table 
1.1. 
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         Tylosin (Tylan, Elanco Animal Health, Guelph, ON) has been used in the 
treatment of “pinkeye” (Moraxella bovis), respiratory disease in swine, cattle and 
poultry and intestinal disease in dogs, swine, poultry and cats.  It can be used to reduce  
the incidence of liver abscesses in feedlot cattle and has also been used as a 
growth promoter in swine, cattle and poultry (Prescott 2000).  
Clarithromycin (Biaxin, Abbott Laboratories, Chicago, IL) is a new semi-synthetic 
derivative of erythromycin.  It is tolerated better in humans, has a wider spectrum of 
activity and a longer half-life.  Its use has not been widely reported in veterinary 
medicine (Papich and Riviere 2001) .  
Azithromycin (Zithromax, Pfizer Inc., St. Louis, MO) is also derived from 
erythromycin but is classified as an azalide.  It has many advantages over erythromycin 
including better oral absorption, longer half life (especially in tissues) and a broader 
spectrum of activity.  It is more active against organisms such as Haemophilus spp., but 
has reduced activity against Staphylococcus spp..  The major advantage of azithromycin 
is the dramatic accumulation and the prolonged half life in tissues.  Azithromycin 
accumulates especially in leukocytes.  Veterinary uses for azithromycin are similar to 
erythromycin, and it has been used in dogs, cats, birds and horses (Papich and Riviere 
2001).  More recently the pharmacokinetics of azithromycin and clarithromycin have 
been described in foals (Jacks, Giguere et al. 2001; Jacks, Giguere et al. 2002). 
Tulathromycin (Draxxin, Pfizer Animal Health, Kirkland, QC) is a new macrolide 
antimicrobial belonging to the new triamilide class.  It was developed by Pfizer and is 
marketed under the name Draxxin for the treatment of Bovine Respiratory Disease 
(BRD).  Tulathromycin is a semi-synthetic derivative of erythromycin with three polar 
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amine groups.  Tulathromycin is thought to have enhanced penetration of Gram negative 
bacteria, and enhanced penetration and accumulation in pulmonary tissue.  This 
increases the spectrum of action and the pharmacokinetics are ideal for an antimicrobial 
for use in treating pneumonia. 
Draxxin is formulated as 100 mg/mL aqueous solution for use at a dose 2.5 mg/kg 
SC in cattle and IM in swine.  Similar to tilmicosin, tulathromycin accumulates at high 
concentrations in lung tissue (Cmax 4.1 µg/g vs. 0.5 µg/mL plasma) with a greatly 
prolonged tissue half-life (184 hours lung vs. 90 hours plasma) (Evans 2005).  This drug 
has now been shown to be highly effective in the treatment of respiratory disease in both 
swine (Nanjiani, McKelvie et al. 2005) and feedlot cattle (Rooney, Nutsch et al. 2005). 
Tilmicosin (20-deoxo-20-(3,5-dimethyl-piperidin-1-yl) desmycosin) is a chemical 
modification of the naturally occurring macrolide tylosin (Ose 1987).  It is chemically 
closely related to erythromycin.  The spectrum of activity is mainly Gram positive 
aerobes, but includes the Gram negative respiratory pathogens Pasteurella spp., 
Mannheimia spp. and Histophilus spp..  The spectrum also includes some Mycoplasma 
spp.  The MIC breakpoint for Mannheimia haemolytica and Pasteurella multocida is set 
at <8 µg/mL (NCCLS 1999)  In one study, the MIC90 of M. haemolytica and P. 
multocida isolates was less than 6.2 µg/mL (Ose and Tonkinson 1988).  In another 
study, the MIC95 of 155 M. haemolytica isolates was 3.12 µg/mL (Ose 1987).  However, 
in vitro susceptibility is not always a good predictor of clinical efficacy for tilmicosin  
(Musser, Mechor et al. 1996) with bacterial strains reported as resistant in the laboratory 
responding well in the field.  Tilmicosin is considered bacteriostatic at concentrations 
equivalent to the MIC, concentrations four times the MIC are considered bactericidal 
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(Ose 1987).  At concentrations as low as ¼ the MIC there is still a decrease in bacterial 
growth.  The post-antibiotic effect (PAE) of tilmicosin may be up to 8 hours when 
concentrations exceed the MIC (Diarra, Malouin et al. 1999; Lim and Yun 2001). 
Tilmicosin is currently available in a 300 mg/mL solution in 25% propylene 
glycol / water pH buffered to 7.0 with phosphoric acid (Micotil, Provel, Eli Lily Canada 
Inc. Guelph On). The product is licensed for the treatment of respiratory disease in cattle 
and sheep at a single dose of 10 mg/kg SC and is one of the most widely used 
medications for the treatment and control of feedlot pneumonia in cattle.  Tilmicosin is 
also available as a feed premix containing 20% tilmicosin (Pulmotil- Elanco Animal 
Health Guelph, ON).  The product is licensed for use in growing swine at a dose of 200 
ppm in feed.  
 An alternative injectable formulation of microcrystallized tilmicosin as a fatty 
acid salt (IDEXX Pharmaceuticals, Durham, NC) has also been developed.  This 
product has been formulated with the intention of using it in dogs and cats but it has 
been used in horses (Fenger 2000; Womble, Giguere et al. 2006). 
Tilmicosin has mainly been used for the treatment of respiratory infections in 
cattle and sheep in its injectable form.  More recently, the drug has been formulated as a 
feed additive for the treatment of respiratory disease in swine (Pulmotil).  Publications 
have also described its use in the treatment of foot rot, pinkeye and the oral form has 
also been used experimentally in the treatment of enzootic pneumonia in calves.  The 
main advantages of tilmicosin are the high concentrations of the drug that accumulate in 
the lung tissue and its persistence at this site.  It has been widely used in the treatment of 
BRD complex, for the treatment of individual animals, metaphylaxis and also 
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prophylaxis.  The widespread use of tilmicosin has been prevented by problems with 
toxicity in other animals (Prescott 2000).  More recently, an injectable tilmicosin 
product (Micotil) has been licensed for use in rabbits in Italy. 
The efficacy of tilmicosin for treating bacterial pneumonia in food producing 
animals is beyond question; tilmicosin has been widely studied in cattle feedlots and is 
as effective, or more effective than other commonly used medications such as 
oxytetracycline, florfenicol or ceftiofur (Schumann, Janzen et al. 1991; Musser, Mechor 
et al. 1996; Jim, Booker et al. 1999).  Tilmicosin is also effective in the treatment of 
enzootic pneumonia of calves (Ose and Tonkinson 1988; Picavet, Muylle et al. 1991; 
Fodor, Varga et al. 1993).  Clinical efficacy in sheep (Naccari, Giofre et al. 2001; 
Christodoulopoulos, Warnick et al. 2002) and pigs (Moore, Basson et al. 1996; Hoflack, 
Maes et al. 2001; Mateusen, Maes et al. 2001) is also well documented.  The clinical 
efficacy of tilmicosin has also been assessed in a number of non-target animal species 
including chickens (Jordan and Horrocks 1996; Kempf, Reeve-Johnson et al. 1997) and 
rabbits (McKay, Morck et al. 1996). 
The main advantage of tilmicosin over tylosin is its pharmacokinetics.  Tilmicosin 
has a longer elimination half-life and accumulates in lung tissue at higher 
concentrations.  The pharmacokinetics in cattle are well described.  In the first 
pharmacokinetic study, researchers treated 15 steers with a mean body weight of 240 kg 
with a label dose of tilmicosin (10 mg/kg SC).  Analysis of serum samples and lung 
samples collected at timed euthanasia periods demonstrated low serum concentrations 
(Cmax 0.71 µg/mL) and a long plasma half-life (t1/2) of 30 hours (Thompson and 
Lawrence 1994).  By contrast, lung concentrations reached a Cmax of  7.17 µg/g with a 
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t1/2 of approximately 48 hours.  Tissue concentrations exceeded the MIC of M. 
haemolytica for at least 72 hours.  These pharmacokinetics are ideal for a single 
treatment antimicrobial for use in the treatment of feedlot BRD. 
A more detailed evaluation of the pharmacokinetics is reported by Ziv et al (Ziv, 
Shem-Tov et al. 1995).  14 cows received the standard 10 mg/kg SC dose and 3 cows 
received the same dose intravenously (1 as a bolus and 2 as an infusion 0.5 mg/kg/min).  
The intravenous bolus resulted in severe adverse reactions; however, sufficient data was 
collected to model the pharmacokinetics (it should be noted that these kinetics were 
obtained from animals in a state of cardiovascular shock and their validity may be 
questioned).  The results show a typical two compartment model.  The volume of 
distribution (Vdarea) is 2.89 L/kg and the half-lives of the two compartments are 14 
minutes and 46 minutes.  The Cmax is 2.39 µg/mL.  The two animals receiving the IV 
infusion also showed signs of toxicity.  The data from their study gives a 1 compartment 
model with a t1/2 of approximately 1 hour and Vdarea of 2.25 L/kg.  In contrast, the 
animals receiving the SC dose had a Cmax of 0.13 µg/mL at 1.84 hours post-injection and 
a t1/2 of 4.18 hrs.  The bioavailability of tilmicosin was calculated as 22%.  Tilmicosin 
also partitioned well into the udder of lactating cows reaching concentrations that were 
typically 50 times higher than those seen in plasma. 
 Another study in 10 adult cows (Modric, Webb et al. 1998) found a serum Cmax 
of 0.87 µg/mL and a serum t1/2 of 29.4 hours similar to that originally described by 
Thompson (Thompson and Lawrence 1994).  More recently, a detailed 
pharmacokinetics study of tilmicosin in cattle has again been investigated comparing a 
SC dose with slow IV infusion (Hunter, Hassfurther et al. 2006).  The IV infusion was 
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conducted using 10 mg/kg diluted in saline and administered over 5 hours.  The Vdss was 
calculated to be 15 L/kg and, interestingly, the t1/2 of the two groups are very similar at 
28 hours.  However, the MRTs of the two groups were considerably different (IV 23 
hours, SC 32 hours), but the reason for this difference was not investigated. 
The values of Cmax and t1/2 described in the studies differ markedly.  The reasons 
for this discrepancy are not clear, but each study used a different method of measuring 
tilmicosin concentrations; bioassay (Ziv, Shem-Tov et al. 1995) vs. HPLC (Thompson 
and Lawrence 1994; Modric, Webb et al. 1998) or LC/MS (Hunter, Hassfurther et al. 
2006).  No details are given as to the suitability of the HPLC method used by Thompson 
and Lawrence (Thompson and Lawrence 1994), the HPLC used by Modric et al 
(Modric, Webb et al. 1998) had an LOD of 2.6 ng/mL and an LOQ of 50 ng/mL and a 
CV <10%.  The bioassay used by Ziv et al (Ziv, Shem-Tov et al. 1995)  has an LOQ of 
150 ppb and a coefficient of variation of 10%.  Hunter at al (Hunter, Hassfurther et al. 
2006) simply describe that their LC/MS assay had been validated.  Consequently, all 
plasma concentrations reported by Ziv et al (Ziv, Shem-Tov et al. 1995) are below the 
LOQ of the assay.  There is also a possibility that there was a difference in the injection 
technique between the studies influencing the absorption kinetics.  Finally, Ziv et al. 
(Ziv, Shem-Tov et al. 1995) used lactating, pregnant dairy cows while all other studies 
were conducted in non-pregnant beef cattle. 
These results reveal a number of important features about tilmicosin.  The drug 
appears to be slowly absorbed from the SC injection site.  The slow absorption for the 
injection site is beneficial; tilmicosin may have a short elimination t1/2 in plasma of 46 
minutes (Ziv, Shem-Tov et al. 1995), however, the delayed absorption from the injection 
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site results in “flip flop kinetics” with an elimination t1/2 ranging from 4.2 – 30 hours.  
Tilmicosin is not formulated for slow release.  Therefore, the delay in absorption may be 
related to the severe inflammatory reaction that occurs at the site of injection (Van 
Donkersgoed, Dubeski et al. 2000).  The bioavailability of the SC dose  of  22% (Ziv, 
Shem-Tov et al. 1995) is excessively low and may be an artifact caused by the slow 
absorption and rapid sequestration of tilmicosin into a tissue site separate from the 
plasma artificially decreasing the AUC.  It should be noted that Hunter et al (Hunter, 
Hassfurther et al. 2006) found the plasma elimination half-life to be much longer and 
independent of absorption from the SC injection site. 
The pharmacokinetics of tilmicosin in sheep are similar to those described for 
cattle.  The first report of the pharmacokinetics administered doses of 10 or 20 mg/kg 
SC over the chest wall (Parker, Patel et al. 1994).  The Cmax in plasma is 1177 (± 208) or 
2282 (± 692) ng/mL respectively, with a Cmax in lung of 14817 (± 3532) or 35542 (± 
4657) ng/g.  The t1/2 in plasma had two phases 7.9 hrs and 29.6 hrs and the t1/2 in lung 
was 26.9 hours.  These results are similar to those previously described in cattle.  
Modric et al. (Modric, Webb et al. 1998) specifically compared the plasma 
pharmacokinetics of tilmicosin in sheep and cattle and concluded that the results are 
very similar; only the Tmax differed significantly between the species (3.8 hrs in sheep 
vs. 0.5 hrs in cattle).  Cmax is 0.87 µg/mL in cattle and 0.82 µg/mL in sheep.  Half-life in 
cattle is 29.4 hours vs 34.6 hrs in sheep. 
Naccari et al. (Naccari, Giofre et al. 2001) modeled the plasma pharmacokinetics 
in 5 healthy and 5 pneumonic sheep.  The pharmacokinetics in the healthy sheep are 
similar to those described by Modric et al. (Modric, Webb et al. 1998) but the half-lives 
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are shorter (Tmax 6 hours, Cmax, 1.32 µg/mL, t1/2 13 hours), the values in the pneumonic 
sheep (with the exception of Tmax) were significantly different (Cmax 1.97 µg/mL, t1/2 20 
hours). 
Tilmicosin is also licensed for use in swine.  However, due to adverse reactions 
associated with injection (Jordan, Byrd et al. 1993) the drug is only used as a feed 
additive.  The pharmacokinetics are described in this species (Thomson, Darby et al. 
1994).  Swine were fed rations containing either 200 or 400 ppm (approximating to a 
daily intake of 10 or 20 mg/kg/day).  Serum concentrations in the 200 ppm group are 
barely above the LOQ of the assay, serum concentrations in the 400 ppm group were 
also low with a Cmax of 230 ng/mL.  Lung concentrations are much higher with a Cmax of 
1.43 µg/g and 2.59 µg/g respectively. 
The pharmacokinetics of tilmicosin are described in a number of non-target 
animals.  In elk, the pharmacokinetics appear to be similar to those described for cattle 
(Clark, Woodbury et al. 2004).  Cochrane and Thomson (Cochrane and Thomson 1990) 
describe plasma concentrations in horses following SC doses of 3, 10 or 30 mg/kg.  
Analysis of their data reveals that at doses of 3, 10 and 30 mg/kg the Cmax in plasma is 
0.17, 0.36 and 1.07 µg/mL respectively.  The MRT is somewhat variable at 22.5, 42 and 
38.4 hours respectively.  The Tmax ranged from 8-12 hours.  Rabbits treated with a dose 
of 25 mg/kg SC had a plasma Cmax of 1.91 µg/mL at 2 hours.  The t1/2 in plasma was 
5.97 hours.  Lung concentrations reached a maximum of 14.43 µg/g at 2 hours falling to 
5.1 µg/g at 24 hours (McKay, Morck et al. 1996).   
In all species studied, the consistent pharmacokinetic features of tilmicosin are the 
slow absorption from the injection site, low plasma / serum concentrations, high lung 
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concentrations and a prolonged elimination half-life (especially from lung tissue).  A 
number of researchers have investigated the nature of the tilmicosin accumulation in 
lung tissue.  Brown et al. administered 10 mg/kg tilmicosin SC to mice (Brown, 
Deleeuw et al. 1995).  Perfusion of the lung with saline and removal of the blood did not 
affect the tilmicosin concentration in the lung tissue.  When the same study was repeated 
with ceftiofur, perfusion of the lung removed approximately 75% of the ceftiofur.  The 
study indicates that unlike ceftiofur, the tilmicosin is actually sequestered in the lung 
tissue.  
The accumulation of tilmicosin into lung tissue can be enhanced in pneumonia but 
the results are somewhat confusing.  In rats (Modric, Webb et al. 1999), the lung 
concentrations of tilmicosin are significantly higher in pneumonic rats and the 
elimination half-life of the tilmicosin from the pneumonic lung appears significantly 
longer.  In contrast, Thompson et al. (Thompson, Laudert et al. 1994), report that the 
concentration of tilmicosin in the consolidated lung tissue is less than that of normal 
lung 17.87 µg/g versus 9.5 µg/g.  Pulmonary macrophages recovered from the lungs of 
clinically healthy calves and incubated with radio-labelled tilmicosin media (10 or 20 
µg/mL) contained 651 µg/mL or 1450 µg/mL tilmicosin respectively after 24 hours of 
incubation indicating that the drug actively accumulates in these cells (Thompson, 
Laudert et al. 1994).  A similar study using porcine alveolar macrophages found similar 
results (Thomson, Darby et al. 1994) with tilmicosin concentrations of 517 and 1500 
µg/mL respectively. 
The most detailed examination of the subcellular distribution of tilmicosin in 
bovine white blood cells was conducted by Scorneaux and Shryock (Scorneaux and 
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Shryock 1999).  Macrophages, neutrophils and epithelial cells were recovered from the 
mammary gland of lactating cattle.  Activated cells were recovered from two cows that 
were exposed to either S. aureus or E. coli lipopolysaccaride.  Monocytes and 
neutrophils were recovered from blood and pulmonary macrophages were recovered 
from the lungs of a freshly euthanized cow.  All cells accumulated tilmicosin, but the 
pulmonary macrophages accumulated the most, concentrations reaching 195 x that of 
the extracellular concentration after 4 hours of incubation; 80% of tilmicosin is found in 
the lysosomes. 
It is generally assumed that the accumulation of an antimicrobial within the 
lysosomes of phagocytic cells is beneficial.  The assumption is based on the fact that this 
is a site where phagocytosed bacteria reside and are killed by the phagocytic cell.  It is 
also the environment in which a number of pathogenic bacteria (notably R. equi) are 
able to survive.  The interaction of an antimicrobial with the phagocytic cell is highly 
complex.  The simplistic view that the accumulation of an antimicrobial will result 
automatically in enhanced microbial killing is therefore probably not correct.  
Brumbaugh et al. (Brumbaugh, Herman et al. 2002) demonstrated that tilmicosin did not 
affect chemotactic or phagocytic activities of bovine or porcine alveolar macrophages.   
Tilmicosin enhanced the bacterial killing of the macrophages but the relationship 
between tilmicosin concentration and effect was not clear. 
 The nature of the complexity between cellular accumulation and antimicrobial 
activity is becoming apparent for tilmicosin.  The first study of the interaction between 
tilmicosin and the neutrophil in pneumonia revealed some surprising results (Chin, 
Morck et al. 1998).  Tilmicosin not only resulted in significant clearance of M. 
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haemolytica from the lungs but also increased apoptosis of neutrophils.  Tilmicosin did 
not impair infiltration, phagocytic function or oxidative metabolism (clarithromycin and 
azithromycin impair phagocytosis in human peripheral neutrophils (Wenisch, Parschalk 
et al. 1996)).  The apparent contradiction in action between increased neutrophil action 
and apoptosis is thought to be beneficial in cases of M. haemolytica as the neutrophil 
plays a key role in the tissue damage that occurs during disease (Radostits, Gay et al. 
2007).  The same group of researchers (Chin, Lee et al. 2000) demonstrated that the 
apopototic effect of tilmicosin occurs regardless of the presence of M. haemolytica  and 
that the apopototic cells are rapidly cleared by macrophages.  The effect is also specific 
to tilmicosin and was not seen with any other antimicrobials or anti-inflammatory drugs.   
Another group (Fajt, Apley et al. 2000; Fajt, Apley et al. 2003) has conducted 
similar work comparing tilmicosin and danofloxacin and was not able to demonstrate 
any difference between the two antimicrobials in cattle experimentally infected with M. 
haemolytica. The authors concluded that that tilmicosin did not have any effect on 
neutrophil function or apoptosis.  The reason for the discrepancies between the two 
studies is not known. 
A final tool that has been used to investigate the activity of tilmicosin is 
immunohistochemistry.  Tilmicosin is a high molecular weight molecule and it has been 
possible to generate monoclonal antibodies to the molecule (Beier, Creemer et al. 2005).  
Immunohistochemistry using these antibodies has allowed the precise location of 
tilmicosin in treated lung to be mapped.  There are at present few reports of the use of 
these techniques.  The technique has been used in healthy swine and shows tilmicosin 
accumulation in bronchial epithelial cells and glandular areas.  Tilmicosin also 
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accumulates in macrophages in the alveolar wall, the interstice, and in the lumen and on 
the surface of the bronchi (Jackman, Spencer et al. 1997). 
 
1.2.2.  The use of macrolide antimicrobials in the horse 
The most widely used macrolide in the horse is erythromycin, which is used 
almost exclusively for the treatment of pyogranulomatous pneumonia in foals due to 
infection with R. equi (Lakritz and Wilson 2002).  It is often used for this purpose in 
conjunction with rifampin.  The initial studies regarding this treatment were based on 
the observed pharmacokinetics of erythromycin (Prescott, Hoover et al. 1983) and in 
vitro sensitivities of collected R. equi isolates (Prescott 1981; Prescott and Nicholson 
1984; Prescott and Sweeney 1985).  The initial clinical trials of the efficacy of this 
treatment remain the only published clinical trials for the treatment of R. equi (Hillidge 
1987; Sweeney, Sweeney et al. 1987).  The first of these studies is in reality a simple 
retrospective analysis of 48 clinical cases of R. equi pneumonia in foals.  The foals were 
treated with a variety of antibiotics, both singly and in combination (Sweeney, Sweeney 
et al. 1987).  The authors concluded that treatment with erythromycin was associated 
with an increased chance of survival.  In the second study (Hillidge 1987), 89 foals were 
treated with erythromycin and rifampin.  There was no control and the case definition 
was relatively loose as it included animals with clinical signs, but no positive culture for 
R. equi.  However, the authors demonstrated an approximately 85% recovery rate in the 
treated foals.  
Before addressing the studies looking at the pharmacokinetics of erythromycin in 
the horse it is worth recognizing two potential problems:   
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First, there is the method by which the plasma drug concentrations are measured.  
In the earlier studies plasma concentrations were routinely measured by means of a 
bioassay (Prescott, Hoover et al. 1983; Ewing, Burrows et al. 1994), while later studies 
have used HPLC methods.  HPLC has the advantage of being able to measure plasma 
concentrations of erythromycin, anhydroerythromycin and erythromycin base 
independently.  When the results of the 2 assays were compared (Lakritz, Wilson et al. 
1999), substantial differences were noted.  In particular the bioassay consistently over 
estimated the concentration of drug in the body measured as AUC.  Rate kinetics and 
mean residence time were also significantly different.  These differences may be 
because the bioassay does not measure the concentration of the parent drug and the 
metabolites or conjugated pro-drug individually. 
Second, all studies conducted have referenced the initial studies looking at in vitro 
sensitivity of R. equi isolates to erythromycin (Prescott 1981) in which the MIC was 
determined to be 0.25 μg/mL.  These studies have assumed that plasma concentrations 
in excess of this concentration should be effective.  Such an assumption is hard to justify 
given the intracellular nature of the bacteria and its location in a pyogranulomatous 
abscess within the lung.  It is generally assumed that the concentration of drug in the 
lung should exceed plasma concentrations, but there is no evidence to support this 
theory in the horse or any other species.  There is also no evidence to suggest how long 
the plasma concentration should exceed the MIC. 
The first assessment of the potential use of erythromycin in horses looked at the 
pharmacokinetics in both foals and horses (Prescott, Hoover et al. 1983).  The study 
used mare/foal pairs and looked at the pharmacokinetics in foals at 1, 3, 5, 7, and 10-12 
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weeks of age.  The mares were also used to evaluate the pharmacokinetics in adult 
horses.  Erythromycin was administered in the form of gluceptate at 5 and 20 mg/kg IV, 
estolate at 5-20 mg/kg orally and free base at 10 mg/kg IM.  Minimal analysis was 
conducted on the plasma concentrations which were measured using a bioassay.  The 
results demonstrated that erythromycin is rapidly eliminated from the plasma after 
intravenous administration.  However, after intra-gastric or intramuscular administration 
there is a slowed absorption phase resulting in sustained plasma concentrations (flip-flop 
kinetics).  Bioavailability of the oral estolate formulation appears to be relatively low.  
The base form resulted in unacceptable swellings at the site of injection. 
Subsequent studies have used alternative forms of erythromycin.  Ewing at al. 
(Ewing, Burrows et al. 1994), used estolate (37.5 mg/kg bid), phosphate (25 mg/kg tid), 
stearate (25 mg/kg tid) and ethylsuccinate (25 mg/kg tid).  Their study used adult horses 
and plasma concentrations were analyzed using a bioassay.  The authors concluded that 
the simple salts were better absorbed than the esters (in contrast to studies conducted in 
humans) and that erythromycin phosphate or stearate should be used for R. equi therapy 
in foals as plasma concentrations were significantly higher than those seen with the 
estolate used by Prescott et al. (Prescott, Hoover et al. 1983).  However, all forms of the 
drug resulted in peak concentrations in excess of 0.25 μg/mL, the recommended MIC 
for R. equi.  The authors also concluded that a dose interval of 12 hours is the most 
appropriate.  Unfortunately, the authors did not address the issue of performing the 
study in adult horses when the target population for therapy is unweaned foals. 
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Lakritz et al. (Lakritz, Wilson et al. 2000) compared the pharmacokinetics of 
erythromycin estolate and erythromycin phosphate when administered intragastrically to 
non-fed foals.  The plasma analysis in this study was conducted using HPLC and plasma  
anhydroerythromycin A (an inactive degradation product) was also measured.  Once 
again erythromycin phosphate showed significantly greater plasma concentrations.   
Administration of the estolate did result in reduced concentrations of 
anhydroerythromycin A, but the majority of the drug in the plasma was in the inactive 
estolate form.  The authors finally concluded that the phosphate should be administered 
at a dose of 25 mg/kg every 6 hours, but that the potential exists for the estolate to be 
more effective. No evidence is given to support this claim. 
The same group of researchers also looked at the effects of feeding on the 
absorption of erythromycin base in foals (Lakritz, Wilson et al. 2000).  The study was a 
crossover design in which 25 mg/kg of microencapsulated erythromycin base was 
administered to fasted and non-fasted foals.  The results indicated that the bioavailability 
of the drug in fasted foals was 26% (+/- 15.4) compared with 7.7% (+/- 6.7) in fed foals.  
This decrease in absorption was not mediated through an increase in the degradation of 
the active drug as determined by measurement of anhydroerthromycin in plasma. 
A final study by the same research group looked at the pharmacokinetics of 
erythromycin ethylsuccinate (Lakritz, Wilson et al. 2002).  Twenty five mg/kg were 
administered orally to fasted foals.  Concentrations did not exceed 0.25 μg/mL for more 
than 4 hours and a large amount of anhydroerythromycin was measured in plasma.  The 
authors did not recommend the use of this product for the treatment of R. equi infection 
in foals. 
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The results of these studies demonstrate several interesting points:  Firstly, 
erythromycin has a poor oral bioavailability in the horse.  The bioavailability is 
dependent on the formulation of the drug and the fed state of the horse.  While it is 
understandable that a researcher should attempt to control this variability as much as 
possible by administering the drug intragastrically to a fasted horse, the practical 
application of this approach must be considered as the target treatment group is young 
foals that must be treated 3 – 4 times daily, often for more than one month.  The second 
major problem is the continual assumption that the plasma concentrations of the drug 
must exceed the MIC for R. equi.  There is no evidence that this is an appropriate 
marker of efficacy for the treatment of R. equi pneumonia.  The pharmacodynamics of 
the macrolide antimicrobials has not been fully determined and it is unclear whether 
they should be considered either concentration or time dependent in their mechanism of 
bacterial killing.  Furthermore, the macrolide antimicrobials have a very high volume of 
distribution with only a small percentage of the drug being present in plasma.  The 
majority of the drug is sequestered in the tissues.  R. equi is an intracellular pathogen 
causing pyogranulomatous lesions in the lung tissue.   One must, therefore, question the 
applicability of plasma concentrations to concentrations achieved / required at the site of 
infection.  There are very few studies of the efficacy of erythromycin with which to 
compare these pharmacokinetic studies.  While the pharmacokinetics seem to suggest 
that the simple phosphate base has the best pharmacokinetic profile, the only clinical 
trial used either the estolate or the succinate form three times daily (Hillidge 1987) 
The concerns regarding the variability of erythromycin absorption, the potential 
for adverse reactions (Stratton-Phelps, Wilson et al. 2000) coupled with increasing 
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anecdotal reports of isolates of R. equi resistant to erythromycin have led to the use of 
newer macrolides in foals. 
The frequent dosing associated with erythromycin treatment has led researchers to 
look at the new generation of macrolide antimicrobials which typically have higher oral 
bioavailability and prolonged elimination half-lives.  As a result, the pharmacokinetics 
of azithromycin have been investigated by two research groups (Jacks, Giguere et al. 
2001; Davis, Gardner et al. 2002).  In the first of these studies, doses of 10 mg/kg were 
compared when administered intragastrically and intravenously (foals were not fasted).  
Analysis of drug concentrations was conducted using a bioassay.  The oral 
bioavailability was 56% and the plasma elimination half-life was very long (20.3 hours 
after IV administration).  In addition to plasma concentrations, azithromycin 
concentrations were also determined in synovial and peritoneal fluid where the 
concentrations were found to be similar to those seen in plasma.  Bronchoalveolar 
lavage fluid (BAL) was also collected and estimates were made of the concentration of 
azithromycin found in bronchoalveolar cells and in pulmonary epithelial lining fluid 
(PELF).  Azithromycin accumulated in the PELF at concentrations approximately 50 
times those seen in plasma; the concentrations in the bronchoalveolar cells were even 
higher at approximately 500x plasma concentrations.  The authors suggest that once 
daily dosing for 5 days followed by a dose interval of 48 hours should be sufficient to 
treat R. equi.  However, the basis for these recommendations (i.e. nature of target drug 
concentrations) is not clear. 
The second study (Davis, Gardner et al. 2002) was similar using slightly older 
foals and the azithromycin was administered orally (10 mg/kg).  The analysis was 
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conducted using HPLC.  The results are similar with slightly reduced oral bioavailability 
(39%) and the elimination of the azithromycin was faster.  The concentration of 
azithromycin in peripheral polymorphonuclear (PMN) cells was also measured in 
addition to BAL fluid and bronchoalveolar cells.  The concentration of azithromycin in 
PMNs was approximately 25 times greater than that seen in plasma and the 
concentrations persisted for several days (T1/2  49.2 hrs).  The authors again suggest that 
azithromycin shows potential for the treatment of R. equi pneumonia. 
Clarithromycin is a semi-synthetic derivative of erythromycin.  It is reported to be 
approximately twice as active against bacteria as erythromycin on a weight by weight 
basis and has a half life approximately twice that of erythromycin (Giguere 2006).  In 
addition, the bioavailability is higher and volume of distribution is also improved.  
Finally, the incidence of adverse reactions in humans is reduced when compared with 
erythromycin (Giguere 2006).  The pharmacokinetics of clarithromycin in foals have 
been reported (Jacks, Giguere et al. 2002).  Administration of 10 mg/kg intra-gastrically 
in non-fasted foals resulted in a Cmax of 0.92 (+/- 0.17) μg/mL at 1.5 hrs.  The t½ is 4.81 
hrs.  The MIC90 of R. equi for clarithromycin has been reported as 0.12 μg/mL and the 
authors, therefore, suggest an oral dose of 7.5 mg/kg q 12 h for the treatment of R. equi 
pneumonia.  Unfortunately, the concentrations of clarithromycin in lung tissue were not 
measured and plasma concentrations were measured using a bioassay.   
Since the publication of all these pharmacokinetic trials, two additional studies 
have been published.  The first of these investigated the in vitro susceptibility of R. equi 
to the macrolide antimicrobials (Jacks, Giguere et al. 2003).  The MIC90 for 
azithromycin, clarithromycin and erythromycin were 1.0, 0.12 and ≤0.25 µg/mL 
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respectively.  This covers quite a range with clarithromycin being almost 10 times as 
potent as azithromycin. 
A retrospective study of therapy for R. equi pneumonia has also been conducted 
(Giguere, Jacks et al. 2004).  The study followed 81 foals with naturally acquired R. 
equi infection that presented at Florida State University.  Twenty foals received 
azithromycin, 18 received clarithromycin and 24 received erythromycin (stearate).  Most 
foals also received rifampin.  Foals treated with clarithromycin showed a significantly 
greater survival rate in both long and short term follow up and better resolution of 
radiographic change in the lungs.  The authors concluded that clarithromycin was the 
treatment of choice and that azithromycin did not offer any advantages over the 
traditional therapy of erythromycin.  Interestingly, azithromycin has become the 
accepted standard for treatment for R. equi pneumonia (Cohen – personal 
communication). 
The use of tilmicosin in the horse has not been well investigated due to concerns 
about potential toxicity (Prescott 2000).  However, there are no reports of toxicity in 
horses in the veterinary literature to support these concerns.  There is one case report 
(Fenger 2000) that reports the successful use of a novel microcrystalline injectable form 
of tilmicosin to treat R. equi pneumonia in two foals.  The foals were both suffering 
from an infection that was refractory to erythromycin treatment.  The tilmicosin 
preparation used in this study has not been widely available.  However, a study of its 
pharmacokinetics has now been published (Womble, Giguere et al. 2006).  The 
tilmicosin formulation consists of a fatty acid salt formulation (250 mg/ml; IDEXX 
Pharmaceuticals, Durham, NC).  It was administered to 7 foals between 5 and 8 weeks 
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of age at a dose of 10 mg/kg via the intramuscular route using the muscles of the 
hindlimb.  Samples collected included plasma, BAL fluid, cerebrospinal fluid (CSF), 
peritoneal fluid and lung biopsies.  Tilmicosin concentrations were measured in serum, 
CSF, peritoneal fluid, lung tissue, PELF, BAL cells and blood neutrophils using HPLC-
MS/MS.   
Serum concentrations of tilmicosin peaked at 0.19 µg/mL with an MRT of 34.5 
hours.  As expected, the lung concentrations were considerably higher at 1.9 µg/g with a 
MRT of 323 hours (although the time to Tmax was much longer 30.8 hours vs. 5.5 hours 
for serum).  The Cmax for PELF, BAL cells and serum neutrophils were 2.91, 20.1 and 
66 µg/mL respectively, with MRTs of 180, 117 and 99 hours respectively.  The 
researchers found the MIC90 for R. equi to be 32 µg/mL.  Administration of the 
tilmicosin formulation resulted in swelling at the site of injection and self limiting 
diarrhea in four foals.  One foal developed tachypnea and profuse sweating.  The 
researchers believed that their results warrant further investigation of the use of 
tilmicosin for the treatment of pneumonia caused by R. equi despite the very high MIC90 
(32 µg/ml). 
 Although the results of a wide variety of pharmacokinetic studies using different 
macrolide formulations are reported for horses, interpretation of the data is difficult.  
Most studies have simply administered the antimicrobial orally (often by stomach tube 
in a fasted foal) and measured plasma concentrations of the drug.  The significance of 
these plasma concentrations for a drug with such a high volume of distribution must be 
questioned.  The macrolide antimicrobials rarely excerpt their activity within the plasma 
(especially in the case of pyogranulomatous pneumonia caused by R. equi) and the 
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relationship between efficacy and plasma concentration is not known.  The use of the in 
vitro MIC90 as a target for plasma concentrations is without basis.  Furthermore, many 
of these studies have used unvalidated bioassays to measure drug concentrations and 
these assays have been shown to have a number of weaknesses (Lakritz, Wilson et al. 
1999).  In contrast to the horse, most food animal studies of macrolide pharmacokinetics 
have focused on tissue (especially lung) concentrations of the drug.  Again the 
usefulness of these concentrations is not clear but they seem to equate with clinical 
efficacy and tissue concentrations are certainly closer to the site of action. 
 A number of recent studies in the horse have attempted to answer some of these 
questions by using repeated samples such as BAL fluid to assess macrolide 
concentrations in PELF and leucocytes.  What is really needed are studies which attempt 
to link the tissue distribution of the antimicrobial and the efficacy of treatment so that 
we can better understand the complex pharmacodynamics of antimicrobial activity and 
their highly complex interaction with the immune system. 
 
1.2.3.  Review of macrolide toxicity (especially tilmicosin) 
The macrolide class of antimicrobials generally has a very good safety profile 
(Periti, Mazzei et al. 1993).  The most commonly reported adverse reaction is 
gastrointestinal disturbance.  Other reported adverse reactions include allergic skin 
eruptions, cholestatic hepatitis, transient ototoxicity and irritation at the site of injection.  
Also, there have been reports of unusual reactions which are considered rare or 
questionable affecting a wide variety of body systems. 
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A number of researchers have investigated a possible linkage between macrolides 
and cardiovascular toxicity.  Wakabayashi and Yamada (Wakabayashi and Yamada 
1972) demonstrated that erythromycin, oleandomycin, leucomycin and spiramycin all 
caused decreased blood pressure in dogs.  The administration of macrolides was 
associated with an increase in blood histamine concentrations and the effect was 
attenuated by pretreatment with diphenhydramine.  They concluded that the macrolides 
stimulate the release of histamine which resulted in the observed cardiovascular effects.  
More recently, a study was conducted that compared the effects of various macrolides 
on isolated beating rat atria (Tamargo, De Miguel et al. 1982).  Josamycin and 
erythromycin produced dose dependent decreases in rate and contractile force.  They 
also affected the sinus node recovery time and the refractory period.  The effect is not 
attenuated by atropine, pentolamine, practolol, diphenhydramine, cimetidine, 
methysergide, or indomethacine.  The authors finally concluded that erythromycin and 
josamycin inhibit the transmembrane flux of calcium into atrial cells.   
There is one clinical case report of erythromycin being associated with a 
ventricular arrhythmia in a human patient (Freedman, Anderson et al. 1987).  The 
patient suffered from idiopathic long QT syndrome and was treated with erythromycin.  
This resulted in syncope.  A controlled erythromycin infusion and monitoring of the 
electrocardiogram (ECG) demonstrated T-wave alternans and premature ventricular 
complexes.  The effect was blocked by the use of propranalol. 
Tilmicosin is unusual compared to other macrolides as it is linked to acute cardiac 
toxicity.  The cardiac toxicity of tilmicosin has been extensively reviewed (Jordan, Byrd 
et al. 1993).  The oral median lethal dose (MLD) in fasted rats is 800-850 mg/kg.  If the 
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animals were recently fed, the oral MLD rose to 2250 mg/kg.  Deaths were per acute 
occurring within 2 hours and no specific tissue lesions were found at post-mortem 
examination.  The MLD following SC injection was 100 mg/kg in mice and 185-440 
mg/kg in rats (range due to sex differences).  Once again, effects were acute and no 
lesions were found at post-mortem examination. 
Primates appear to be more susceptible to toxicity.  A small study in Rhesus 
monkeys found signs of toxicity at 20 mg/kg SC.  A dose of 30 mg/kg resulted in 
vomiting, behavioral changes, labored breathing and death. 
The nature of the effect of tilmicosin on the heart is not known.  The most detailed 
study on the cardiovascular effects of tilmicosin was conducted in dogs (Main, Means et 
al. 1996).  Administration of intravenous tilmicosin to unrestrained dogs results in 
negative ionotropic and chronotropic effects with resultant tachycardia.  These effects 
are exacerbated by treatment with propranalol.  Dobutamine infusion attenuated some of 
the effects.  It is now thought that the toxic effects of tilmicosin on the heart may be 
mediated through rapid depletion of calcium (Main, Means et al. 1996). 
Chronic dosing studies have been conducted in a wide range of species.  Rats 
dosed daily with tilmicosin ranging from 50 – 600 mg/kg PO for 2 weeks did not show 
any overt signs of toxicity.  There were mild increases in serum AST and induction of 
hepatic microsomal enzymes but no evidence of tissue toxicity was found.  In a separate 
study, oral doses ranging from 25- 1000 mg/kg were administered to rats for 3 months.   
Deaths were seen at the higher doses along with non-specific changes such as decreased 
body weight. 
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Beagle studies used oral doses of 4 – 36 mg/kg bid for a year.  All dogs survived, 
but the animals receiving the higher doses showed some signs of cardiac toxicity.  
Tachycardia was seen as well as depression in the ST segment of the ECG.   These 
animals showed moderate cardiomegally at post-mortem examination but no 
histopathological changes were found. 
Toxicity studies in cattle have demonstrated a wide margin of safety when the 
drug is used according to the label dose (10 mg/kg SC).  Four doses of 150 mg/kg SC 3 
days apart resulted in 50% mortality.  Death was acute and associated with tachycardia 
and changes in the ECG.  At necropsy small foci of myocardial necrosis were evident in 
the papillary muscles of the left ventricle.  The higher dose was also associated with 
very severe reactions at the site of injection, characterized by severe edema and some 
necrosis of the underlying muscle.  The loss of plasma proteins into the site resulted in a 
measurable decrease in plasma total protein. In a separate study, doses ranging from 10-
50 mg/kg were administered subcutaneously every 72 hours for 3 doses.  There were no 
overt signs of toxicity, but at necropsy, lesions were again found in the papillary 
muscles of the left ventricle. 
A dose of 5 mg/kg IV in feedlot cattle resulted in labored breathing and lethargy 
with a 50% mortality rate.  No lesions were found at necropsy.  In a pharmacokinetic 
study, Ziv et al. (Ziv, Shem-Tov et al. 1995) administered a 10 mg/kg IV bolus, or as a 
slow infusion over 20 minutes at 0.5 mg/kg/min.  The cow receiving the bolus 
developed ataxia, tachycardia, jugular pulses, hyperpnea and collapsed although the 
animal recovered.  The cows receiving the infusion dose showed less pronounced signs.  
The intravenous dosing resulted in plasma concentrations above 1 µg/mL in contrast to 
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the standard 10 mg/kg SC dose with a Cmax of 0.13 µg/mL suggesting that the toxic 
effects of tilmicosin are dependent on plasma concentrations and that the toxic 
concentrations are very hard to achieve with either oral dosing or injection by either the 
PO, SC or IM routes. 
Toxicity in non-target agricultural animals has been assessed in neonatal calves.  
Doses of 5 or 10 mg/kg IV resulted in labored breathing and lethargy.  One calf 
receiving the 10 mg/kg IV dose died.  No lesions were found at necropsy (Jordan, Byrd 
et al. 1993).   
Pigs appear to be more susceptible to tilmicosin toxicity.  Intra-muscular doses 
ranging from 10 -30 mg/kg resulted in recumbency and convulsions at the 10 mg/kg 
dose.  At the higher doses there was ataxia, restlessness and labored breathing with 75% 
mortality at 20 mg/kg and 100% mortality at 30 mg/kg.  There was severe reaction at the 
injection sites.  Oral dosing with medicated feed containing 5- 500 ppm for 6 weeks had 
no adverse reactions.  Tilmicosin has since been licensed for use in swine feed at 200 
ppm for the treatment and prevention of respiratory disease in growing pigs. 
Studies in sheep found the toxicity profile to very closely resemble that of cattle 
and the drug was licensed for use in sheep to treat respiratory disease (Modric, Webb et 
al. 1998).  The injectable product has also been licensed for use in rabbits in Italy. 
Jordan (Jordan, Byrd et al. 1993) reports that SC and IM dose of >10 mg/kg 
resulted in toxic reactions in horses and goats and that both species exhibited adverse 
reactions to IV doses of less than 10 mg/kg.  The details of the horse studies are found in 
(Cochrane and Thomson 1990).  Horses received a range of doses;  3, 10, 30 mg/kg SC, 
2.5, 5, 7.5 mg/kg IV and 1 mg/kg IM.  Horses were monitored for adverse reactions and 
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plasma was collected to measure tilmicosin concentrations.  A detailed necropsy was 
conducted upon completion of the study. 
Intravenous doses of 2.5 or 5 mg/kg did not result in any adverse reactions; a dose 
of 7.5 mg/kg resulted in signs of colic, convulsions and labored breathing.  The horse 
was recumbent within 15 minutes and died within 1 hour.  The intramuscular dose 
resulted in stiffness at the site of injection lasting 3 – 4 days.  The subcutaneous doses 
resulted in swelling and reaction at the injection site.  Administration of subcutaneous 
tilmicosin was well tolerated at 3 or 10 mg/kg.  A dose of 30 mg/kg resulted in signs of 
toxicity during the following 24 hours (anorexia, labored respiration, recumbency, 
depression), horses then appeared normal.  One horse receiving 30 mg/kg SC died 6 
days post injection. 
The two horses that died during the study had similar findings in their heart 
muscle.  There were multiple foci in the left ventricle of subacute necrosis characterized 
by loss of sarcoplasm, minimal cellular infiltration and increased prominence of small 
blood vessels within the damaged areas.  Of the remaining horses in the study 2 had no 
cardiac lesions, one had focal lymphoid cell infiltration and one had mild lesions similar 
to the two that died (this horse had received a SC dose of 30 mg/kg and an IV dose of 
2.5 mg/kg). 
A second study fed horses diets containing 400, 1200 or 2000 ppm tilmicosin for 
14 days (approximating to a daily intake of 4 mg/kg, 12 mg/kg and 20 mg/kg 
tilmicosin)(Buck and Thomson 1997).  Horses receiving the 400 ppm showed minimal 
reaction with 2 out of 6 horses showing a slight decrease in feed intake during the 
treatment period. Two of the horses were recorded as showing signs of toxicity 
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(lethargy, anorexia loose stool).  All of the horses receiving 1200 ppm had significantly 
reduced feed intake during the second week of tilmicosin administration.  All six horses 
were reported to show signs of toxicity.  Mainly lethargy, soft stool, signs of colic and 
anorexia.  The etiology of the loose stool was not investigated. 
The horses receiving 2000 ppm had highly variable feed intakes throughout the 
study.  Five of the six horses in this group showed similar signs to those previously 
reported and one horse was found dead on the eleventh day on feed (a post-mortem 
examination was not conducted). 
The potential for human toxicity following accidental self injection has been a 
particular concern with the use of Micotil.  A 1 mL injection of Micotil (300mg) would 
be a dose of 5 mg/kg for an average 60 kg human which is very close to the dose 
causing toxic effects in monkeys (Jordan, Byrd et al. 1993).  A number of accidental 
injections in farm workers have been reported.  One review reports 36 cases of 
accidental exposure in Canada (McGuigan 1994); all but two cases occurred in adults, 
72% of cases were injections, the remainder were splashes to skin, eyes or mouth, 75% 
of cases involved less than 1 mL of Micotil.  No long term adverse effects were 
described and most patients were treated with simple supportive care 
In another case a worker injected 0.5 – 1 mL tilmicosin into his left, fifth finger 
(Crown and Smith 1999).  His presenting complaint was dizziness, weakness and ataxia.  
He was also found to be tachycardic and lost the ability to speak or perform purposeful 
movement.  The patient developed severe chest pain that resolved with nitrogycerine 
treatment.  There was also headache, abdominal pain and vomiting.  The patient 
recovered without ill effects with simple supportive care. 
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Another case involved a worker who injected up to 6 mL Micotil into his forearm 
while attempting to treat an animal (Von Essen, Spencer et al. 2003).  5 hours later the 
worker reported severe chest pain and was rushed to hospital.  He was tachycardic and 
had ECG abnormalities.  He was treated with nitroglycerine and morphine without 
apparent reduction in pain.  He was managed symptomatically and was released from 
hospital in 3 days. 
A more recent review of human exposure to tilmicosin documents 3168 accidental 
exposures (Veenhuizen, Wright et al. 2006).  Information on the route of exposure was 
available for 1980 of the cases of which 1207 were by injection.  29% of cases in which 
the route of exposure were recorded indicate no adverse reactions.  The recorded 
reactions were generally mild including injection site pain, bleeding and swelling.  
Severe adverse effects were reported in 156 cases (5%), clinical signs categorized as 
severe included heart rate disorder, hypertension, hypotension, chest pain or death.  
There have been 13 human deaths linked to tilmicosin, but 11 of these were determined 
to be suicides and all are assumed to be due to injection (in one case the exposure may 
have been oral).  The effect of tilmicosin in the fatal suicide cases and in 7 additional 
attempted suicide cases is complicated by the concurrent use of other medications. 
The overall risk of tilmicosin to human health is considered to be small (2 cases 
per 1 million doses administered).  The risk of death is extremely small (1 per 41 million 
doses administered) (Veenhuizen, Wright et al. 2006). 
All these data suggest that tilmicosin differs from other macrolide antimicrobials 
in having a direct effect on the heart.  The effect appears to be dose dependent and 
related to the plasma concentration of tilmicosin.  The high Vd of tilmicosin and its slow 
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absorption after SC or oral dosing ensure that at label doses plasma concentrations are 
low (<1 µg/mL) consequently toxic effects are rare.  However, following overdose, IV 
or IM administration concentrations may be much higher resulting in acute cardiac 
toxicity manifesting as ECG abnormalities, tachycardia and decreased cardiac output.  If 
the individual survives the acute toxicity, it is likely that there will be focal areas of 
necrosis scattered throughout the myocardium, especially the left ventricle in the region 
of the papillary muscles. 
Use of erythromycin in foals is not without risk.  There have been numerous 
anecdotal reports of adverse reactions including diarrhea, hyperthermia and respiratory 
distress.  There has been one retrospective study which attempted to look at the 
incidence of these adverse reactions in a controlled manner (Stratton-Phelps, Wilson et 
al. 2000).  The study identified 73 foals that had been treated with erythromycin either 
alone or in combination with either rifampin or gentamicin.  This was compared with a 
control group consisting of 70 foals treated with either procaine penicillin G or 
Trimethoprim – sulfonamide combination (TMS).  When the two groups were compared 
significant difference were observed including age, treatment with bronchodilators and 
previous treatment with antibiotics.  Analysis of the data demonstrated a relative risk for 
development of diarrhea of 8.3 (95% CI 2.6-26.2), this effect was not modified by any 
of the reported confounders.  The relative risk for development of hyperthermia was 25 
(95% CI 14 to 36) after foals with pyrexia at the time of presentation were ruled out.  
This effect did show modification for increased risk in foals treated by the field service 
and foals treated during the summer.  The relative risk for respiratory distress was 15 
(95% CI 6-24) this also occurred more frequently in the summer. 
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1.2.4.  Antimicrobial Associated Diarrhea 
The syndrome of antimicrobial associated diarrhea (AAD) is not specific to equine 
medicine.  It exists in the field of human medicine (Job and Jacobs 1997) and other 
subspecialties of veterinary medicine.  While the syndrome has been widely discussed, 
there is actually very little published research available.  The majority of literature 
consists of scattered case reports and case series; most include a report of diarrhea, but 
in only very few cases are there evidence that the etiology of the diarrhea was 
investigated.  Review of this information is further hampered by the fact that in almost 
all cases of apparent AAD, the animals were being treated for an underlying 
pathological condition (in many cases surgical colic) and were stressed and often housed 
within a veterinary facility; all risk factors for the development of diarrhea (Traub 
Dargatz, Salman et al. 1990). 
An antimicrobial could potentially cause diarrhea in one of three ways:  
1. The antimicrobial may exert a direct action on the gastrointestinal tract resulting 
in diarrhea.  This may be as a result of a pharmacological action distinct from 
its antimicrobial action or as the result of a direct toxicity; 
2. The antimicrobial may disrupt the normal intestinal flora preventing normal hind 
gut fermentation leading to the development of diarrhea; and 
3. The antimicrobial may selectively disrupt the normal fecal flora resulting in over 
growth by a resistant pathogen and an overt bacterial colitis e.g. Salmonella 
spp. or Clostridium spp. 
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Within the veterinary field, ADD seems to be of greatest concern in the horse, 
although the true incidence of the condition is unknown in most species.  The concern in 
the horse is probably less due to its frequency than difficulties in managing a horse with 
severe colitis, the poorer prognosis and risk of complications such as laminitis. 
The concerns of the equine veterinarian fall largely into two categories: 
Firstly, there is Hippocrates’ dictum that we should “first do no harm”.  No one 
wants the condition of a patient to deteriorate as a result of his/her actions; and 
Secondly, there is the concern that should an animal develop colitis following a 
course of antimicrobials the veterinarian may be held legally responsible for the 
subsequent health problems of the animal. 
In an absence of good data, anecdotal experience has become accepted as fact.  
The syndrome was named “colitis X”, with recommendations made for its avoidance 
(Vaughan 1973; Carlson 1976; Schiefer 1981).  This is surprising as the etiology of the 
disease and the risk factors for development were unknown. 
The subject of AAD has been reviewed in the past (Fey and Sasse 1997; Jones 
2004) but none of these reviews has extensively reviewed the past and current literature 
available on the subject. 
There is only one controlled epidemiological study that truly investigated the 
development of antimicrobial associated diarrhea in the horse (Wilson, MacFadden et al. 
1996).  In this report, records from the equine hospital at the College of Veterinary 
Medicine, University of Missouri were analyzed in two separate studies.  The first study 
was a case-control study comprising 28 diarrheic animals and 107 controls.  
Administration of a potentiated sulfonamide or penicillin was not associated with 
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development of diarrhea.  Administration of other antibiotics was associated with the 
development of diarrhea (OR 3.2 (1.17-8.76)); length of stay in the hospital (>15 days) 
was also associated with the development of diarrhea (OR 3.43 (1.04-11.68)). 
The second portion of the study was a historical cohort study using a total of 784 
horses; 27 horses developed diarrhea.  Administration of potentiated sulfonamides was 
again not associated with the development of diarrhea.  However, administration of 
penicillin (RR 2.3 (1.08-4.76)), penicillin and potentiated sulfonamides (RR 2.7 (1.17-
6.2)) or another antibiotic (RR 2.8 (1.29-6.07)) was associated with an increased risk of 
diarrhea. 
This study indicates that the risk of antimicrobial associated diarrhea in the horse 
is relatively low (27/784) and that many antimicrobials may be implicated as risk 
factors.  However, it should be noted that the greatest risk factor identified was the 
length of stay in the hospital. 
1.2.4.1.  The normal fecal flora of the horse 
Any discussion of acute bacterial enteritis will naturally focus on disturbances of 
the normal bacterial flora present within the intestines.  Before discussing these 
disturbances it would seem prudent to define the normal fecal flora present in the equine 
intestines.  Unfortunately, there is little published research in this area.  Most of this 
research is restricted to analysis of fecal flora because it is easily accessible.  It is likely 
that the fecal flora does not truly represent the normal flora present throughout the entire 
intestinal tract.  However, it is accessible to sampling and is typically used in the 
diagnosis of acute colitis. 
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         The most detailed assessment of the normal fecal flora was conducted by Wierup 
(Wierup 1977).  He used quantitative bacteriological techniques to define the normal 
fecal flora of 91 horses.  These results are summarized in Figure 1.3.  The technique 
involved collecting feces and diluting a weighed sample in sterile saline.  The solution 
was then serially diluted and a known volume of solution applied to an agar plate and 
incubated.  In this relatively simple assay the feces were found to consist primarily of α-
hemolytic streptococci, β-hemolytic streptococci and coliforms.  (Since this research 
was published Streptococcus faecalis the most likely α-hemolytic streptococci isolated 
by Wierup has been renamed Enterococcus faecalis).  There were much lower numbers 
of Bacillus spp., and occasional moulds.  Cl. perfringens was rarely isolated from the 
feces of healthy horses. 
The study was repeated using a population of adult horses presenting with acute 
colitis.  The horses with acute colitis had slightly reduced numbers of β-hemolytic 
streptococci and slightly higher numbers of coliforms than the healthy horses (Figure 
1.4).  Unfortunately no data was given in this series regarding the number of Cl. 
perfringens isolated.  In a separate group of 25 horses the median number of Cl. 
perfringens isolated per gram of feces was 100,000 (Wierup 1977).  Under normal 
circumstances the feces contained low numbers of Cl. perfringens.   
1.2.4.2  Causes of acute bacterial colitis in the horse. 
There are a number of species of bacteria associated with diarrhea in the horse.  
Some such as Lawsonia intercellularis are associated only with chronic disease (Lavoie, 
Drolet et al. 2000).  Other pathogens such as Neorickettsia risticii (Potomac Horse 
Fever) cause a systemic disease state which results in colitis (Palmer and Benson 1992).  
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Three main bacterial pathogens are associated with colonization of the intestines 
resulting in acute, severe colitis.  The association of each pathogen with disease, the 
pathophysiology and the difficulty of confirming the diagnosis will be discussed in 
detail below. 
1.2.4.2.1.  Salmonella 
Salmonella infection has long been associated with acute colitis in the horse and is 
perhaps the most studied cause of diarrhea in the horse.  The disease has been 
extensively reviewed (Jones 2004).  A wide variety of serotypes have been identified as 
causing disease.  The most common serotype identified is Salmonella Typhimurium 
(Jones 2004).  Discussion of the role of Salmonella as a cause of acute colitis in the 
horse is complicated by the fact that a large number of horses carry Salmonella in their 
intestines without signs of disease.  The incidence of the carrier state has been estimated 
by a number of researchers and may range from as low as 1-2% to as high as 20% of 
adult horses (Traub Dargatz, Salman et al. 1990).  It is likely that the variation in the 
study results occurs due to the differences in methodology of isolating Salmonella and 
the population of horses studied.  Excretion of Salmonella by carrier animals may be 
influenced by stresses such as transport, surgery and by the administration of antibiotics 
(Owen, Fullerton et al. 1983).  It would also seem likely that concurrent illness would be 
a factor (Traub Dargatz, Salman et al. 1990). 
The virulence of the bacteria varies greatly even within serotypes.  Disease is 
caused by a combination of toxin production and invasion of the intestinal wall causing 
severe inflammation.  In some cases the intestinal barrier is lost resulting in septicemia 
and endotoxemia (Jones 2004). 
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The diagnosis of Salmonella infection in the diseased or carrier state is 
complicated by the fact that the organisms may be shed intermittently and in very small 
numbers.  It is typically recommended that fecal samples be collected daily for 5 days 
and cultured using a selective enrichment technique.  Culture of a rectal biopsy 
specimen may improve the chances of culturing Salmonella (Palmer, Whitlock et al. 
1985).  More recently PCR techniques have distinguished themselves as the most rapid 
and sensitive test for Salmonella in equine feces (Cohen, Martin et al. 1996).  
1.2.4.2.2.  Clostridium perfringens 
Cl. perfringens is a Gram positive anaerobic bacteria that has been associated with 
enterocolitis in many species (Jones 2000).  Cl. perfringens may be sup-typed on the 
basis of the production of 5 major toxins, alpha, beta, epsilon, iota and Cl. perfringens 
enterotoxin. (CPE).  The production of CPE is most commonly associated with Cl. 
perfringens Type A, although its production has been demonstrated from other types.  
Equine enterocolitis has been mainly associated with Cl. perfringens Type A, although it 
has also been associated with Type C (Jones 2004).  An ELISA test is now available to 
detect CPE in feces to facilitate the diagnosis. 
Large numbers of Clostridium perfringens are not a component of the normal 
fecal flora of the horse.  Wierup and DiPietro (Wierup and DiPetro 1981) found that 
87.5% of normal horses had <10 CFU/g feces.   However, the association of the number 
of Cl. perfringens isolated from the feces and with enterocolitis is less clear.  Wierup 
and DiPietro (Wierup and DiPetro 1981) suggested that quantization of the number of 
Cl. perfringens per gram of feces could be used to predict whether Cl. perfringens was a 
likely etiology of the disease.  However, this association between high numbers of Cl. 
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perfringens and clinical disease has more recently been shown to be very poor (Weese, 
Staempfli et al. 2001).  The key tool for defining the significance of Cl. perfringens in 
equine enterocolitis is the detection of CPE (Weese, Staempfli et al. 2001). 
1.2.4.2.3.  Clostridium difficile  
The discovery that Cl. difficile plays a role in acute equine colitis is relatively 
recent (Jones 2000).  Diarrhea is due to the production of two specific toxins A and B.  
Toxin A causes vasodilation and secretion into the intestines.  This is caused by 
inducing neutrophil influx and activation of neutrophils and mast cells to produce 
vasoactive compounds such as serotonin, histamine and other cytokines.  Involvement 
of the enteric nervous system is also implicated via substance-p.  The role of toxin B is 
less clear (Jones 2004). 
The culture of Cl. difficile from equine feces is not easy.  The organism does not 
survive well in aerobic storage, is particularly fastidious and is easily overgrown, 
requiring specific culture methodologies (Weese, Staempfli et al. 2000).  In addition, not 
all strains of Cl. difficile produce the toxins and identification of the organism is not 
sufficient to confirm the diagnosis.  In human medicine, the diagnosis is now commonly 
made through the use of a fecal ELISA for the toxins.  This same test has been used with 
success in horses (Weese, Staempfli et al. 2000).  The most sensitive test is currently a 
PCR to detect the genes used for toxin production; however, the test may suffer from a 
lack of specificity as it is able to detect exceptionally low numbers of Cl. difficile that 
may not be clinically relevant complicating the interpretation of the results (Weese, 
Staempfli et al. 2000). 
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1.2.4.3. Antimicrobials associated with ADD 
Most classes of antimicrobials have been associated with AAD in the horse at 
some time; although certain classes of antimicrobials most noticeably oxytetracycline 
and the macrolides, are more associated with colitis than the others. 
1.2.4.3.1.  Oxytetracycline 
Oxytetracycline was the first antimicrobial to be reported as being associated with 
the development of colitis in the horse.  The original report (Andersson, Ekman et al. 
1971) is also one of the most detailed investigations to determine the mechanism by 
which the colitis was induced.  In the study, 4 out of 4 adult horses receiving a single 
pre-operative dose of 15g oxytetracycline IV (approximating to 27-40 mg/kg) developed 
profuse diarrhea.  The investigators treated a further 4 horses with oxytetracycline 40 
mg/kg IV and monitored the animals extremely closely to determine the effect of the 
drug on the horses’ health.  All four horses developed severe diarrhea within 3 to 4 days 
of commencing therapy and 3 of the 4 horses died.  It seems likely from the post-
mortem examination that Cl. perfringens was the cause of the disease, but the techniques 
to confirm the diagnosis were not available at the time.  However, the researchers in this 
study used a form of quantitative fecal bacteriology to define the effects of the 
oxytetracycline administration on the normal fecal flora of the horse.  They 
demonstrated that administration of oxytetracycline was associated with a rapid 
overgrowth of fecal coliforms (approximately 100,000 fold increase).  The change in the 
fecal flora occurred within 24 hours and persisted throughout the entire study.  They 
also demonstrated that there was a marked overgrowth of Cl. perfringens.  Cl. 
perfringens was not found in the feces prior to the administration of oxytetracycline.  
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The overgrowth of Cl. perfringens occurred more slowly than the coliforms, reaching a 
peak of approximately 100,000 per gram in 48 hours.  In one horse the Cl. perfringens 
was cleared within 3 days.  In the other horses the numbers persisted throughout the 
study.  They also investigated other possible methods of toxicity (renal, hepatic and 
cardiovascular) and although changes in these systems were noted, it is probable that 
these changes were secondary to the severe colitis, dehydration and electrolyte 
imbalances. 
The publication of Andersson’s (Andersson, Ekman et al. 1971) paper led to a 
flurry of letters in the Veterinary Record describing similar scenarios around the UK.  
Cook (Cook 1973) described clinical cases which were treated with a much lower dose 
of oxytetracycline (approximately 5 mg/kg) used prophylactically for a variety of 
surgeries.  Fatal colitis is described in three horses developing within three days of the 
onset of oxytetracycline therapy.  The authors also described a number of anecdotal 
reports of similar cases associated with either IV or oral treatment with low dose 
oxytetracycline and suggested that stress may be a factor in the development of colitis. 
Baker and Leyland (Baker and Leyland 1973) described 5 further cases treated 
with low dose oxytetracycline either for surgical prophylaxis or prophylaxis for 
respiratory disease.  In all cases, a fatal colitis developed although no etiological 
diagnosis was made.   Finally, Mackellar et al. (MacKellar, Vaughan et al. 1973) 
resported that they had observed similar cases but had minimized the effects by 
prophylactically treating horses with vitamin B preparations. 
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 Baker reviewed these cases and concluded that oxytetracycline should never be 
used prophylactically in horses and should only be used with caution in “exceptional 
cases” (Baker 1975). 
More recently, a herd outbreak of enterocolitis was described associated with a 
feed manufacturing problem in which an equine ration was inadvertently prepared 
containing 10 ppm oxytetracycline (Moore Keir, Stampfli et al. 1999).  Four out of 7 
horses developed diarrhea and one animal died of “colitis X”.  A bacterial etiology for 
the diarrhea was never confirmed.  Salmonella spp. was not isolated from any of the 
horses.  Moderate numbers of Cl. perfringens were cultured from the intestinal contents 
of the animal that died.  The significance of this finding is not known since no assay was 
conducted for clostridial toxins. 
White and Prior (White and Prior 1982) repeated the quantitative fecal 
bacteriology conducted by Andersson et al. (Andersson, Ekman et al. 1971).  The study 
however differed in two important aspects.  Firstly, the oxytetracycline was 
administered orally at a rate of 10 or 40 mg/kg/day.  Secondly, the researches 
investigated the changes in a wider range of fecal bacteria.  Their results were similar to 
those of Andersson et al. (Andersson, Ekman et al. 1971) in that they showed a marked 
increase (10,000 fold) in the number of coliforms isolated from the feces after 
administration of oxytetracycline.  This effect occurred rapidly (with 24 hours) but the 
fecal flora began to return to normal within 4 days despite continued administration of 
the oxytetracycline.  There was a slight dose dependent effect with the higher dose of 
oxytetracycline resulting in higher fecal coliform counts.  The effect of oxytetracycline 
on the fecal streptococci counts was almost identical to that of the coliforms with 
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marked increases in the total number (1000 fold) and a gradual return to normal before 
the cessation of treatment. This effect was also seen with the Bacteroides spp. present in 
the feces.  The effect on Bacteroides spp. counts was less than that seen with the 
coliforms or streptococci and the dose dependent nature of the response was also lost. 
All horses treated with oxytetracycline also developed marked overgrowth of Cl. 
perfringens.  This overgrowth occurred slowly (within 48 hours) and persisted 
throughout treatment.  The number of Cl. perfringens present in the feces after treatment 
was typically 1,000,000 per gram.  All horses receiving oxytetracycline developed 
diarrhea within 24 hours of the first dose.  The horses receiving 10 mg/kg remained 
bright and the fecal consistency normalized before completion of the study.  The horse 
receiving 40 mg/kg also developed diarrhea and became depressed.  This animal 
received only two doses of oxytetracycline before it was withdrawn from the study.  The 
horse recovered fully without further treatment. 
While it may be expected that an orally administered dose of oxytetracycline 
would disrupt the fecal flora as the drug is actually present in the intestines, this did not 
explain the effect of intravenously administered drug.  Horspol and McKellar (Horspool 
and McKellar 1991)  demonstrated that following an intravenous dose of 10 mg/kg 
oxytetracycline, very high concentrations could be detected in the feces.  The amount of 
oxytetracycline found in the feces reached a peak of 5-10 µg/g and the concentrations 
persisted for up to 7 days.  The concentrations of oxytetracycline found in the feces 
exceeded those found in plasma at all time points (Horspool and McKellar 1990).  
While there were minor changes in the consistency of the feces, the dry matter content 
of the feces did not change significantly and none of the animals showed signs of 
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clinical disease.  Oxytetracycline is known to be cleared mainly through the kidneys, but 
there is a component of hepatic excretion and a large amount of the drug undergoes 
enterohepatic circulation (Prescott 2000).  Consequently, it is not surprising that 
relatively large concentrations of oxytetracycline are found in the feces.  
The horses involved in these studies were healthy animals.  Most cases of 
antimicrobial associated diarrhea occur in animals that are sick or stressed for some 
reason, hence the administration of the antimicrobial.  Owen et al. (Owen, Fullerton et 
al. 1983) attempted to define the relative significance of these factors. Fifteen horses 
previously infected with a Salmonella Typhimurium resistant to oxytetracycline were 
exposed to the stresses of surgery and/or transport with or without oxytetracycline 
administration (10 mg/kg IV bid for 5 days).  Unfortunately, there were insufficient 
numbers of animals within the study to separate the relative importance of transport, 
surgery and oxytetracycline administration as risk factors for the development of 
diarrhea.   Eight horses developed diarrhea and 9 horses increased their excretion of 
Salmonella. 
As part of a research project to determine the pharmacokinetics of a long-acting 
oxytetracycline product in horses, Dowling (Dowling and Russell 2000) also 
investigated the effects of the drug on the fecal flora.  Six yearlings were dosed with 
oxytetracycline and daily fecal samples were cultured for Salmonella.  No horses 
developed diarrhea.  One sample on one day was positive for a strain of Salmonella.  
Susceptibility testing showed that the isolate was in fact sensitive to oxytetracycline. 
In conclusion, it is apparent that administration of oxytetracycline by the oral or 
intravenous route to healthy horses has on occasion resulted in severe and occasionally 
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fatal enterocolitis.  While this condition is typically referred to as “colitis “X”, there is 
some evidence to suggest that it may be associated with either Salmonella spp. or 
clostridial infection.  The incidence of this adverse reaction is not known and 
oxytetracycline has also been used in both healthy and sick horses without ill effect 
(Prescott 2000).   
1.2.4.3.2.  β-lactam antibiotics 
The β-lactam antibiotics are among the most widely used antimicrobials in equine 
medicine.  There is some published information linking their use to the development of 
enterocolitis.  In their epidemiological survey, Wilson et al. (Wilson, MacFadden et al. 
1996) found that the administration of penicillin was significantly linked with the 
development of diarrhea in both the case-control and the cohort study.  However, 
anecdotally, little is heard of this association.  More recently an association has been 
made between the administration of crystalline penicillin G preparations and diarrhea.  
This effect is very rapid in onset and is seen most commonly with the potassium salts of 
penicillin G.  The extremely rapid nature of the association implies that this is a direct 
pharmacological effect on intestinal motility rather than an effect influencing the normal 
intestinal fecal flora (Roussel, Hooper et al. 2003).  Based upon what we know of the 
pharmacokinetics of the penicillins and the semisynthetic penicillin drugs, these 
compounds would not be expected to exert much effect on the intestinal bacterial flora.  
The drugs generally have a relatively low volume of distribution due to the fact that they 
are electrically charged and do not easily cross lipid membranes.  They are, therefore, 
largely confined to the extracellular fluid.  As a result the drugs would not be expected 
to penetrate the intestinal mucosa or intestinal contents to any great degree.  The drugs 
58 
are also exclusively cleared by rapid renal filtration and active secretion.  There is little 
or no hepatic clearance and therefore, the drugs cannot enter the intestines through the 
bile.  This is confirmed in a study by Horspool and McKellar (Horspool and McKellar 
1995) in which 3 horses were each treated on two occasions with IV sodium penicillin G 
at 10 mg/kg.  Fecal samples were collected from the rectum and in two horses samples 
of cecal liquor were obtained from canulae.  Penicillin was never found in feces (LOD 
0.07 µg/g).  In one horse on one occasion penicillin was found in the cecal samples 
reaching a peak of 0.6 µg/g.  The penicillin was only detectable during the four hours 
immediately after administration. 
 However, a recent controlled study has demonstrated that administration of 
procaine penicillin G IM can influence the excretion of Cl. difficile (Gustafsson, 
Baverud et al. 2004).  In the study, 10 mature horses were inoculated with an oral Cl. 
difficile broth prepared from a Cl. difficile strain isolated from a clinical case of AAD.  
The broth was administered alone or following three days treatment with procaine 
penicillin 20 mg/kg sid IM.  Fecal samples were collected twice daily for 10 days after 
challenge and any Cl. difficile collected was analyzed for toxin production.  No horses 
developed diarrhea and no horses tested positive for Cl. difficile toxin production.  
Horses treated with penicillin were more likely to excrete Cl. difficile and more likely to 
excrete it for longer periods than untreated animals. 
The cephalosporins, in contrast, although closely related to the penicillins 
possesses some properties that may allow them to more easily disrupt the fecal flora.  
They typically have a wider spectrum of activity and while they are primarily excreted 
through the kidneys, there may be significant hepatic elimination (Prescott 2000).  
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Consequently, the cephalosporins are among the antimicrobials most commonly 
implicated in AAD in humans especially associated with Cl. difficile (Job and Jacobs 
1997). 
Ceftiofur is a broad spectrum cephalosporin that is widely used in equine 
medicine.  There are many anecdotal reports of diarrhea linked to ceftiofur use and Cl. 
difficile is typically implicated although there are no published reports.  There is one 
published study regarding AAD and ceftiofur.  The study consisted of 4 subsets of 
horses.  The first consisted of 30 pairs of recently transported horses with respiratory 
infections treated either with a control or ceftiofur (2.2 mg/kg IM sid).  The second 
group consisted of 16 pairs of animals with the same history treated with either ceftiofur 
as before or with ampicillin 6.6 mg/kg IM bid.  The third group consisted of 18 young 
horses with “strangles” receiving either procaine penicillin G (22,000 IU/kg IM bid) or 
ceftiofur.  The final group consisted of 36 ponies undergoing experimental ventral 
midline laparotomies and treated either with a control or ceftiofur twice daily. 
The results of the first and second group studies were combined and while 
diarrhea was reported as being more prevalent in the ceftiofur treated group the results 
are hard to interpret as the author reports a high prevalence of diarrhea in this group 
prior to the onset of treatment.  No difference was seen in the third group.  Colitis was 
more prevalent in the surgical group treated with ceftiofur.  However, surgery is a 
known risk factor for the development of colitis and no attempts were made during the 
study to identify the etiology of the colitis.  Consequently, the study is of limited value. 
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1.2.4.3.3. Sulfonamides 
 
There are anecdotal reports linking the use of oral or injectable potentiated 
sulfonamides to the development of acute colitis.  However, there are no documented 
case reports.  Furthermore, the only detailed epidemiological study conducted on AAD 
in the horse was primarily designed to look at this association (Wilson, MacFadden et al. 
1996).  No significant association was found. 
White and Prior (White and Prior 1982) compared the effects of  oxytetracycline 
and trimethoprim potentiated sulphadiazine (TMS) on the fecal flora of horses and 
found that TMS had relatively little effect on the fecal flora when compared to the 
effects of the oxytetracycline.  They concluded that TMS was unlikely to have a high 
risk of producing colitis. 
1.2.4.3.4. Fluoroquinolones 
 
The use of fluoroquinolones in the horse is a relatively recent advance and there 
are no licensed products in North America.  Consequently, we have little information on 
any adverse reactions.  There is one documented case series reporting four cases of 
enterocolitis in relatively healthy animals following the administration of ciprofloxacin 
(Weese, Kaese et al. 2002).  The animals were treated following the development of 
mild respiratory infections.  The dose used was 3750 mg sid po (approx 7.5 mg/kg).  In 
all cases the onset of colitis was somewhat delayed several days after the start of 
treatment.  Two horses recovered with intensive therapy; the other 2 were euthanized on 
humane grounds.  An etiological diagnosis was made in only two cases.  One was 
diagnosed with Cl. difficile, and the other with Salmonella Kentucky.   
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1.2.4.3.5.  Florfenicol 
Following the licensing of florfenicol for the treatment of bovine respiratory 
disease there were a number of anecdotal reports of its use in horses and subsequent 
development of colitis (McKellar and Varma 1996).  Dowling (Dowling 2001) 
investigated the pharmacokinetics in horses combined with an assessment of the effects 
on the fecal flora.  Administration of florfenicol resulted in an increase in E. coli and a 
corresponding decrease in streptococci.  There was also an increase in the number of Cl. 
perfringens isolated.  Salmonella spp. was isolated from two samples, Cl. difficile was 
never isolated.  No animals developed diarrhea at any time during the study. 
1.2.4.3.6.  Macrolides and related antimicrobials 
The macrolide antimicrobials have long been associated with AAD in many 
species.  Erythromycin is the antimicrobial most commonly implicated in ADD but 
discussion of the effects of erythromycin is complicated by the fact that this drug has 
recently been shown to have a direct prokinetic effect on the intestinal smooth muscle 
via the motolin receptors (Lester, Merrit et al. 1998; Nieto, Rakestraw et al. 2000; 
Roussel, Hooper et al. 2000).   
The lincosamide antimicrobials have also been implicated as being associated with 
diarrhea (Raisbeck, Holt et al. 1981).  The use of lincomycin coupled with intestinal 
contents from a horse that had died of colitis (later implicated as resembling Cl. 
cadaveris) to reliably reproduce fatal colitis is described (Prescott, Staempfli et al. 
1988).  However, the successful use of lincomycin to treat unresponsive bacterial 
infections without colitis is also reported (Plenderleith 1988). 
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Due to concerns of AAD erythromycin has not been widely used in adult horses.  
However, it has been widely used in foals for the treatment of R. equi pneumonia 
(Lakritz and Wilson 2002).  Diarrhea has been described in foals being treated for 
pneumonia (Stratton-Phelps, Wilson et al. 2000), the relative risk for erythromycin 
being 8.3 (CI 2.6-26.2) compared to foals treated with other antimicrobials.  The 
etiology of the diarrhea was not determined. 
Even treatment of the foal with erythromycin is associated with colitis in the mare 
(Gustafsson, Baverud et al. 1997).  This has led research trying to further understand the 
association between the use of erythromycin and colitis in the horse.         
In the first study, 6 normal adult horses were treated with a low dose of oral 
erythromycin ethylsuccinate (0.125 – 1.25 mg/kg tid) (normal dose 25 mg/kg) and/or a 
low dose of oral rifampicin (0.02 – 0.25 mg/kg bid)(Normal dose 5 
mg/kg)(erythromycin ethylsuccinate is an interesting choice as researchers have 
suggested that its pharmacokinetics in the horse make it a poor choice for therapy 
(Lakritz, Wilson et al. 2002)).  In all cases the drug concentrations in the feces were 
measurable ranging from 1.3 – 8.9 µg/g for erythromycin and 0.2 -0.7 µg/g for rifampin.  
Two of the study horses developed acute diarrhea, one developed loose stool and one 
had reduced feed intake. The effects on fecal flora are reported for only one horse that 
developed diarrhea and indicate an increase in the number of coliforms per gram of 
feces.  Cl. difficile was isolated from two of the study horses (one with diarrhea and one 
with reduced feed intake).  The horse with the loose feces also excreted very high 
numbers of Cl. perfringens. Adverse reactions were seen only in the horses treated with 
erythromycin. The study demonstrates that only very small doses of erythromycin are 
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required to disrupt the normal fecal flora of the horse and that this disruption can be 
associated with clinical disease and the presence of known pathogenic bacteria 
especially Cl. difficile.         
In a second study, a form of case-control study was conducted using 79 mares 
with foals (Baverud, Franklin et al. 1998).  Eleven mares had developed colitis while 
their foals were treated with erythromycin and rifampin.   The mares were compared 
with three groups of controls, including mares with foals treated as above (4), mares 
with foals treated with gentamicin and rifampin (8) and mares with untreated foals (56).  
Five of the clinically affected mares tested positive for Cl. difficile and none of the other 
mares.  The strains of Cl. difficile isolated were resistant to both erythromycin and 
rifampin.  The fecal flora of the affected mares was considered to be within normal 
limits when compared to Wierup’s data (Wierup 1977).  The other factor that all mares 
affected with colitis had in common was that they had all recently visited a veterinary 
facility before the onset of diarrhea.          
It should be noted that acute colitis was never mentioned in any of the 
pharmacokinetic studies conducted in horses using erythromycin or any of the other 
macrolide antimicrobials.  It would seem that only very low doses of oral macrolide 
antimicrobials are required to disrupt the fecal flora of horses.  In susceptible animals 
this disruption can be associated with overgrowth of pathogenic bacteria most notably 
Cl. difficile.                                                                                                                                                    
 The syndrome of AAD in horses is well recognized and it has been discussed at 
great length in an anecdotal manner.  There is, however, very little in the area of 
directed research in this area.  The technique of quantitative fecal bacteriology is very 
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simple and yet it has been rarely used to investigate this syndrome.  Certainly, there 
have been no studies to use the technique proactively as part of the general safety 
assessment of the use of an antimicrobial in horses.  From the literature review it would 
appear that Salmonella spp., Cl. perfringens and Cl. difficile all have the potential to be 
associated with the syndrome of AAD. 
 
1.2.5.  Analytical techniques for tilmicosin 
A large number of publications are available describing many different analytical 
techniques for detecting macrolide residues in biological matrices.  Most of the earlier 
studies used biological assays involving inhibition of bacteria growth (typically 
Micrococcus lutea)(Ziv, Shem-Tov et al. 1995).  The major problem with biological 
assays is the lack of specificity.  Biological matrices may contain a number of 
bactericidal and bacteriostatic compounds and cells which may vary with the immune 
status of the research subject and may be subject to a number of biases.  In addition, 
such biological assays may not distinguish between pro-drug, drug and active 
metabolites seriously complicating any pharmacokinetic analysis.  Lakritz et al (Lakritz, 
Wilson et al. 1999) compared a bioassay with HPLC for erythromycin in horses and 
found a lack of specificity with the bioassay apparently because the bioassay was also 
detecting the metabolite anhydroerythromycin which led to a significant overestimation 
of a number of pharmacokinetic parameters. In light of this finding, it would be prudent 
to avoid bioassays when other techniques are available.  An evaluation of a bioassay for 
tilmicosin has been published (Coleman, Peloso et al. 1995).  The technique is simple 
and easy to perform with a Limit of Detection (LOD) of 50 ng/mL, recovery was 
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estimated as 93.4-97.5% and the coefficient of variation ranged from 0.7-3.1%.  The 
main disadvantage of this assay was its inability to distinguish between tilmicosin and 
tylosin (Moran, Turner et al. 1997).   
HPLC has been the main method for analyzing tilmicosin residues.  Formal 
evaluation and validation of tilmicosin assays is relatively rare.  However, a number of 
researchers have described HPLC techniques to measure tilmicosin concentrations in a 
variety of tissues.  An HPLC technique developed to overcome the disadvantages of the 
bioassay (Moran, Turner et al. 1997), was validated for bovine and porcine serum.  The 
technique simply used a C18 solid phase extraction (SPE) cartridge to clean up the serum 
extract.  The tilmicosin was eluted and dried, resuspended in water, methanol and 
dibutylammonium phosphate buffer, and analyzed by HPLC with UV detection at 280 
nm.  The assay was determined to have an LOD of 50 ng/mL and an LOQ of 
approximately 100 ng/mL.  The relative standard deviation (RSD) ranged from 1.6-2% 
and the recovery ranged from 86-95%.  An identical technique has been used to 
determine tilmicosin residues in bovine and porcine milk (Ngoh 1996).  The only real 
difference is that the milk is centrifuged at -4◦C to remove the fat.  This technique used 
standards from 50 – 200 ng/mL.  The LOD was 13 ng/mL and LOQ 20 ng/mL.  
Recovery ranged from 80-106% and the coefficient of variation was 3-9%.  This 
technique was further refined by (Stobba-Wiley and Readnour 2000) who extracted the 
milk with acetonitrile (ACN) prior to the SPE and used a gradient HPLC system to 
detect the tilmicosin.  This technique improved the sensitivity of the assay with a LOQ 
of 10 ng/mL for bovine milk and 25 ng/mL for ovine milk. 
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 While all these techniques were being described, a fully validated assay for 
tissue (bovine liver and kidney) (Chan, Gerhardt et al. 1994) had already been 
developed.  In this technique, tilmicosin was extracted from the tissue using ACN and a 
phosphate buffer.  The resulting supernatant is collected after centrifugation and cleaned 
up using a C18 SPE cartridge.  Tilmicosin is eluted from the cartridge using ammonium 
acetate, and analyzed with a mobile phase consisting of buffered ammonium formate, 
water, ACN and methanol.  This technique was capable of detecting and separating 
tilmicosin and tylosin.  The recovery was 79.9% for tylosin and 92.6% for tilmicosin.  
The LOD of the assay was calculated as 20 ng/mL for tylosin and 10 ng/mL for 
tilmicosin, coefficients of variation were reported as 2.8-5%.  This technique has since 
been adopted by the CFIA as the standard operating protocol for determining tilmicosin 
and tylosin residues in bovine and porcine liver and kidney (Salisbury 1998).  There are 
no reports of a regular HPLC technique using UV detection for tilmicosin in horse 
tissues. 
 Based upon these studies it is apparent that HPLC assays are robust and have the 
potential to be adapted in different tissue matrices and different species.  They are also 
selective for the macrolide drug and are free of some of the problems associated with 
active metabolites or prodrugs.  The equipment required is relatively accessible and the 
techniques required are easy to learn.   
 
1.3. Hypothesis 
 The basic hypotheses of this thesis are that tilmicosin can be safely and 
effectively used in the horse and that the pharmacokinetics will support this.
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CHAPTER 2 
BACTERIAL ISOLATES FROM EQUINE INFECTIONS IN WESTERN 
CANADA (1998-2003)  
Accepted by the Canadian Veterinary Journal July 2007 
 
2.1. Abstract 
All bacterial samples of equine origin submitted to the diagnostic laboratory at the 
Western College of Veterinary Medicine from January 1998 to December 2003 from 
either “in-clinic” or Field Service cases were accessed (1323 submissions).  The most 
common bacterial isolates from specific presenting signs were identified, along with 
their in vitro antimicrobial susceptibility patterns.  The most common site from which 
significant bacterial isolates were recovered was the respiratory tract, followed by 
wounds.  Streptococcus zooepidemicus was the most common isolate from most 
infections, followed by Escherichia coli.  Antimicrobial resistance was not common in 
the isolates and acquired antimicrobial resistance to multiple drugs was rare. The results 
are compared with previous published studies from other institutions and used to suggest 
appropriate antimicrobial treatments for equine infections in western Canada. 
 
2.2 Introduction 
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 In recent years, there have been important changes in antimicrobial therapy in 
equine practice.  New antimicrobials are available and there is a greater database of 
pharmacokinetic information, allowing for more accurate drug dosing.  Concerns over 
drug residues in food animals and antimicrobial resistance led to the development of the 
Canadian Veterinary Medical Association’s prudent use guidelines(2000); these 
guidelines stress obtaining a diagnosis and selecting appropriate antimicrobial therapy. 
In practice situations, it is often difficult to submit samples for microbiologic culture and 
in vitro antimicrobial susceptibility testing, or it may not be prudent to delay treatment 
until such results are available. Empirical antimicrobial selection has been based on data 
from university teaching hospitals and veterinary diagnostic laboratories from eastern 
Canada, the United States, and Europe (Sweeney, Holcombe et al. 1991; Giguere and 
Sweeney 2000; Marsh and Palmer 2001).  These reviews were from tertiary care 
facilities with caseloads not typical of general practice.  Information from these studies 
may not be applicable to equine cases in western Canada, as differences in antimicrobial 
availability and local disease occurrence(2000) may affect bacterial populations and 
their in vitro antimicrobial susceptibility patterns. The Western College of Veterinary 
Medicine (WCVM) at the University of Saskatchewan has a varied equine caseload that 
includes a large number of 1st opinion cases, so bacterial isolates and their in vitro 
antimicrobial susceptibilities are likely to be similar to cases seen in western Canadian 
practices.  The purpose of this study was to identify the causes of bacterial infections 
and to formulate appropriate antimicrobial therapy guidelines for treating horses in 
western Canada. 
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2.3.  Materials and Methods 
The Prairie Diagnostic Services (PDS) database at WCVM was searched to 
identify all bacteriological submissions of equine origin from the Veterinary Teaching 
Hospital (VTH) between 1st January 1998 and 31st December 2003 (Table 1).  The 
majority of the cases (~75%) were 1st opinion cases from the Saskatoon area.  The 
remainder were referral cases from British Columbia, Alberta, Saskatchewan and 
Manitoba. All submissions were examined individually; submissions that resulted in no 
growth or the growth of nonsignificant organisms were not used in the remainder of the 
study.  The clinical significance of isolated bacteria was based upon the number of 
bacteria grown, the opinion that the veterinary bacteriologist expressed in the 
bacteriology report, and the examination of the medical record by a diplomate of the 
American College of Veterinary Internal Medicine in large animal medicine (Clark).  
Bacterial isolates were categorized according to sampling site (Table 2.1).  In the review 
of the WCVM data, musculoskeletal infections were subdivided into traumatic wounds 
(involving skin, muscle, bone, and synovial structures, both acute and chronic) and 
postprocedural infections associated with either soft tissue or orthopedic procedures.  
Isolates recovered from septicemic foals were considered separately and divided into 2 
categories: those isolated from the umbilicus and those isolated from all other tissues 
and fluids, including blood cultures and joint fluid. 
In vitro antimicrobial susceptibility testing was conducted on significant aerobic 
bacterial isolates (antimicrobial susceptibility testing is not routinely conducted on 
anaerobes by PDS) by using the disk diffusion method of Bauer et al.  
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Sample site 
 
No of 
submissions 
resulting in 
significant 
isolates 
Sample criteria 
Eye 19 Any bacterial sample collected from the 
eye or orbit 
Guttural pouch 38 Guttural pouch washes via endoscope 
Other 161 Samples collected from all other sites 
Pleural fluid 8 Samples from pleurocentesis 
Postprocedural (orthopedic) 12 A nosocomial infection after a veterinary 
procedure involving either bone or a 
synovial structure 
Postprocedural (soft tissue) 29 A nosocomial infection after a veterinary 
procedure involving soft tissues 
Septic foal 14 Samples from neonatal foals (<1 week of 
age) excluding umbilical submissions 
Trachea 195 Any samples from either tracheal wash or 
Broncho-alveolar Lavage (BAL) 
Umbilicus 12 Samples collected from the umbilicus of 
neonatal foals 
Urine 25 Any urine submissions 
Uterine 67 Routine uterine culture from pre-breeding 
examination 
Wound (acute) 16 Any wound <24 h old  
Wound (chronic) 53 Any wound >24 h old 
Total 664  
 
Table 2.1.  Criteria for characterizing bacteriological sample sites.   
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(Bauer, Roberts et al. 1959), according to the standards of the Clinical and Laboratory 
Standards Institute (CLSI, formerly known as NCCLS) (NCCLS 2002). Isolates were 
reported as susceptible to an antimicrobial if the diameter of the zone of inhibition was 
greater than the breakpoint for that drug, according to NCCLS Standard M31-A2 
(NCCLS 2002)(It should be noted that although these standards are widely used they 
have for the most part not been validated for equine pathogens (Papitch – personal 
communication)).   
 
2.3. Results 
 Thirteen hundred and twenty-three equine submissions from clinic cases were 
made to the PDS bacteriology laboratory from 1998-2003. Six hundred and sixty-four 
submissions with 1026 significant bacterial isolates were consistent with bacterial 
infection.  Although most samples were from active clinical cases, 84 of the isolates 
were recovered at post mortem examination. Bacterial isolates were categorized 
according to sampling site (Table 2.2).  Streptococcus equi subspecies zooepidemicus (S. 
zooepidemicus) was the most common isolate from all submission sites, accounting for 
22% (221/1026) of all isolates. This was followed by Escherichia coli (E. coli) 
(82/1026), Actinobacillus suis (69/1026), alpha-hemolytic streptococci (45/1026) and 
Enterobacter spp. (42/1026).  Rhodococcus equi (6/1026) and Salmonella spp. (4/1026) 
were infrequent causes of bacterial infections in horses in western Canada. The in vitro 
antimicrobial susceptibility data for the most common bacterial isolates is presented in 
Table 2.3.  
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Site Number of 
sample 
submissions 
Total 
number 
of  
bacterial 
isolates 
Bacterial isolate Number of 
isolates 
(percentage 
of cases 
with this 
isolate) 
Streptococcus 
zooepidemicus 
79  (40.5%) 
Actinobacillus suis 44   (22.6%)
Actinobacillus equuli 30   (15.4%)
Streptococcus spp. (α-
hem) 
27   (13.8%)
Enterobacter spp. 21   (10.8%)
Escherichia coli  21   (10.8%)
Actinobacillus spp. 14    (7.2%) 
Pseudomonas spp. 11     (5.6%)
Serratia spp. 9       (4.6%)
Staphylococcus aureus 7       (3.6%)
Pseudomonas aeruginosa 7      (3.6%) 
Pasteurella spp. 7      (3.6%) 
Trachea 
 
 
 
195 334 
Other 57 
Streptococcus 
zooepidemicus 
31   (46.3%)
Escherichia coli  12   (17.9%)
Staphylococcus spp. 9     (13.4%)
Enterococcus spp.  5     (7.5%) 
Streptococcus spp. (α-
hem) 
4     (6.0%) 
Uterine 67 87 
Other 26 
Streptococcus 
zooepidemicus 
23  (43.4%) 
Escherichia coli  10  (18.9%) 
Enterococcus spp. 6    (11.3%) 
Actinobacillus suis 5    (9.4%) 
Pasteurella spp. 5    (9.4%) 
Wound 
(chronic) 
53 83 
Other 34 
Streptococcus 
zooepidemicus 
10  (26.3%) 
Actinobacillus suis 7    (18.4%) 
Streptococcus equi 7    (18.4%) 
Enterobacter spp. 5    (13.2%) 
Actinobacillus equuli  5    (13.2%) 
Guttural pouch 38 49 
Other 15    
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Escherichia coli 10  (34.5%) 
Staphylococcus aureus 7    (24.2%) 
Pseudomonas aeruginosa 5    (17.2%) 
Streptococcus 
zooepidemicus 
4    (13.8%) 
Enterobacter spp. 4    (13.8%) 
Enterococcus spp. 4    (13.8%) 
Postprocedural 
(soft tissue) 
29 53 
Other 19 
Escherichia coli  9   (36%) 
Streptococcus spp. (α-
hem) 
5   (20%) 
Enterococcus spp. 5    (20%) 
Urine 25 37 
Other 18 
Streptococcus 
zooepidemicus  
13   (68.4%)
Staphylococcus spp. 3     (15.8%)
Streptococcus spp. (α-
hem) 
2     (10.5%)
Corynebacterium spp. 2     (10.5%)
Eye 19 29 
Other 9      
Streptococcus 
zooepidemicus 
6  (37.5%) 
Enterobacter spp. 3  (18.8%) 
Pseudomonas aeruginosa 2  (12.5%) 
Staphylococcus aureus 2  (12.5%) 
Actinobacillus equuli 2  (12.5%) 
Enterococcus spp. 2  (12.5%) 
Wound (acute) 16 22 
Other 5 
Escherichia coli  5   (35.7%) 
Actinobacillus equuli 3    (21.4%) 
Streptococcus 
zooepidemicus 
2   (14.3%) 
Streptococcus spp. (α-
hem) 
2   (14.3%) 
Septic foal 14 20 
Other 8 
Escherichia coli  6  (50%) 
Streptococcus 
zooepidemicus 
5   (41.7%) 
Clostridium perfringens 4   (33.3%) 
Enterococcus spp. 3    (25%) 
Umbilicus 12 23 
Other 5 
 
 
74 
Streptococcus 
zooepidemicus 
6   (50%) 
Enterococcus spp. 2   (16.7%) 
Postprocedural 
(orthopedic) 
12 17 
Other 9     
Fusobacterium spp. 2  (25%) 
Streptococcus 
zooepidemicus 
2   (25%) 
Streptococcus 
pneumoniae 
2   (25%) 
Pleural fluid 8 15 
Other 9 
 
Table 2.2.  Most common bacterial isolates from anatomical sites. 
The table indicates the most common bacterial isolates subdivided by submission site.  
Column 2 indicates the number of submissions and column 3 the total number of 
significant isolates recovered from the site.  Typically the 5 most common bacteria 
isolated are presented along with the frequency of isolation.  The percentage refers to 
the proportion of cases being positive for that isolate.  
  
 
Isolate 
 
No. 
isolates 
Amp Cef Ceph Enro Gen Neo Pen Tet TMS Ery Co-Am Ami Spec 
Streptococcus 
zooepidemicus 
221 92 99 99 91 85 20 95 59 55 91 87 5 87 
E. coli  82 62 94 50 91 80 61 0 65 62 6 84 100 81 
Actinobacillus suis 69 87 100 99 99 70 30 59 91 96 25 100 38 48 
Streptococcus spp. 
(α-ham) 
45 89 100 100 86 89 53 89 93 75 89 83 55 100 
Actinobacillus equuli 44 91 98 100 100 79 47 67 93 93 39 100 46 40 
Enterobacter spp. 42 37 88 29 98 88 67 3 62 79 7 71 96 56 
Staphylococcus 
aureus 
36 55 97 100 97 100 83 55 97 100 84 94 100 29 
Enterococcus spp. 28 96 29 36 46 75 33 86 64 68 50 100 25 67 
Staphylococcus spp. 29 52 90 97 93 86 93 48 79 86 86 93 100 69 
Streptococcus equi 22 100 100 100 95 95 0 100 92 79 100 100 0 100 
Pseudomonas spp. 25 24 33 16 68 64 47 16 40 52 8 63 100 33 
Pseudomonas 
aeruginosa 
26 0 0 0 30 56 13 0 0 0 0 13 92 7 
Actinobacillus spp. 22 95 95 95 100 73 25 68 91 95 14 91 33 18 
Pasteurella spp. 17 94 100 100 100 100 100 72 100 100 67 100 67 100 
Table 2.3.  Antimicrobial in vitro susceptibility data for the most common bacterial isolates (susceptibility determined using the CLSI 
breakpoints for veterinary pathogens (NCCLS 2002)).  Numbers refer to the percentage of isolates classified as sensitive to the 
appropriate antibiotic. (Amp – Ampicillin, Cef – ceftiofur, Ceph – cephalothin, Enro-enrofloxacin, Neo-neomycin, Pen-penicillin, Tet-
tetracycline, TMS- trimethoprim sulfa, Ery-erythromycin, Co-Am-Co-amoxyclav, Ami-Amikacin, Spec-spectinomycin). 
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The respiratory tract was the most frequently sampled site in the study, with 334 
isolates cultured from 195 transtracheal washes, 65 isolates cultured from 37 nasal 
swabs, and 49 isolates cultured from 38 guttural pouch washes. A few isolates were also 
obtained from cultures of lung and pleural fluid. From all sites the most common isolate 
was S. zooepidemicus (150/334), followed by A. suis (57/334), A. equuli (40/334), and 
alpha-hemolytic streptococci (30/334). Infections from S. equi subsp. equi (S. equi) were 
uncommon, with only 22 isolates identified. The low number of S. equi isolates was 
most likely due to practitioners not submitting samples from obvious cases of 
“strangles.” Opportunistic pathogens, such as Pseudomonas spp., Enterobacter spp., 
Serratia spp., and Staphylococcus aureus were typically cultured from cases with 
advanced respiratory tract lesions, such as chronic pleuropneumonia with abscessation.  
Ninety-five percent of S. zooepidemicus isolates were susceptible to penicillin and 
99% were susceptible to ceftiofur. Of the S. equi isolates, 100% were susceptible to both 
penicillin and ceftiofur; only 55% of S. zooepidemicus and 79% of S. equi isolates were 
susceptible to trimethoprim/sulphonamide (TMS) combinations. Other antimicrobials 
with good in vitro activity against S. zooepidemicus were ampicillin (92%), cephalothin 
(99%), and erythromycin (91%). Only 59% of isolates were susceptible to 
oxytetracycline. For S. equi isolates, 100% were susceptible to ampicillin, cephalothin, 
erythromycin, and ampicillin/sulbactam, while 92% were susceptible to oxytetracycline. 
The 2nd most common site for bacterial culture was the reproductive tract of 
mares, reflecting the large equine theriogenology caseload and routine culturing as part 
of the pre-breeding examination. A total of 87 isolates were cultured from 67 uterine 
samples. A further 15 isolates were collected from 11 mares that had recently aborted.  
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The majority of isolates were S. zooepidemicus (31/87). The next most common isolate 
was E. coli (12/87). Pseudomonas spp. were cultured from 2 mares. 
From horses with urinary tract infections, 25 cultures grew 37 isolates and the 
most common pathogen isolated was E. coli (9/37), followed by alpha streptococci 
(5/37) and Enterococcus spp. (5/37). Submissions represent both free catch samples and 
samples collected by catheterization. Pseudomonas spp., Enterococcus spp. or 
Enterobacter spp. were found in 25% of submissions and were resistant to most 
antimicrobials. The remaining isolates were a mixture of gram-positive and gram-
negative bacteria. 
Traumatic wounds involved skin, muscle, bone, and synovial structures.  
Streptococcus zooepidemicus predominated in both acute (6/23) and chronic wounds 
(23/83).  Chronic wounds were more likely to be a mixed infection (83 isolates from 53 
submissions), with a greater variety of bacteria. 
Orthopedic infections occurred after fracture fixation, arthroscopy, arthrocentesis, 
and joint injections.  Mixed infections were less common (17 isolates from 12 cases), 
and half of all animals were affected by S. zooepidemicus (6/12). 
Twenty-nine isolates were cultured from 19 eyes with infectious keratitis. The 
majority of infections were due to S. zooepidemicus (13/29). The other isolates were 
alpha hemolytic streptococci, Staphylococcus spp., and Corynebacterium spp. 
Bacterial isolates from septic foals were divided into 2 categories: isolates from 
the umbilicus and isolates from all other tissues and fluids, including blood cultures and 
joint fluid.  Isolates from the latter category were mainly E. coli (5/20 isolates), similar 
to previous reports (Marsh and Palmer 2001).  Bacterial isolates from the umbilicus 
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were similar to other foal isolates, except that mixed infections were more common (23 
isolates from 12 cases); Clostridium perfringens was also isolated.   
2.5.  Discussion 
2.5.1.  Bacterial submissions 
 The usefulness of a review of clinical material depends on the quality of the 
available data.  In this study, all bacterial isolates of equine origin from WCVM cases 
were evaluated.  However, samples were not submitted from all cases. The decision to 
submit a sample for bacterial culture rested with the attending veterinarian and the 
samples submitted were probably biased towards the more unusual, more complex, or 
cases that had been treated and failed to respond to treatment.  However, this bias may 
have been reduced because clinicians at a teaching institution are more likely to perform 
routine bacterial cultures than are veterinarians at a private practice.   
 
2.5.2.  Antimicrobial susceptibility 
  Diagnostic laboratories routinely perform in vitro antimicrobial 
susceptibility testing on clinical isolates, and veterinarians use the results to guide 
antimicrobial therapy. Many laboratories use the disk diffusion method to determine 
bacterial susceptibility to various antimicrobials, even though the breakpoints for 
susceptibility or resistance have been validated only for ampicillin, ceftiofur, and 
gentamicin in the horse and only ceftiofur has clinical data to support the 
recommendations (M. Papich, personal communication).  The difficulties of applying 
laboratory susceptibility data to the clinical situation have been well described (Walker 
2000), so susceptibility test results should only be considered as a guide to choosing 
appropriate antimicrobial therapy, not as a guarantee of efficacy. The in vitro 
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antimicrobial susceptibility data presented in Table 3 differ from previously published 
data from horses (Giguere and Sweeney 2000).  Antimicrobial resistance was not an 
apparent problem in the WCVM isolates, probably reflecting the large proportion of 1st 
opinion cases seen at this facility. The in vitro susceptibility rates of S.  zooepidemicus to 
TMS combinations were much lower in the WCVM isolates than in those reported from 
veterinary teaching hospitals in other countries (Moore, Schneider et al. 1992; Marsh 
and Palmer 2001; Wilson 2001). The availability of TMS products suitable for use in 
horses varies among countries. With the availability of injectable formulations and 
convenient oral formulations, TMS is frequently administered to horses in western 
Canada for treatment of respiratory disease and other infections. Such frequent use may 
be selecting for TMS resistant populations. A recent study by Feary et al. (Feary, Hyatt 
et al. 2005) described a similar rate of TMS resistance in equine isolates of S. 
zooepidemicus. However, a false rate of resistance may be reported if disk diffusion is 
not conducted according to the exact CLSI standards.  The PDS laboratory in Saskatoon 
follows the CLSI standards for determining susceptibility to TMS,  including the 
running of appropriate quality controls, so the errors described by Feary et al. (Feary, 
Hyatt et al. 2005) were avoided.  Even if culture and sensitivity results indicate efficacy, 
the correlation with clinical efficacy is poor.  Ensink et al. (Ensink, Bosch et al. 2005) 
demonstrated in a clinical study that even prophylactic administration of appropriate 
doses of trimethoprim/sulfadiazine did not prevent infection and abscess formation when 
S. zooepidemicus was inoculated into tissue cages placed in the neck muscle of ponies.  
Only 5% of S. zooepidemicus isolates were susceptible to amikacin.  This finding is 
clinically important, due to frequent recommendations for amikacin in the treatment of 
equine musculoskeletal infections (Moore, Schneider et al. 1992),  especially in regional 
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perfusion treatment protocols (Scheuch, Van Hoogmoed et al. 2002).  For the western 
Canadian caseload with a high frequency of S. zooepidemicus musculoskeletal 
infections, gentamicin is a more appropriate first choice aminoglycoside.  The 
pharmacodynamics of gentamicin are similar to those of amikacin (both are 
concentration dependent antimicrobials and work well for regional perfusion), but 
gentamicin has a broader spectrum of activity than amikacin, with good activity against 
S. zooepidemicus.  Amikacin should be reserved for cases where bacterial culture 
confirms the presence of organisms such as Pseudomonas aeruginosa or S.  aureus 
which are resistant to the more commonly used antimicrobials.  The in vitro 
susceptibility profile of the S. aureus isolates in this study is different compared with 
that in other surveys, in particular antimicrobial resistance is less prevalent (Giguere and 
Sweeney 2000). The antimicrobial susceptibility profiles for E. coli are similar to those 
described previously (Giguere and Sweeney 2000).  The only truly multidrug resistant 
bacterial species that are isolated in any frequency are Pseudomonas aeruginosa and 
Enterococcus spp. These pathogens are typically resistant to many routinely used 
antimicrobials. Such susceptibility profiles are similar to those described previously 
(Giguere and Sweeney 2000), as multiple antimicrobial resistance in these bacterial 
species is both inherent and easily acquired (Tsukayama, Van Loon et al. 2004). 
 
2.5.3.  Bacterial etiology of infection in horses 
At the WCVM, bacterial infections were most commonly caused by organisms 
considered to be commensals of horses. These data are very different to those from 
United States teaching hospitals with tertiary care caseloads, where staphylococci and 
gram-negative pathogens are the most common isolates from equine infections (Moore, 
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Schneider et al. 1992; Marsh and Palmer 2001; Wilson 2001). At the WCVM, infections 
caused by opportunistic pathogens, such as S. aureus and Pseudomonas spp., were 
uncommon and typically associated with severe lesions; their antimicrobial 
susceptibility patterns are suggestive of previous antimicrobial use.  
2.5.3.1. Respiratory tract infection 
The role of S. zooepidemicus and S. equi in equine respiratory tract infections has 
been well documented (Sweeney, Holcombe et al. 1991; Hoffman, Viel et al. 1993; 
Lavoie, Fiset et al. 1994; Oikawa, Kamada et al. 1994; Dixon, Railton et al. 1995; 
Burrell, Wood et al. 1996; Christley, Hodgson et al. 2001).  Streptococcus 
zooepidemicus is considered to be a normal flora of the upper respiratory tract that 
becomes problematic when it invades the lower respiratory tract.  Besides its association 
with “strangles,” S.  equi is known to cause persistent, asymptomatic guttural pouch 
infection (Woolcock 1975; Newton, Wood et al. 1997), although other bacteria may also 
colonize the guttural pouch (Judy, Chaffin et al. 1999).     
Penicillin, ceftiofur, and TMS are the usual 1st line treatment choices for 
streptococcal infections in horses (Wilson 2001).  The results of the WCVM study 
support the use of penicillin and ceftiofur for treatment of bacterial sinusitis and guttural 
pouch infections, since there was a high degree of in vitro susceptibility (> 90%) to these 
antimicrobials; but they suggest that TMS should only be used with appropriate culture 
and sensitivity results. 
Pneumonia and pleuropneumonia are often polymicrobic in horses, with the lower 
respiratory tract being initially colonized by S. zooepidemicus, followed by gram-
negative and anaerobic pathogens (Sweeney, Holcombe et al. 1991).  The gram-negative 
bacteria A. suis and A. equuli were the most common isolates from pneumonia and 
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pleuropneumonia cases after S. zooepidemicus. This is in contrast to a previous study 
that found that E coli and Pasteurella spp. were the most common gram-negative 
isolates (Sweeney, Holcombe et al. 1991).  Anaerobes are likely to be present in those 
cases with a putrid breath odor, although lack of a putrid odor does not rule out the 
possibility of an anaerobic infection (Sweeney, Divers et al. 1985).  In the WCVM study, 
only 9 anaerobes were isolated from transtracheal washes and they tended to be from 
cases with advanced disease. More virulent pathogens, such as Pseudomonas spp., 
Serratia spp., and S. aureus, were isolated from chronic cases with severe lesions. 
Enrofloxacin or gentamicin showed the greatest activity against the respiratory 
pathogens isolated at the WCVM; however, neither drug is efficacious against obligate 
anaerobes, and the susceptibility of Pseudomonas spp. and Klebsiella spp. was variable 
to both drugs.  Mycoplasma spp. appear to be  opportunistic pathogens in equine 
respiratory tract infections (Wood, Chanter et al. 1997).  Mycoplasma spp. were isolated 
from 6 horses with respiratory disease and in all cases were part of chronic, mixed 
infections. Isolates from pleural fluid were submitted only from severe cases of 
pleuropneumonia and were most often mixed infections.  The bacterial populations 
isolated were similar to those previously described (Raphel Sweeny, Divers et al. 1985; 
Sweeney, Holcombe et al. 1991), except that  anaerobes were not isolated as frequently.   
 From the WCVM data, the most logical treatment choice for bacterial pneumonia 
or pleuropneumonia is a combination of penicillin, ampicillin, or ceftiofur with 
gentamicin or enrofloxacin. The use of gentamicin or enrofloxacin for respiratory 
infections in horses is extralabel, but it is consistent with prudent use guidelines in that it 
is based on culture and sensitivity testing. Practitioners should be familiar with the 
potential for adverse effects from either of these drugs and client consent should be 
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obtained before initiating treatment (Wilson 2001). Antimicrobial therapy targeted 
against anaerobes improves survival rates of horses with pleuropneumonia (Sweeney, 
Divers et al. 1985). Although the β-lactam antimicrobials are highly effective against 
most anaerobes, resistance by betalactamase-producing Bacteroides fragilis has been 
documented (Sweeney, Holcombe et al. 1991). Oral metronidazole can be added to β-
lactam therapy, as it is inexpensive and has excellent activity against all anaerobes, 
including B. fragilis, and good tissue distribution characteristics.  While the WCVM data 
can guide practitioners in choosing initial therapy of respiratory tract infections, due to 
the frequency of mixed infections and variable susceptibilities of gram-negative isolates, 
culture and susceptibility testing from a transtracheal wash or pleural fluid sample 
should always be conducted. Follow-up sampling should be considered, as bacterial 
populations and susceptibility patterns may shift as the disease progresses. 
2.5.3.2.  Reproductive tract infections 
 Except for the low prevalence of Pseudomonas spp., the culture results agreed 
with those of previous studies from other teaching hospitals (Hinrichs, Cummings et al. 
1988; McCue, Hughes et al. 1991).  The majority of reproductive tract infections are 
limited to the mucosa and superficial endometrium; therefore, intrauterine therapy is the 
preferred method of treatment (Perkins 1999).  Systemic therapy should be limited to 
cases of postpartum metritis where the mare shows systemic illness or where a uterine 
biopsy suggests deep inflammation and infection. Currently, treatment regimens 
(including drug, dose, frequency, and method of infusion) for endometritis in the mare 
are based more on convenience and practicality than on scientific evidence (Perkins 
1999).  In Canada, only gentamicin and amikacin are approved for intrauterine use in 
mares with endometritis. Based on the results from the WCVM study, gentamicin is the 
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first choice for intrauterine treatment of endometritis. Since only 5% of S. 
zooepidemicus isolates showed in vitro susceptibility to amikacin, its use should be 
reserved for gram-negative isolates with documented resistance to gentamicin 
2.5.3.3.  Urinary tract infections 
Infection of the urinary tract in horses typically occurs as an ascending infection 
from skin and gastrointestinal flora (Wilson 2001).  Previous reports of bacterial isolates 
of urinary origin demonstrate similar results to those presented here (MacLeay and Kohn 
1998). Disk diffusion susceptibility breakpoints are based on achievable plasma 
concentrations, but most antimicrobials are eliminated in high concentrations in the 
urine. Therefore, in vitro susceptibility results do not always predict therapeutic efficacy 
for bacterial cystitis, as drugs reported as “resistant” may be clinically effective. From 
the WCVM data, ceftiofur is appropriate for initial therapy, due to its activity against E. 
coli and streptococci, but gentamicin or enrofloxacin may be necessary for treatment of 
Pseudomonas spp. or Enterobacter spp. infections, and ampicillin is the best choice for 
enterococcal infections.   
2.5.3.4.  Wounds 
Bacterial isolates from musculoskeletal infections have been extensively reviewed 
(Moore, Schneider et al. 1992; Schneider, Bramlage et al. 1992; Butt, Bailey et al. 
2001), but  all forms of musculoskeletal infection (septic arthritis, iatrogenic infections, 
and neonatal septicemia) were grouped together, regardless of the etiology . 
Consequently, the most commonly isolated bacteria were Enterobacteriacae, non-β-
hemolytic streptococci, and coagulase negative staphylococci.  Due to the inclusion of 
septic foals and iatrogenic infections, there was a high rate of antimicrobial resistance in 
these studies. From these data, the combination of a cephalosporin and amikacin became 
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the standard recommended antimicrobial therapy for all musculoskeletal infections 
(Moore, Schneider et al. 1992).   
Bacterial isolates from acute wounds must be cautiously interpreted as they may 
represent environmental contamination rather than active infection.  The distinction 
between contamination and colonization is not absolute and must be based on the type of 
bacterium, history of the wound, and number of bacteria isolated.  As infections become 
established, the bacterial populations may change. Streptococcus zooepidemicus and 
Enterococcus spp. were the only bacteria found in both categories. 
 Based on the data in Table 2 when a traumatic open wound that is either 
contaminated or infected or likely to become infected is treated, the chosen antimicrobial 
must be active against S. zooepidemicus.  Since mixed infections are common (Table 2), 
a broad spectrum antimicrobial, such as ampicillin or ceftiofur, may be indicated while 
awaiting the results of bacterial culture (Table 3). Although the WCVM results support 
the in vitro efficacy of amikacin against S. aureus and Pseudomonas spp. isolates (100% 
susceptible), its in vitro activity against other common isolates was poor. Very few S. 
zooepidemicus bacteria were susceptible to amikacin (5%). Although gentamicin was 
deemed poorly effective for musculoskeletal infections in a previous study (Moore, 
Schneider et al. 1992), it was highly active  (> 90% in vitro susceptibility) against the 
pathogens from the WCVM cases and is considerably less expensive than amikacin. 
Ceftiofur is also an appropriate antimicrobial choice for WCVM pathogens, except for 
poor activity against enterococcal infections (29% in vitro susceptibility).  
2.5.3.5.  Post-procedural infections 
Iatrogenic infections differed between those involving soft tissue and orthopedic 
procedures.  The majority of soft tissue infections were suture line infections.  Most 
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occurred following laparotomy and were likely related to anesthetic recovery in a 
“recovery room” that was wet and contaminated by fecal material. Surgical 
contamination appeared unlikely as peritonitis was not a feature of these cases.  
Consequently, E. coli predominated (10/53) and mixed infections were common (53 
isolates from 29 submissions).  Unlike in traumatic wound infections, S. aureus was 
relatively common (7/53 isolates) in iatrogenic infections.  Staphylococcus aureus can 
be isolated from normal equine skin lesions (Shimozawa, Anzai et al. 1997); however, 
the specific association with iatrogenic wounds in this study raises the question as to 
whether humans represent a potential source of infection.  Conversely, Pseudomonas 
aeruginosa (5/53) is often an environmental opportunist with inherent antimicrobial 
resistance mechanisms.  The routine use of certain antimicrobials may directly select for 
infections caused by this bacterium. (Hariharan, McPhee et al. 1995) . 
The antimicrobial susceptibility patterns of the gram-negative isolates were highly 
variable; however, the S. aureus isolates were routinely susceptible to cephalosporins, 
enrofloxacin, aminoglycosides, tetracycline, and TMS.  The frequency of S. 
zooepidemicus isolates and the lack of multidrug resistant strains of S. aureus suggest 
that these infections result from contamination with cutaneous flora, in contrast to the 
multiresistant strains associated with environmentally acquired infections reported from 
other equine hospitals (Traub-Dargatz, George et al. 2002).  
The data from the WCVM cases indicate that a β-lactam antimicrobial is the 
treatment of choice for prophylaxis of orthopedic infections and that gentamicin is a 
better choice for soft tissue infections. These recommendations are appropriate for initial 
treatment; however, culture and susceptibility testing is mandatory for postsurgical 
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infections in order to select appropriate antimicrobial therapy and to identify emerging 
nosocomial problems. 
2.5.3.6.  Bacterial keratitis 
The large number of S. zooepidemicus isolates differs from a previous report of 63 
cases of infectious keratitis in horses, where 58% of cultured isolates were gram-positive 
organisms and 48% were gram-negative, with nearly 50% of the gram-negative isolates 
being Pseudomonas spp. (Moore, Collins et al. 1995)  Due to the consequences of 
nonresponsive or inadequately treated corneal infections in horses, it is reasonable to 
initiate treatment with broad spectrum antimicrobial therapy effective against 
staphylococci and pseudomonads (Moore, Collins et al. 1995).  Gentamicin or triple 
antibiotic preparations are good initial choices. Triple antibiotic contains neomycin, 
bacitracin, and polymixin. Neomycin has good activity against Staphylococcus spp. and 
gram-negative bacteria. Polymixin B is rapidly bactericidal against gram-negative 
bacteria; including Pseudomonas spp. Polymixin B also binds and inactivates endotoxin, 
reducing inflammation and tissue destruction.  Due to systemic toxicity, polymixin B is 
only used topically, typically it is not included on susceptibility reports from 
microbiology services. However, P. aeruginosa veterinary isolates are routinely 
susceptible to polymixin B (Hariharan, McPhee et al. 1995).  Like polymixin B, 
bacitracin is a topical product not routinely included on susceptibility reports. Bacitracin 
is active against gram-positive bacteria, with a mechanism of action similar to that of the 
ß-lactam antibiotics. Penicillins and cephalosporins are not used as commercial 
ophthalmic formulations, because of the risk of contact sensitization, so bacitracin is 
their equivalent (Dowling 2006).  Human ophthalmic formulations of tobramycin and 
ciprofloxacin are available for the treatment of resistant Pseudomonas infections. 
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2.5.3.7.  Neonatal Sepsis 
Escherichia coli was the most common isolate from foals.  However, recent reports 
of sepsis in humans indicate the reemergence of gram-positive bacteria, such as 
Enterobacter spp. and Enterococcus spp., as the major causes of systemic sepsis coupled 
with  resistance to multiple antimicrobials (Tanowitz and Chan 2000).  This trend was 
also documented in a study of critically ill neonatal foals from Pennsylvania (Marsh and 
Palmer 2001); however, we found no evidence of this trend in our small sample of foals 
from western Canada. 
The mixed bacterial isolates recovered from the foals’ navels probably indicate 
environmental contamination of the umbilical remnant.  A previous report of umbilical 
infection in foals isolated bacteria from only 4 of 16 cases (Adams and Fessler 1987). 
Escherichia coli, Streptococcus spp., and Proteus spp. were the only organisms isolated 
in that study.  Data from the WCVM isolates emphasize the need for culture and 
susceptibility testing of samples from septic neonates, but the majority of foal bacterial 
isolates were susceptible to ceftiofur.  
 
2.6.  Conclusion 
There has been much discussion about the importance and scale of antimicrobial 
resistance in veterinary medicine (Apley, Brown et al. 1998).  The results of this survey 
indicate that while there are a few specific instances of acquired antimicrobial resistance, 
it is uncommon in bacteria of equine origin in western Canada. Procaine penicillin G and 
gentamicin still appear efficacious for most equine infections, but the results presented 
here suggest that S. zooepidemicus has developed resistance to TMS.  Potent, narrow 
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spectrum antimicrobials, such as amikacin, should be reserved for those cases in which 
their need has been confirmed by bacterial culture and susceptibility testing.   
Computerization has made database review practical and such reviews need to be 
conducted periodically, as pathogenic organisms and their in vitro antimicrobial 
susceptibilities may change with time or treatment.  Practitioners can use this 
information to select appropriate initial antimicrobial therapy. Final selection of the 
optimal antimicrobial must also consider other factors, such as the site of infection, 
pharmacokinetics of the drug, risks of adverse side effects, cost of therapy, and effect of 
underlying diseases. 
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CHAPTER 3 
DEVELOPMENT AND VALIDATION OF A METHOD FOR 
DETERMINATION OF TILMICOSIN RESIDUES IN EQUINE PLASMA AND 
TISSUES USING HPLC 
 
Prepared for submission to Journal of Liquid Chromatography and Related 
Technologies 
 
3.1 Abstract 
A sensitive liquid chromatographic method with UV detection has been developed 
for the analysis of tilmicosin concentrations in equine tissues and biological fluids.  
Tilmicosin is extracted from tissues using acetonitrile and a phosphate buffer.  The 
extract is centrifuged, filtered and cleaned up on a conditioned C18 solid phase extraction 
cartridge.  Tilmicosin is eluted with ammonium acetate in methanol (8 mg/mL) and 
diluted with (0.1M) ammonium acetate.  It was analyzed by reversed phase liquid 
chromatography with UV detection at 287 nm.  The method was shown to be effective 
for detecting tilmicosin in plasma, muscle, liver, kidney and lung.  The LOD was 24 
ng/mL in plasma and 381 ng/g in lung.  The assay was used to determine the 
pharmacokinetics of tilmicosin in horses. 
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3.2. Introduction 
 Tilmicosin is a macrolide antibiotic formed from a chemical modification of 
tylosin.  Micotil (Elanco Animal Health, Guelph, ON) is licensed for subcutaneous 
injection for the treatment of respiratory disease in sheep and cattle and is used 
extensively in North American feedlots. Pulmotil (Elanco Animal Health, Guelph, ON) 
is licensed as a feed additive for the prevention and control of respiratory disease in 
swine.  Tilmicosin has been tested and used in various other species including rabbits 
and poultry (McKay, Morck et al. 1996; Charleston 1998) and is licensed for use in 
these species in Europe.  Tilmicosin is efficacious for the treatment of respiratory 
disease due to its accumulation in pulmonary tissues, its long elimination half-life, and 
antimicrobial spectrum of activity that includes most Gram-positive aerobes, Gram-
negatives associated with respiratory disease, some anaerobes and Mycoplasma spp. 
(Prescott 2000). With these characteristics, tilmicosin would be ideal for treatment of 
equine bacterial respiratory infections. 
 Experimental study of the use of tilmicosin in horses requires that the 
concentration in plasma be determined in order to determine the plasma 
pharmacokinetics.  Since tilmicosin has a large volume of distribution and is known to 
selectively accumulate in tissues, especially the lung, it is also necessary to determine 
the concentration of tilmicosin in other tissues.  The concentration of tilmicosin in these 
tissues could be used to determine potential dosing regimens as well as estimations of 
withdrawal intervals since the horse is used as a food animal in some countries. 
 An HPLC method for measuring tilmicosin residues in animal tissues has been 
described for bovine and porcine kidney, liver and muscle (Chan, Gerhardt et al. 1994) 
but there has been no technique described for equine plasma, serum or tissues. 
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 This paper describes the analytical method that was adapted from the method of 
Chan et al. (Chan, Gerhardt et al. 1994) and validated for the determination of tilmicosin 
residues in equine plasma, lung, liver, kidney and muscle tissues. 
 
3.3.  Materials and methods 
3.3.1.  Apparatus 
 Solid phase extraction (SPE) cartridges, C18 500 mg (6 mL capacity) were 
obtained from Varian (Harbor City, CA). 
 
3.3.2.  HPLC System 
 Analysis was conducted using a Waters 590 pump, Waters 490 Programmable 
Detector set at 287 nm, and a Waters 712 WISP Autosampler.  The liquid 
chromatography (LC) column, was an Inertsil ODS-2, 5μm, 150 x 4.6mm column 
(Lablink inc. Rockford, IL) with a guard column, Inertsil ODS-2, 5 μm, 4.0 x 10 mm 
(Lablink inc. Rockford, IL). Separation was achieved under isocratic conditions with the 
mobile phase at room temperature and a flow rate of 1 mL/ min. 
 
3.3.3.  Reagents 
 All solvents used in this study including acetonitrile and methanol were of HPLC 
grade obtained from VWR Canlab (Mississauga, ON).  Ammonium acetate, ammonium 
formate, ortho-phosphoric acid Sodium phosphate and trifluroacetic acid were of reagent 
grade and were also obtained from VWR Canlab (Mississauga, ON).  The tilmicosin 
standard was generously provided by Elanco Animal Health (Guelph, ON).  The tylosin 
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tartrate standard was obtained from Sigma-Aldrich (Oakville, ON).  Water was obtained 
from a reverse osmosis still. 
 A 0.2 M ammonium formate solution (pH 5.0) was prepared by dissolving 12.62 
g ammonium acetate in approximately 800 mL water and adjusting the pH to 5.0 with 
trifluroacetic acid.  It was mixed and made up to volume with water in a 1000 mL 
volumetric flask.  
 Elution solution for eluting adsorbed tilmicosin and tylosin from the C18 SPE 
cartridge was prepared by dissolving 0.771g ammonium acetate in approximately 80 mL 
methanol and making it up to volume with methanol in a 100 mL volumetric flask.  A 
0.1 M ammonium acetate solution was prepared in the same way using water instead of 
methanol. 
 A 0.1 M phosphate buffer (pH 2.5) was prepared by dissolving 6.90g monobasic 
sodium phosphate in approximately 400 mL water.  The pH was adjusted to 2.5 with 
ortho-phosphporic acid.  The solution was mixed and made up to volume in a 500 mL 
volumetric flask. 
 The mobile phase was prepared by mixing 0.2 M ammonium formate solution 
(pH 5.0), water, methanol and acetonitrile.  The exact composition was varied according 
to the tissue being analyzed. 
 
3.3.4.  Preparation of standard solutions 
 Stock standard solutions of tilmicosin (TIL) and tylosin (TYL) (1 mg/µl) were 
prepared by dissolving 113.1 mg tilmicosin (88.4% purity) or 113.3 mg tylosin tartrate 
(88.3% purity) in 80 mL methanol.  The solution was thoroughly mixed and brought up 
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to volume in a 100 mL volumetric flask.  The stock solutions were stored at -20˚C and 
new solutions prepared every 6 months. 
 Working standard solutions were prepared from the stock solutions by using the 
appropriate dilution with methanol.  For tilmicosin the working standards consisted of 5 
(TIL 5) and 50 µg/mL (TIL 50), for tylosin they consisted of 50 (TYL 50) and 100 
µg/mL (TYL 100).  Working standards were also stored at -20˚C and replaced each time 
a new stock standard was prepared.   
  
3.3.5.  Sample Preparation 
 The method of sample preparation varied slightly depending on the tissue of 
interest.  The concentrations of tilmicosin used in the standard curve reflect the 
concentrations of tilmicosin found in the tissue following administration of a 10 mg/kg 
intramuscular dose (Clark, Dowling et al. 2008(6)).  Portions (5 ±0.05 mL plasma, 5 
±0.05 g Muscle, 2.5 ±0.05 g liver, lung, kidney) of thawed test sample were accurately 
measured into individual 50 mL polypropylene centrifuge tubes (tissues were finely 
diced).  Four other tubes were prepared containing drug free tissue samples.  The 
quantities of tilmicosin added to each sample and the amount of tylosin (internal 
standard) added to prepare matrix fortified calibration standards are shown in Table 3.1 
(the concentration of the internal standard was typically higher that the tilmicosin 
standard since the tylosin response from the detector array is much lower than that of 
tilmicosin). 
Samples were allowed to sit for 15 minutes.  Each plasma test sample or fortified 
control plasma was mixed with 20 mL Acetonitrile and 5 mL of 0.1 M Phosphate buffer 
(pH 2.5), the solution was then vortexed for 1 minute.  The extraction procedure for the  
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Tissue 
matrix 
Standard 1 Standard 2 Standard 3 Standard 4 Tylosin  
Internal 
standard 
 Volume 
added  
(µL) 
Final 
Conc.  
ng/g 
Volume 
added  
(µL) 
Final 
Conc 
ng/g 
Volume 
added  
(µL) 
Final 
Conc 
ng/g 
Volume 
added  
(µL) 
Final 
Conc 
ng/g 
Volume 
added  
(µL) 
Final 
Conc 
ng/g 
Plasma 
5 mL 
40   
TIL 5 
40 15   
TIL 50 
150 25  
TIL 50 
250 50  
TIL 50 
500 50  
TYL 50 
500 
Lung 
2.5 g 
25 
TIL 50 
500 50 
TIL 50 
1000 100 
TIL 50 
2000 150 
TIL 50 
3000 200 
TYL 
100 
8000 
Liver 
2.5 g 
25 
TIL 50 
500 50 
TIL 50 
1000 100 
TIL 50 
2000 150 
TIL 50 
3000 200 
TYL 
100 
8000 
Muscle 
5 g 
25 
TIL 50 
250 50 
TIL 50 
500 100 
TIL 50 
1000 150 
TIL 50 
1500 200 
TYL 50 
4000 
Kidney 
2.5 g 
25 
TIL 50 
500 50 
TIL 50 
1000 100 
TIL 50 
2000 150 
TIL 50 
3000 200 
TYL 
100 
8000 
 
Table 3.1.  Details of standard curve preparation for the 5 tissue matrices.  
Tilmicosin (TIL) Tylosin (TYL) numbers refer to the concentration (µg/mL). 
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tissues was slightly different.  10 mL of acetonitrile was added to the polypropylene 
centrifuge tube and the tissue was homogenized (Polytron Model PT 10-35 (Brinkman 
Instruments Ltd., Rexdale, Ont)) at high speed for 20 seconds.  The probe was rinsed 
with 2 x 2 mL aliquots of acetonitrile into the sample tube.  The solutions were placed 
on a benchtop shaker for 5 minutes and then centrifuged at 200 g for 5 minutes.  The 
supernatant was decanted and collected in a clean labeled centrifuge tube.  The tissue 
plug was re-suspended in 10 mL acetonitrile and 5 mL of phosphate buffer, vortexed and 
placed on the bench top shaker at high speed for a further 5 minutes.  This solution was 
then centrifuged at 2250 g for 5 minutes and the supernatant from this extraction 
combined with the first supernatant. 
For all tissue matrices the resulting extracts were centrifuged at 2000 g for 5 
minutes after which they were filtered through a Whatman GF/B, 5.5 cm filter paper, 
and diluted with approximately 70 mL of water. 
 The SPE cartridges were conditioned by washing with 10 mL methanol followed 
by 10 mL water (it is important that the columns not be allowed to dry out after this 
point).  The extracted solutions were loaded onto the columns and allowed to drain 
under gravity.  The columns were then washed with 20 mL water.  The columns were 
dried for 5 minutes under a vacuum of 20 mm/Hg.  The compounds were eluted from the 
column using 2 x 750 µL of the elution solution into a 2 mL volumetric tube.  The 
volume of the eluent was brought up to 2 mL using 0.1 M ammonium acetate.   
 The final solution was prepared for HPLC analysis by mixing and filtering 
through an Acrodisc syringe filter, 0.45 µm.  The HPLC setting for the different 
matrices are shown in Table 3.2.   
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Tissue matrix Mobile phase 
(0.2 M ammonium formate 
(pH 5), water, acetonitrile, 
methanol) 
Injection 
volume (µl) 
AUFS 
Plasma 20:32:24:24 50 0.01 
Muscle 20:32:24:24 50 0.04 
Liver 30:25:25:20 20 0.02 
Lung 30:25:25:20 20 0.02 
Kidney 30:25:25:20 20 0.02 
 
Table 3.2.  HPLC settings used for each of the different tissue matrices.
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3.3.6.  Liquid Chromatographic Analysis 
 Peak heights of the peak responses of tilmicosin and tylosin in the extracts from 
the fortified control tissue standards and the test samples were measured using digital 
calipers.  Response ratios (peak height of tilmicosin/peak height of tylosin) were 
calculated at each concentration of tilmicosin added. A standard curve of response ratios 
versus tilmicosin concentration added was plotted using linear regression.  If tilmicosin 
was detected in the test extract, its response ratio was calculated and its concentration 
determined by interpolation from the regression curve. 
 
3.3.7.  Validation 
Sensitivity and Specificity 
 The selectivity of the method (i.e. the ability of the test method to detect truly 
negative samples as negative) was demonstrated by analyzing control (drug free) tissues 
obtained from six horses (the horses represented both sexes and a variety of ages and 
breeds with a known history that they had never been treated with a macrolide 
antimicrobial) using the developed analytical method.  Figure 3.1 (a) is a typical 
chromatogram of an extract obtained from control equine plasma fortified with the 
internal standard (tylosin) processed and analyzed according to the described procedure.  
Figure 3.1 (b) is a chromatogram of a plasma sample fortified with tilmicosin (til) and 
the same fixed amount of the internal standard, processed and analyzed using the 
described method.  Figure 3.1 (c) is a typical chromatogram of an extract obtained from 
control equine lung tissue fortified with the internal standard (Tylosin) processed and 
analyzed according to the described procedure.  Figure 3.1 (d) is a chromatogram of a  
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Figure 3.1. 
 
Typical chromatograms of (a) an extract of negative control (drug-free) equine 
plasma containing tylosin (Tyl) as an internal standard, (b) an extract of negative control 
equine plasma fortified with 150 ng/mL tilmicosin (Til) (c) an extract of negative control 
(drug-free) equine lung tissue containing tylosin as the internal standard and (d) an 
extract of negative control equine lung containing the internal standard and 2000 ng/g 
tilmicosin. Each horizontal division is equivalent to 1 minute.  The vertical axis is in 
arbitrary absorption units. 
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lung tissue sample fortified with tilmicosin and the same fixed amount of the internal 
standard, processed and analyzed using the described method. 
Since the assay was to be used in a controlled setting for pharmacokinetic analysis, 
the assay was not evaluated further for interference with other commonly used 
veterinary pharmaceuticals since the subjects of the study would not be receiving any 
other medications. 
3.3.8.  Quantitative Analysis 
 Standard calibration curves were generated from four negative control matrix 
samples individually fortified with working solutions according to Table 3.1.  The 
samples were analyzed as previously described.  An unweighted least squares regression 
curve was generated by plotting the response ratio (i.e., detector response [peak height] 
of tilmicosin/detector response [peak height] of tylosin) vs. concentration of tilmicosin 
added to the control tissue.  For all tissue matrices the relationship between tilmicosin 
concentration and response ratio was highly linear (R2 >0.99).  Response ratios obtained 
for any test samples found to contain tilmicosin were measured and used to calculate the 
concentrations of tilmicosin in those test samples. 
 
3.3.9.  Recovery, Inter-Assay, and Intra- Assay Precision for Plasma and Lung 
 The absolute recovery of tilmicosin from the tissue was calculated by comparing 
the detector responses obtained from a set of negative control tissues fortified for the 
typical calibration curve (Matrix-fortified samples) (Table 3.3) with the detector 
responses obtained from chemical standards that were added to negative control tissue 
extract that had passed through the extraction procedure (matrix-matched samples).  To 
demonstrate the presence or absence of matrix effects, the detector responses were also  
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Table 3.3a (02 apr 2004) 
 
Detector response in arbitrary units Amount of 
tilmicosin added 
per mL of plasma 
(ng) 
Matrix-
matched 
standards 
Tilmicosin 
in elution 
solution 
Matrix-fortified 
standards 
Absolute 
recovery (%) 
Tissue 
standard/post-
extraction 
40 7.8 8.3 7.6 97 
150 25.2 26.6 25.9 103 
250 45.2 47.3 41.4 92 
500 89.4 97.2 85.5 96 
 
Detector response in arbitrary units Amount of 
tylosin added per 
mL of plasma 
(ng) 
Matrix-
matched 
standards 
Tylosin in 
elution 
solution 
Matrix-fortified 
standards 
Absolute 
recovery (%) 
Tissue 
standard/post-
extraction 
500 59.6 (0.6) 62.9 (0.3) 52.2 (1.4) 88 
 
Table 3.3b (aug 17 05 phase 1 rpt) 
Detector response in arbitrary units Amount of 
tilmicosin added 
per gram of lung 
(ng) 
Matrix-
matched 
standards 
Tilmicosin 
in elution 
solution 
Matrix-fortified 
standards 
Absolute 
recovery (%) 
Tissue 
standard/post-
extraction 
500 8.3 10.2 3.3 40 
1000 18.0 19.4 7.5 42 
2000 30.2 36.66 16.3 54 
3000 49.1 57.0 25.7 52 
 
Detector response in arbitrary units Amount of 
tylosin added per 
gram of lung (ng) Matrix-matched 
standards 
Tylosin in 
elution 
solution 
Matrix-fortified 
standards 
Absolute 
recovery (%) 
Tissue 
standard/post-
extraction 
8000 52.2 (9.2) 45.6(3.4) 42.1 (2.8) 80 
 
Table 3.3.  Recovery of tilmicosin and tylosin from equine tissues.  Table 3a 
shows the recovery of tilmicosin and tylosin from plasma and Table 3b shows the 
recovery from lung.  For tylosin studies the result represents the mean detector response 
and the number in parenthesis represents the standard deviation. 
 102
compared with samples of elution solution that contained the same standards that had 
not been subjected to any sample preparation procedures (Table 3.3). 
Intra-assay precision and accuracy was determined by preparing three sets of three 
spiked samples within the standard curve.  These three sets of samples were analyzed on 
the same day and the results compared (Table 3.4).  Inter-assay precision and accuracy 
was determined by preparing the same set of spiked samples on three separate days and 
comparing the results (Table 3.5). 
The accuracy of the analytical method was verified by using the described 
procedure to analyze tissue samples prepared by the laboratory quality manager or 
designate, randomized, coded and presented “blind” to an analyst familiarized with the 
method (Table 3.6). 
 
3.3.10.  Limit of Quantitation and Limit of Detection 
 The limit of detection (LOD) of the method for tilmicosin detection was 
calculated only for plasma and lung.  The LOD was calculated by analyzing five sets of 
matrix calibration standards over three days in the region at which the assay was 
anticipated to be used (Plasma, 60, 250, 400 ppb; Lung 600, 1200, 2500).  An 
unweighted linear least squares regression equation was generated for each set of 
standards and the background noise was estimated from the standard deviation of the 
intercept of the y-axis.  The LOD was calculated as being the concentration at which the 
signal-to-noise ratio (S/N) was equal to 3.  The LOD for plasma was 13 ng/mL and 181 
ng/g for lung.  The limit of quantitation (LOQ) was defined as the concentration at 
which the S/N ratio was equal to 10.  The LOQ for plasma was 43 ng/mL and 626 ng/g 
for lung. 
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(a)  
 
Tilmicosin (ng/mL) 
Experimentally determined in 
fortified plasma replicates 
Tilmicosin 
Conc. in 
plasma 
ng/mL 1 2 3 
Mean 
determined 
tilmicosin 
conc. 
(ng/mL) 
 
Accuracy 
(%) 
400 423 428 411 421 ±8.5a +5.2 
250 267 279 273 273 ± 5.6 +9.1 
60 63 62 79 68 ± 9.4 +13.3 
 
(b) 
 
Tilmicosin (ng/mL) 
Experimentally determined in 
fortified lung replicates 
Tilmicosin 
Conc. in 
plasma 
ng/mL 1 2 3 
Mean 
determined 
tilmicosin 
conc. 
(ng/mL) 
 
Accuracy 
(%) 
600 593 649 647 630 ± 32a +4.9 
1200 1262 1366 1306 1311 ± 52 +9.3 
2500 2532 2637 2583 2584 ± 53 +3.4 
a Mean ± S.D. 
 
Table 3.4.  Intra-assay precision and accuracy of the analytical method for plasma (a) 
and lung (b)
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(a)  
 
Tilmicosin (ng/mL) 
Experimentally determined in 
fortified plasma on 
Tilmicosin 
Conc. in 
plasma 
ng/mL Day 1 Day 2 Day 3 
Mean 
determined 
tilmicosin 
conc. 
(ng/mL) 
 
Accuracy 
(%) 
400 376 411 356 381 ± 27.9  -4.7 
250 242 273 231 248 ± 21.7 -0.7 
60 60 79 67 69  ±  9.3 +14.8 
 
 
 
(b) 
 
Tilmicosin (ng/mL) 
Experimentally determined in 
fortified lung on 
Tilmicosin 
Conc. in 
lung 
ng/mL Day 1 Day 2 Day 3 
Mean 
determined 
tilmicosin 
conc. 
(ng/mL) 
 
Accuracy 
(%) 
600 889 593 550 677 12.9 
1200 1541 1262 1107 1303 8.6 
2500 2953 2532 2225 2570 2.8 
 
Table 3.5.  Inter-assay precision and accuracy of the analytical method for plasma (a) 
and lung (b)
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Sample ID Tilmicosin 
concentration in 
ng/mL added to 
control plasma 
(ng/mL) 
Concentration of 
tilmicosin found in 
control plasma 
fortified with 
tilmicosin (ng/mL) 
Accuracy (%) 
1 30 28 -6.7
12 40 36 -10
2 60 57 -5
11 60 62 3.3
3 100 94 -6
10 100 100 0
4 150 141 -6
9 150 138 -8
5 300 288 -4
8 300 277 -7.7
6 400 376 -6
7 400 398 -0.5
   
Sample ID Tilmicosin 
concentration in 
ng/g added to 
control equine lung 
(ng/g) 
Concentration of 
tilmicosin found in 
control lung 
fortified with 
tilmicosin (ng/g) 
Accuracy (%) 
10 600 574 -4.3
2 600 469 -21.8
6 600 532 -11.3
12 1600 1617 1.1
8 1600 1616 1.0
4 1600 1777 11.1
3 2400 2330 -2.9
11 2400 2610 8.7
7 2400 2313 -3.6
5 2800 3078 9.9
9 2800 2162 -22.8
1 2800 2790 -0.4
Note:  Accuracy (%) = [(amount found-amount added)/amount added]*100 
 
Table 3.6. Verification of the accuracy of the analytical method on blind-fortified 
samples.  
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3.3.11.  Stability Studies  
Stability of Standard Solutions and Tissue Extracts During Analysis 
The stability of the standard solutions and the tissue extracts during analysis under 
typical laboratory room temperature conditions were evaluated by analyzing tissue 
extracts containing the chemical standards over three cycles of analysis over a 12 hour 
period. 
 
Stability of fortified negative control tissues under freezer storage conditions. 
The stability of control tissue matrices fortified with tilmicosin (250 ng/mL plasma 
and 1000 ng/g lung) and frozen at -20˚C were also monitored over a period of 12 months 
for plasma and 4 months for lung to evaluate the effects of freezing storage and 
freeze/thaw cycles on the stability of tilmicosin (Figure 3.2). 
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Figure 3.2.  Long term storage stability studies for tilmicosin in equine plasma (3.3a) 
and equine lung (3.3b) using identical samples stored at -20◦C (Lines indicate mean and 
mean ± S.D.)
3.2a 
3.2b 
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3.4.  Results and Discussion 
 
Figure 3.1 shows a typical chromatogram of an extract of negative control plasma 
and lung tissue fortified with the internal standard, tylosin, at concentrations of 500 
ng/mL and 8000 ng/g, respectively.  The tissues were processed according to the 
described procedure.  Figures 3.1b and 3.1d show chromatograms derived from control 
tissues fortified with tilmicosin and tylosin at concentrations of 150 ng/mL plasma and  
2000 ng/g lung.  It can be seen from Figure 3.1 that tilmicosin and tylosin eluted from 
the analytical column with a retention time of approximately 6 and 7 minutes, 
respectively.  Minor changes in the mobile phase needed for the chromatographic 
separation of the lung and the other organ extracts (with exception of muscle) were 
necessary to ensure baseline separation from other endogenous components.  The 
tilmicosin peak was always coupled with a much smaller peak eluting approximately 30 
seconds prior to the main peak.  The tylosin (internal standard) peak typically had an 
association with 1or 2 lesser peaks.  The presence or absence of these lesser peaks had 
no effect on the separation of the lung and other organ extracts. 
Both compounds were resolved from all other tissue co-extractives and there were 
no endogenous tissue components that were likely to interfere with the analysis.  The 
results of the analysis of the negative control tissues indicated that the analytical method 
was able to detect truly negative samples as negatives regardless of the age, breed or sex 
of the horse from which the sample was taken.  It was, therefore, concluded that the 
HPLC method was selective. 
Table 3.3 summarizes the results of experiments conducted to determine the 
recovery of tilmicosin added to control plasma and lung using the described method.  
The method is able to recover approximately 96% of the tilmicosin from plasma and 
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88% of tylosin from plasma.  Slight differences can be seen comparing the peak shape in 
plasma matrix to elution solution suggesting that the tissue matrix has a minor effect on 
tilmicosin detection; however the effect is very slight.  The recovery was lower for lung 
tissue with only 46% of tilmicosin recovered and 80% of tylosin.  Although the 
techniques used by the two methods are similar, this is a remarkable difference.  The 
reason is likely that plasma is a liquid matrix which is simply mixed with acetonitrile 
during the extraction process.  The only material disposed of during the process is the 
precipitated plasma proteins.  This is in contrast to the solid tissues which must be 
homogenized in buffered acetonitrile and centrifuged with all solid waste being 
discarded.  Presumably the unrecovered portion of the drug remains trapped in the 
discarded tissue.  The marked difference in the recovery of tylosin and tilmicosin may 
simply reflect that tilmicosin partitions into tissues better than tylosin. 
Matrix fortified calibration curves generated for tilmicosin in all tissue were found 
to be linear within the analytical ranges described in Table 3.1.  The LOD for the 
analytical method was found to be 13 ng/mL for plasma and 181 ng/g for lung.  The 10 
fold difference in the LOD for the two assays is in part due to the concentrations of 
tilmicosin used in the calibration curve (Table 3.1) reflecting the concentrations of 
tilmicosin found in different body tissues (Clark, Dowling et al. 2008(6)).  The other 
reason is the difficulty in extracting the tilmicosin from the solid tissues compared to 
plasma.  Lung in particular is a difficult tissue with which to work.  The tissue matrix is 
spongy and air-filled; consequently it is extremely difficult to homogenize resulting in 
inherent variability in the method.  While the LOD of the other tissues would also be 
higher than plasma it is unlikely that they would be as high as that found in lung since 
they are much easier to process. 
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The accuracy of the method was determined by examination of blind-fortified 
samples prepared by a laboratory quality manager (Table 3.4).  These results confirm 
that the method is suitable for quantifying tilmicosin concentrations in “real unknown 
samples”.  The accuracy of the method for tilmicosin detection was <10% for plasma 
and <23% for lung tissue. 
Tilmicosin tissue extracts were shown to be stable under analysis conditions.  
Control tissues fortified with tilmicosin and stored at -25˚C were stable for 12 months in 
the case of plasma and at least 4 months for lung. 
 The method described in this study is accurate and effective for determining 
tilmicosin concentrations in equine tissues for pharmacokinetic studies of tilmicosin in 
the horse. 
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CHAPTER 4 
PHARMACOKINETICS OF TILMICOSIN IN EQUINE TISSUES AND 
PLASMA 
Accepted for publication by the Journal of Veterinary Pharmacology and 
Therapeutics, September 2007 
 
4.1.  Abstract 
The macrolide antibiotic tilmicosin has potential for treating bacterial respiratory 
tract infections in horses. A pharmacokinetic study evaluated the disposition of 
tilmicosin in the horse after oral (4 mg/kg) or subcutaneous (10 mg/kg) administration. 
Tilmicosin was not detected in equine plasma or tissues after oral administration at this 
dose. With s.c. injection, tilmicosin concentrations reached a maximum concentration of 
approximately 200 ng/mL in the plasma of the horses. Tilmicosin concentrations in 
plasma persisted with a mean residence time (MRT) of 19 hours. Maximum tissue 
residue concentrations (Cmax) of tilmicosin measured in equine lung, kidney, liver and 
muscle tissues after s.c. administration were 2784, 4877, 1398, and 881 ng/g, 
respectively. The MRT of tilmicosin in these tissues was approximately 27 hours.  
Subcutaneous administration of tilmicosin resulted in severe reactions at the injection 
sites. 
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4.2.  Introduction 
 Tilmicosin is a macrolide antibiotic formed from a chemical modification of 
tylosin.  Micotil 300® (Elanco Animal Health, Guelph, ON) is licensed for 
subcutaneous injection for the treatment of respiratory disease in sheep and cattle and is 
used extensively in North American feedlots. Pulmotil® (Elanco Animal Health, 
Guelph, ON) is licensed as a feed additive for the prevention and control of respiratory 
disease in swine.  In Europe, tilmicosin is also labeled for use in rabbits and chickens 
(McKay, Morck et al. 1996; Charleston 1998). It is efficacious for the treatment of 
respiratory disease because of its accumulation in pulmonary tissues, its long elimination 
half-life, and antimicrobial spectrum of activity that includes most Gram-positive 
aerobes, Gram negative aerobes causing pneumonia (M. haemolytica, P. multocida and 
Histophilus somni)  some anaerobes and Mycoplasma spp. (Giguere 2006) . With these 
characteristics, tilmicosin would be ideal for treatment of equine bacterial respiratory 
infections. 
 Use of the injectable product in non-ruminant species has been associated with 
acute cardiac toxicity in swine, dogs  and horses  (Jordan, Byrd et al. 1993; Main, Means 
et al. 1996). However, overt cardiac toxicity was not seen in unpublished manufacturer 
reports evaluating oral (400 parts per million (ppm) in feed) or s.c. (10 mg/kg) tilmicosin 
in horses (Cochrane and Thomson 1990; Buck and Thomson 1997). An alternative 
injectable formulation of tilmicosin was used to successfully treat Rhodococcus equi 
infection in two foals with no reported adverse effects (Fenger 2000).  The 
pharmacokinetics of the same product (a fatty acid salt formulation) were recently 
described no serious adverse effects were reported although 4/7 foals developed self 
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limiting diarrhea and 5/7 foals developed some degree of swelling at the site of injection 
(Womble, Giguere et al. 2006). In this pilot study, we investigated the plasma and tissue 
pharmacokinetics of tilmicosin in the horse after oral and subcutaneous administration to 
determine its suitability for use in horses. 
 
4.3.  Materials and methods 
4.3.1.  Study animals 
 This study was approved by the University of Saskatchewan’s Committee on 
Animal Care and Supply in accordance with the guidelines provided by the Canadian 
Council on Animal Care (CCAC). The study was performed on 12 recently weaned 
cross-bred, female foals acquired from a Pregnant Mare Urine (PMU) ranch in western 
Canada.  The foals were approximately 6 months old at the start of the study. Their 
weights ranged from 130 - 245 kg.  Ten of the 12 foals were used in a laparoscopic 
ovariectomy study prior to entering the tilmicosin study.  A 4 week washout period 
separated the two studies. 
 
4.3.2.   Phase 1 – single dose study 
 Foals were randomly allocated using a coin toss to receive either the label 10 
mg/kg s.c. tilmicosin or 4 mg/kg  p.o. tilmicosin, as a single dose. The 4 mg/kg p.o. dose 
was chosen based on the study of Buck and Thomson (Buck and Thomson 1997) where 
a dose approximating to 4 mg/kg p.o. had minimal effects on the health of the animals in 
the study.  The dose of 4 mg/kg sid also approximated to the same total dose as the 
animals receiving 10 mg/kg q 72 hrs.  Micotil 300® was administered s.c. in the neck.  
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Pulmotil® was weighed out and placed in a catheter tip syringe, diluted with 20 mL of 
water and 10 mL of corn syrup and administered into the back of the mouth. 
 Blood samples were collected from a jugular catheter immediately prior to drug 
administration and at 15, 30, 45, 60 and 90 minutes after administration. Additional 
blood samples were drawn at 2, 2.5, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, 72, 84, and 96 h. 
Blood was collected into EDTA collection tubes and immediately centrifuged.  The 
plasma was harvested and frozen at -80 ºC until analyzed. 
 
4.3.3.   Phase 2 - multiple dose study 
 Following the completion of the phase 1 study, all foals had a minimum of a two 
week washout period. Foals remained allocated to the same groups and received either 
10 mg/kg s.c. tilmicosin every 72 h or 4 mg/kg tilmicosin p.o. every 24 h, so that each 
foal received approximately the same total dose of tilmicosin during the study. For the 
first four treatments, blood was collected by jugular venipuncture immediately prior to 
drug administration and 8 h post-administration. Foals were treated with tilmicosin for a 
minimum of two weeks and then individually euthanized at 4, 16, 26, 40, 50 and 64 h 
post-treatment.  Blood samples were collected immediately prior to euthanasia. A post-
mortem examination was performed and samples of liver, lung, kidney and muscle were 
collected, immediately frozen, and stored at -80 ºC until analyzed. 
 
4.3.4.   Drug residue analysis 
Sample Preparation 
Extraction of tilmicosin and tylosin from plasma samples 
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5.0 ± 0.05 mL of test (unknown) plasma, were accurately measured into a 
polypropylene centrifuge tube.  5.0 ± 0.05 mL each of drug-free plasma were measured 
into five polypropylene centrifuge tubes. Appropriate volumes of the tilmicosin standard 
solution were added to each drug-free plasma sample to prepare matrix fortified plasma 
samples containing 40, 150, 250, and 500 ng/mL of tilmicosin with a constant 
concentration of 500 ng/mL of tylosin (as internal standard). No tilmicosin was added to 
the fifth drug-free plasma sample, but tylosin was added at a concentration of 500 
ng/mL. An appropriate volume of the internal standard solution was added to each test 
(unknown) sample at a concentration of 500 ng/mL. Plasma samples were allowed to sit 
for 15 min.  Each plasma sample was mixed with 20 mL acetonitrile and 5 mL of 0.1 M 
phosphate buffer (pH 2.5), vortex mixed for 1 min and centrifuged at 2250 g for 5 min. 
The supernatant was filtered through a Whatman GF/B, 5.5 cm filter paper and diluted 
with approximately 70 mL of water. The sample was loaded onto a conditioned  C18 
cartridge as described below for the tissue sample extracts. 
 
Extraction of tilmicosin and tylosin from tissue samples 
 Five ± 0.05 g thawed muscle, 2.5 ± 0.05 g thawed liver, lung, or kidney (each 
tissue sample must be finely diced) test (or unknown) samples were accurately measured 
into individual 50 mL polypropylene centrifuge tubes. Equivalent weights of drug-free 
tissue were measured into five polypropylene centrifuge tubes. For muscle, appropriate 
volumes of the tilmicosin standard solution were added to prepare tissue standards 
containing 250, 500, 1000, and 1500 ng/g tilmicosin and 4000 ng/g tylosin as internal 
standard. No tilmicosin was added to the fifth drug-free tissue sample, but tylosin at a 
concentration of 4000 ng/g was added.  
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To the kidney, liver and lung tissues, appropriate volumes of the tilmicosin 
standard were added to prepare tissue standards containing 500, 1000, 2000, and 3000 
ng/g tilmicosin with tylosin at a concentration of 8,000 ng/g. No tilmicosin was added to 
the fifth drug-free tissue sample, but tylosin was added at a concentration of 8000 ng/g. 
Appropriate volumes of the internal standard solution were added to each test 
(unknown) sample. The samples were allowed to sit for 15 min. 
10 mL of acetonitrile was added to the tissue samples and homogenized 
(Polytron Model PT 10-35 (Brinkman Instruments Ltd., Rexdale, Ont)) at high speed for 
20 seconds. The probe was rinsed with 2 x 2 mL aliquots of acetonitrile into the sample 
tube.  The solutions were placed on a benchtop shaker for 5 minutes and centrifuged at 
200g for 5 minutes.  The supernatant was decanted and collected into a separately 
labeled centrifuge tube.  The tissue plug was re-suspended in 10 mL acetonitrile and 5 
mL of phosphate buffer, vortex mixed for 20 s and placed on the bench top shaker at 
high speed for a further 5 minutes. This solution was then centrifuged at 2250 g for 5 
minutes and the supernatant was combined with the first supernatant. The resulting 
supernatant was filtered through a Whatman GF/B, 5.5cm filter paper. The resulting 
solution was diluted with approximately 70 mL of water. 
 
Plasma and Tissue Sample Extract Clean Up 
The SPE cartridges were conditioned with 10 mL methanol followed by 10 mL 
water (it is important that the cartridges not be allowed to dry out after this point). The 
extracted solutions were loaded onto the cartridges and allowed to pass through under 
gravity.  The cartridges were then washed with 20 mL water, after which time they were 
allowed to dry for 5 minutes under a vacuum of 20 mm/Hg.  The retained analytes were 
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eluted from the cartridge with 2 x 750 µl of the elution solution into a 2 mL graduated 
centrifuge tube.  The volume of the solution in the centrifuge tube was adjusted to 2 mL 
using 0.1 M ammonium acetate. The solution was mixed and filtered through a 0.45µm 
Acrodisc syringe filter for HPLC analyses.  
Analysis was performed using a Waters 590 pump, a Waters 490 Programmable 
Detector set at 287 nm, and a Waters 712 WISP Autosampler.  The liquid 
chromatography (LC) column, was an Inertsil ODS-2, 5μm, 150 x 4.6mm column 
(Lablink inc. Rockford, IL) with a guard column, Inertsil ODS-2, 5μm, 4.0 x 10mm 
(Lablink inc. Rockford, IL). Separation was achieved under isocratic conditions with 
varying mobile phase compositions consisting of 0.1 M ammonium formate 
buffer/water/acetonitrile/methanol at a flow rate of 1 mL/min. The HPLC conditions for 
the different matrices are shown in Table 4.1. Chromatograms were recorded on a chart 
recorder with the sensitivity set at 10 mV and the chart speed at 2 mm/min.   
 
4.3.5.  Data analysis 
 Peak heights of tilmicosin and tylosin (as internal standard) were measured using 
digital calipers.  Response ratios (peak height of tilmicosin/peak height of tylosin) were 
calculated at each concentration of tilmicosin added. A standard curve of response ratios 
versus tilmicosin concentration added was plotted using linear regression, and the 
concentrations of the drug in the unknowns were calculated using the regression 
equation. Pharmacokinetic analysis was performed using WinNonLin (ver 2.1 Pharsight 
Corp., Raleigh, NC), Cmax and Tmax were simply determined from the data at the highest 
recorded concentration.  Elimination kinetics were calculated employing a non-
compartmental extravascular input model with uniform weighting (Riviere 1999). 
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Tissue /matrix Mobile phase 
(0.2 M ammonium formate (pH 5), water, 
acetonitrile, methanol) 
Injection 
volume (µl) 
AUFS 
Plasma 20:32:24:24 50 0.01 
Muscle 20:32:24:24 50 0.04 
Liver 30:25:25:20 20 0.02 
Lung 30:25:25:20 20 0.02 
Kidney 30:25:25:20 20 0.02 
 
Table 4.1. Mobile phase conditions used for the isocratic analyses of tilmicosin residues 
in equine plasma and tissue extracts. 
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4.4.  Results 
 Tilmicosin concentrations in tissues were determined using an HPLC 
method developed by Chan et al. (Chan, Gerhardt et al. 1994) for bovine muscle and 
kidney tissues which we modified and adapted for tilmicosin residue analyses in equine 
plasma and tissues. The limit of detection (LOD) of the modified method for plasma and 
lung were determined to be 13 ng/mL and 181 ng/g, respectively.  
 Plasma pharmacokinetics of a single 10 mg/kg s.c. dose of tilmicosin are shown 
graphically in Figure 4.1 and calculated pharmacokinetic parameters are summarized in 
Table 4.2. Tilmicosin was undetectable in the plasma following a single oral dose of 4 
mg/kg. With s.c. injection, absorption of tilmicosin appeared multiphasic, with no 
distinct time to maximum concentration (Tmax).  This made it impossible to calculate 
meaningful values for the maximum concentrations (Cmax). The mean highest measured 
concentration of tilmicosin in plasma was 258 ± 92 ng/mL occurring at a mean time of 
6.0 ± 9.2 h. Plasma concentrations persisted with a mean retention time (MRT) of 19 
hours. 
 With multiple dosing at 10 mg/kg s.c. every 72 h, some plasma accumulation of 
tilmicosin occurred.(Table 4.3, Figure 4.2) As in the single dose phase, plasma 
concentrations were still undetectable following oral administration.  
 Results of the analysis of the tissue residues at the time of euthanasia are shown 
in Figure 4.3. Calculated pharmacokinetic parameters in tissues (lung, kidney, liver and 
muscle) are shown in Table 4.4. Compared to plasma, tilmicosin selectively accumulates 
in equine tissues, especially kidney, liver and lung. The calculated tilmicosin kidney 
Cmax was 4877 ng/g at 16 h. It is worthy to note that this concentration is 33 times  
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Figure 4.1.  Disposition of tilmicosin in plasma of 6 foals following s.c. administration 
of 10 mg/kg tilmicosin (mean values ± S.D.)
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Horse No.  AUC 
(h⋅ng/mL) 
MRT (h) Tmax (h) Cmax (ng/mL) 
1 5825 18.1 2 248 
3 5935 23.1 24 171 
5 5246 14.1 0.25 311 
7 8600 18.4 0.5 402 
9 7089 27.3 1.5 154 
11 7789 14.9 8 259 
Median 
(interquartile 
range) 
6512  
(5680-7991) 
18.25  
(14.7 – 24.2) 
1.75 (0.44-12) 253 (166-334) 
 
 
Table 4.2. Pharmacokinetic parameters for tilmicosin in plasma following a single s.c. 
administration of 10 mg/kg (Cmax was defined as the highest observed concentration and 
Tmax the time at which the concentration occurred). 
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Time Mean ± SD (ng/mL) 
Day 1: pre-dosing 0 
Day 1: 8 hours post-dose 149.2 ± 50.1 
Day 6: pre-dosing 43.1 ± 55.8 
Day 6: 8 hours post-dose 205.6 ± 127.4 
Day 9: pre-dosing 46.2 ± 72.8 
Day 9: 8 hours post-dose 238.1 ± 114.7 
 
 
Table 4.3.  Mean plasma concentrations of tilmicosin following repeated dose 
administration of 10 mg/kg s.c. every 72 h. 
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Figure 4.2.  Plasma concentrations of tilmicosin following repeated dose administration 
of 10 mg/kg s.c. every 72 h. 
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Figure 4.3. Distribution profile of the concentrations of tilmicosin measured in 
equine tissues and plasma following multiple dose administration of 10 mg/kg s.c. (one 
foal per time point). 
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Tissue MRT 
 (h) 
 Tmax  
  (h) 
 Cmax   
(ng/g) 
AUC  
(h⋅ng/g) 
Lung 28.3 16 2784 90957 
Kidney 26.7 16 4877 142906 
Liver 26.5 16 1398 44210 
Muscle 28.8 26 881 28900 
 
Table 4.4 Pharmacokinetic parameters following administration of 10 mg/kg s.c. 
tilmicosin every 72 h for two weeks. 
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greater than the corresponding plasma concentration. Similarly, the tilmicosin lung Cmax 
of 2783 ng/g is 20 times greater than the corresponding concentration in plasma. 
 Injection of tilmicosin resulted in severe edematous painful swellings which 
were initially very large but regressed over several days. In one case there was necrosis 
of the skin overlaying the injection site. Administration of tilmicosin by either route did 
not result in colitis. 
 
 
4.5.  Discussion 
Tilmicosin is highly lipophilic and extensively accumulates in tissues (Giguere 
2006).  With minimal concentrations in plasma, tissue concentrations must be measured 
to determine therapeutic dosing regimens. Tissue disposition results in horses were 
similar to cattle (http://www.fda.gov/cvm/FOI/1496.htm; Thompson, Laudert et al. 
1994) and elk (Clark, Woodbury et al. 2004), in that tilmicosin accumulated in kidney 
and lung, likely because of the high blood flow to these tissues. However, the measured 
tilmicosin concentrations in equine lung were lower than those seen in elk (9.2 µg/g @ 
48 h (Clark, Woodbury et al. 2004)), cattle (7.17 µg/g @ 24 h 
(http://www.fda.gov/cvm/FOI/1356.htm 1992), or mice (5.29 µg/g @ 2 h (Brown, 
Deleeuw et al. 1995)). The MRT of 1.2 days in lung tissue was shorter than the 1.8 days 
for reported for cattle and 4.6 days reported for elk. The accumulation seen in liver was 
expected due to the hepatic clearance of tilmicosin.  There is limited information on the 
susceptibility of equine pathogens to tilmicosin.  The MIC90 for Staphylococcus aureus 
and Streptococcus agalactiae are reported as being 1 µg/mL and 4 µg/mL respectively 
(Giguere 2006).   Tissue concentrations in lung exceeded the MIC for Staphylococcus 
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aureus for 40 hours but never reached the MIC for Streptococcus agalactiae.  However, 
in vitro susceptibility is not always a good predictor of clinical efficacy (Musser, 
Mechor et al. 1996) with bacterial strains reported as resistant in the laboratory 
responding well in the field.   
In a recent study, Womble et al. (Womble, Giguere et al. 2006) investigated the 
pharmacokinetics of 10 mg/kg of a fatty acid salt of tilmicosin administered 
intramuscularly.  The product produced similar peak concentrations in lung (Cmax = 
1900ng/g) with a much longer MRT (323 hours).  Plasma concentrations were very low 
and declined rapidly in a manner similar to those observed in this study. 
Subcutaneous injection of tilmicosin in cattle causes inflammation at the 
injection site (Van Donkersgoed, Dubeski et al. 2000). Horses reacted more to s.c. 
tilmicosin than cattle, with severe swelling and edema (Clark, Dowling et al. 2008 (8)). 
The injection site reactions may have affected tilmicosin absorption and caused the 
erratic absorption pattern. The prolonged absorption phase suggests the plasma 
elimination rate of tilmicosin is governed by the rate of absorption, otherwise known as 
“flip-flop” kinetics (Riviere 1999).  It is likely that tilmicosin residues would persist at 
the injection site due to the high concentration following injection and the inflammatory 
changes, unfortunately the residues at the injection site were not measured in this study 
as the severity of the injection site reaction would prevent the use of tilmicosin in this 
manner. 
Despite ideal pharmacokinetics and antimicrobial activity, the severity of 
injection site reactions precludes the use of s.c. tilmicosin in the horse. Oral tilmicosin 
was easy to administer and well-tolerated by foals, but failed to produce detectable 
plasma or tissue concentrations at the dose investigated.  Most macrolide antimicrobials 
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have a good oral bioavailability (although bioavailability is dependent on the species and 
the formulation of the product) and tilmicosin is well absorbed orally in other species.  
Oral administration of Pulmotil® to pigs at a dose of 400 ppm in feed (equivalent to a 
dose of 20 mg/kg of tilmicosin assuming a 5 % body weight consumption) resulted in 
high concentrations of tilmicosin residues in many tissues (kidney 4.3 μg/g, liver 4.5 
μg/g). Tilmicosin administered orally to calves at a dose of 12.5mg/kg or 25mg/kg was 
also found to be effective for the treatment of bacterial pneumonia (Fodor, Reeve-
Johnson et al. 2000). Other oral macrolide antibiotics such as azithromycin and 
clarithromycin have been used effectively in the horse (Lakritz and Wilson 2002), and 
azithromycin has good oral bioavailability in foals (Davis, Gardner et al. 2002). Further 
dose titration studies with oral tilmicosin in horses are planned to determine the dose 
that will achieve therapeutic tilmicosin concentrations in lung tissue. 
 Use of tilmicosin in horses is extra-label (the U.S. label for Micotil states that the 
use of tilmicosin in horses is contraindicated) and although horses can no longer be 
slaughtered for human consumption in the U.S. this is common in other countries.  There 
are no maximum residue levels determined for tilmicosin in horses in countries were 
horses are slaughtered for human consumption.  If administered to a horse destined for 
human consumption, a prolonged withdrawal period would be required. There is not 
sufficient information from this pilot study to estimate a withdrawal interval or 
determine the target tissue.  
 
 
 
 
 129
4.6.  Acknowledgements 
 This study was funded by the Western College of Veterinary Medicine, Equine 
Health Research Fund.  Micotil 300®, Pulmotil® and the tilmicosin reference standard 
were generously provided by Elanco Animal Health, Eli Lilly Canada Inc. Guelph, ON. 
 130
 
 
 
CHAPTER 5 
PHARMACOKINETICS OF ORAL TILMICOSIN IN UNWEANED 
FOALS 
Formatted for Journal of Veterinary Pharmacology and Therapeutics 
 
5.1 Abstract 
An oral dose of tilmicosin (40 mg/kg PO) resulted in concentrations of tilmicosin 
in equine tissues especially, the lungs, equivalent to those associated with efficacy in 
other species.  Peak concentrations (Cmax) of approximately 4 µg/g, are equivalent to the 
MIC50 of Rhodococcus equi.  The mean residence time (MRT) in lung was 8.8 hours.  In 
contrast, plasma concentrations of tilmicosin were low, Cmax was 58 ng/mL and the 
MRT was 6.2 hours.  The oral bioavailability was estimated as approximately 10% 
compared to a subcutaneous dose.  No adverse effects were noted in the treated foals.  It 
is hypothesized that oral tilmicosin may have potential for the treatment of R. equi 
infection in foals.   
 
5.2 Introduction 
 The macrolide and related classes of antimicrobials are not widely used in equine 
medicine because of fears of antimicrobial associated diarrhea.  They are most 
commonly used for the treatment of Rhodococcus equi pneumonia in foals.  
Erythromycin has been used in this manner in combination with rifampin for more than 
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30 years (Hillidge 1986).  Although erythromycin is effective, it has a number of 
disadvantages.  There are reports of developing antimicrobial resistance (Kenney, 
Robbins et al. 1994), the pharmacokinetics of the various oral erythromycin products are 
less than ideal and typically require frequent dosing (3-4 times daily) (Plumb 2002) and 
there are a number of reports of adverse drug reactions in both foals and their dams 
following the use of erythromycin, mainly acute colitis and hyperthermia (Baverud, 
Franklin et al. 1998; Stratton-Phelps, Wilson et al. 2000). 
Clarithromycin and azithromycin are both used as alternatives to erythromycin for 
the treatment of R. equi pneumonia and their pharmacokinetics are described (Jacks, 
Giguere et al. 2001; Davis, Gardner et al. 2002; Jacks, Giguere et al. 2002).  These are 
both human drugs and there are concerns about their use in animals.  Tilmicosin is a 
macrolide antibiotic formed from a chemical modification of tylosin.  Micotil (Elanco 
Animal Health, Guelph, ON) is licensed for subcutaneous injection for the treatment of 
respiratory disease in sheep and cattle and is used extensively in North American 
feedlots.  The product is also licensed in Italy for use in rabbits.  Pulmotil (Elanco 
Animal Health, Guelph, ON) is licensed as a feed additive for the prevention and control 
of respiratory disease in swine. It is licensed in other parts of the world for use in 
poultry. Tilmicosin is efficacious for the treatment of respiratory disease due to its 
accumulation in pulmonary tissues, long duration of action, and antimicrobial spectrum 
of activity that includes most Gram-positive aerobes, Gram-negative respiratory 
pathogens, some anaerobes and Mycoplasma spp.  (Prescott 2000).  
 Use of the injectable product in non-ruminant species is avoided due to 
suggestions of acute cardiac toxicity in swine, dogs  and horses  (Jordan, Byrd et al. 
1993; Main, Means et al. 1996). No overt cardiac toxicity was described in unpublished 
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manufacturer reports evaluating oral (400 ppm in feed) or SC (10 mg/kg) tilmicosin in 
horses (Cochrane and Thomson 1990; Buck and Thomson 1997).  The use of a 
compounded injectable formulation of tilmicosin was reported to successfully treat R. 
equi infection in two foals (Fenger 2000).  Tilmicosin is a licensed veterinary 
pharmaceutical; it is inexpensive compared to that the newer human macrolide products.  
Consequently it is an ideal choice for investigation as a potential therapeutic agent in 
horses.  
Our previous study (Clark, Dowling et al. 2008(5)) in recently weaned foals 
demonstrates that a subcutaneous dose of 10 mg/kg tilmicosin results in concentrations 
in the lung similar to those seen in other species (Brown, Deleeuw et al. 1995; Ziv, 
Shem-Tov et al. 1995; Modric, Webb et al. 1998; Clark, Woodbury et al. 2004).  These 
concentrations are known to be efficacious for respiratory disease in these species.  
Unfortunately, the local reaction at the injection site in horses prevents the use of 
tilmicosin in this manner (Clark, Dowling et al. 2008 (8)).  An oral dose of 4 mg/kg in 
the same aged animals did not result in detectable concentrations of tilmicosin in plasma 
or any tested body tissues.  Regardless of the route of administration systemic toxicity or 
disease were not observed (Clark, Dowling et al. 2008 (8)). However, the fecal flora was 
significantly disrupted in all treated foals (Clark, Dowling et al. 2008(5)).  
The aim of this study is to investigate the use of higher oral doses of tilmicosin in 
unweaned foals and to determine if therapeutic drug concentrations can be achieved in 
lung tissue. 
 
 
5.3.  Materials and methods 
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5.3.1.  Study animals 
 The study was conducted on 8 newborn cross-bred foals acquired from a 
Pregnant Mare’s Urine (PMU) ranch in Western Canada.  Foals were approximately 2 
weeks old at the start of the study and their weights ranged from 86-160 kg.  Foals were 
kept with their dams and nursed throughout the study.  Mares and foals were housed in 
an outdoor pen at the Western College of Veterinary Medicine (WCVM) with free 
access to alfalfa hay and a supplemental oats ration.  The use of foals in this study was 
approved by the University of Saskatchewan Animal care Committee. 
 
5.3.2.  Phase 1 – single dose study 
 After a 2 week acclimation period, foals were allocated by pulling their names at 
random to receive either10 mg/kg PO, 20 mg/kg PO or 30 mg/kg p.o. tilmicosin, 
initially as a single dose.  Two foals were maintained as control animals to allow 
comparison of the effects of tilmicosin on the fecal flora and evaluation of possible 
tissue toxicity (data not shown).  Tilmicosin premix (200 mg/g) was weighed out and 
placed in a catheter tip syringe, diluted with 20 mL of water and 10 mL of molasses and 
administered into the back of the mouth. 
 Blood samples were collected from a jugular catheter immediately prior to drug 
administration and at 15, 30, 45, 60 and 90 minutes after administration. Additional 
blood samples were drawn at 2, 2.5, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, 72, 84, 96 hours.  
Blood was collected into EDTA collection tubes and immediately centrifuged.  Plasma 
was harvested and frozen at -80 ºC until analyzed.  To facilitate blood collection, mares 
and foals were housed in a stall of the veterinary teaching hospital for the first 24 hours 
of the study.   
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5.3.3.  Phase 2 - multiple dose study 
 A two week washout period separated the two phases of the study.  During this 
time the analysis of the phase 1 plasma samples determined the tilmicosin 
concentrations.  This data was used to determine the dose regimen for the chronic 
administration portion of the study.  Foals received 40 mg/kg PO tilmicosin daily for 14 
days.  Foals were then euthanized using pentobarbital sodium (Euthanyl Forte 
(Vetoquinol N.-A. Inc. Lavaltrie QC) at specific time intervals following the last dose of 
tilmicosin (4, 7, 12, 16, 24 hrs).  Blood samples were collected immediately prior to 
euthanasia. Immediately after euthanasia synovial fluid was aspirated from the 
tibiotarsal joints and CSF collected from the atlanto-occipital joint.  A fecal sample was 
also collected from the rectum.  A post-mortem examination was conducted without 
delay.  The lungs were removed and separated.  A bronchio-alveolar lavage (BAL) tube 
was passed into the right bronchus, wedged and 50 mL of saline was washed into the 
lung to mimic performing a typical BAL.  Samples of liver, left lung, kidney and muscle 
were collected and stored at -80 ºC until analyzed. 
 
5.3.4.  Drug analysis 
Tilmicosin concentrations in tissues and plasma were determined using an HPLC 
method developed by Chan et al. (Chan, Gerhardt et al. 1994)  for bovine tissues and 
adapted for tilmicosin in horses plasma and tissues by Clark et al. (Clark, Dowling et al. 
2008(3)) using tylosin as an internal standard and with a limit of detection (LOD) of 381 
ng/g (tissue) or 24 ng/mL (plasma) and a limit of quantification (LOQ) of 1270 ng/g 
(tissue) or 80 ng/mL (plasma). 
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The plasma technique was adapted for CSF, synovial fluid and the BAL fluid.  
The tissue technique was adapted for feces.  The specific details of the adapted 
techniques are shown in Table 5.1. 
 
5.3.5.  Data analysis 
Response ratios (peak height of tilmicosin/peak height of tylosin) were calculated 
for each concentration of added tilmicosin. A standard curve of response ratios versus 
tilmicosin concentrations was plotted using linear regression, and the concentration of 
the drug in the unknowns was calculated using the regression equation. Pharmacokinetic 
analysis was conducted using WinNonLin (ver2.1 Pharsight Corp., Raleigh NC), 
employing a non-compartmental extravascular input model with uniform weighting 
(Riviere 1999). 
 
5.3.6.  Tilmicosin susceptibility testing of R. equi isolates 
Four field isolates of R. equi were obtained from the WCVM and a further 41 field 
isolates were generously provided by Dr J. Prescott at the Ontario Veterinary College.  
Tilmicosin susceptibility testing was conducted according to the Clinical and Laboratory 
Standards Institute (CLSI, formerly known as NCCLS) standards (NCCLS 2002).  
Tilmicosin dilutions ranged from 0.031 – 16 µg/ml using pure tilmicosin reference 
standard provided by Elanco Animal Health (Guelph, ON).  The MIC50 and MIC90 were 
calculated from the data. 
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Tissue Quantity Standards 
(tilmicosin 
ng/g or ng/mL) 
Internal Standard 
(tylosin ng/g or 
ng/mL) 
Mobile phase 
composition 
(0.2M Am 
For: Water: 
ACN: MeOH 
Inject
vol. 
(µL) 
Detection 
parameters 
(AUFS) 
Feces 1g 2500;5000; 
10,000;15000 
20,000 30:25:25:20 
 
10 0.05 
Bronchio-
alveloar 
lavage 
(BAL) 
fluid 
10mL 20;75;125;250 500 20:32:24:24 50 0.01 
CSF 5mL 40;150;250; 
500 
1000 20:32:24:24 50 0.01 
Synovial 
Fluid 
5mL 40;150;250; 
500 
1000 20:32:24:24 50 0.01 
 
 
Table 5.1.  HPLC operating parameters for non-standard tissues.  Full details see Clark 
et al. (Clark, Dowling et al. 2008(3)). 
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5.4.  Results 
 Foals tolerated the administration of the tilmicosin well.  Pulmotil is not soluble 
in water and forms a thick paste with the water and molasses that can be difficult to 
inject through the dosing syringe.  Cutting the catheter tip off the syringe facilitated 
administration of the tilmicosin paste.  Administration of tilmicosin did not result in 
adverse effects.  One foal was lame at the start of the study.  This was diagnosed as a 
septic fetlock joint during phase 1.  The foal was euthanized on human grounds and was 
not replaced.   
Analysis of the plasma samples collected in phase 1 of the study demonstrated low 
concentrations of tilmicosin in the plasma of the foals receiving the 30 mg/kg dose (Data 
not shown).  Tilmicosin was not measurable in the plasma samples from the foals 
receiving the 10 or 20 mg/kg doses.  The concentrations found in the 30 mg/kg samples 
were in the region of the LOD of the assay (Clark, Dowling et al. 2008(3)) and much 
lower than those found following a 10 mg/kg SC dose (Clark, Dowling et al. 2008(2)).  
Consequently we choose to use a dose of 40 mg/kg PO in phase 2 of the study. 
 Foals tolerated the oral dose of 40 mg/kg well, with no adverse effects noted.  
The results of the phase 2 tissue residue study are shown in Figure 5.1 (no tilmicosin 
was found in the tissues of the two control foals).  No tilmicosin was found in the CSF, 
joint fluid or BAL samples.  Pharmacokinetic analysis is shown in Table 5.2. 
Analysis of fecal samples collected at the time of euthanasia demonstrated 
extremely high concentrations of tilmicosin ranging from 183 µg/g to 483 µg/g (Table 
5.3). 
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Figure 5.1.  Tissue distribution of tilmicosin in equine tissues following an oral dose of 
40 mg/kg.  1 foal per time point. 
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Tissue MRT 
 (h) 
 Tmax  
  (h) 
 Cmax   
(ng/g) 
AUMC  
(h⋅ng/g) 
Lung 8.8 7 4008 335184 
Kidney 7.7 7 7149 446834 
Liver 7.33 7 5828 369506 
Muscle 6.3 7 883 33896 
Plasma  6.22 7 58 2931 
 
Table 5.2. Pharmacokinetic parameters following administration of 40 mg/kg p.o. 
tilmicosin every 24 h for two weeks. 
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Time post tilmicosin 
administration (hours) 
Fecal tilmicosin concentration 
(µg/g) 
4 
 
437 
 
7 
 
238 
 
12 
 
483 
 
16 
 
202 
 
24 
 
183 
 
 
Table 5.3.  Tilmicosin concentrations in feces following oral administration of tilmicosin 
40 mg/kg  
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The analysis of the tilmicosin susceptibility study demonstrates a MIC50 of 4 
µg/mL and an MIC90 of 8 µg/mL (range 1-8 µg/mL).  The distribution of the MICs is 
shown in Figure 5.2.  
 
5.5.  Discussion 
 
The results of the phase 1 dose ranging study demonstrate that an oral dose of a least 30 
mg/kg would be required in order to give detectable plasma concentrations.  We elected 
to use 40 mg/kg in phase 2 to ensure quantifiable plasma concentrations.  We have 
previously shown that tilmicosin concentrations in lung tissue are many times more 
concentrated than those found in plasma (Clark, Dowling et al. 2008(2)).  A 40 mg/kg 
dose of tilmicosin is high compared to the dose of other macrolides used in horses 
(Plumb 2002; Giguere, Jacks et al. 2004) or oral doses of tilmicosin that have been used 
experimentally in calves (Fodor, Reeve-Johnson et al. 2000).  The results imply that 
tilmicosin has a poor oral bioavailability in the horse.  Our estimate of the relative 
bioavailability (F) in this study is approximately 11 % compared to the SC dose.  It is 
possible to estimate the bioavailability of oral tilmicosin using the data generated in this 
study and in our previous study (Clark, Dowling et al. 2008(2)).  The estimate for the 
AUC in this study for plasma following a 40 mg/kg dose is 2.9 µg.h/g.  In our previous 
study the mean AUC following a single sc of 10 mg/kg was 6.7 µg.h /g.   Relative 
bioavailability is estimated by comparing the AUC and factoring in the four fold 
increased dose.  It approximates to 11%. 
It is not possible to fully calculate the absolute bioavailability as intravenous 
administration of tilmicosin results in fatal cardiac toxicity  
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Figure 5.2.  a.  Distribution of minimum inhibitory concentrations (MIC) for 45 R. 
equi isolates to tilmicosin.  b.  Cumulative distribution of R. equi isolate susceptibilities 
(MIC) , for tilmicosin.
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(Cochrane and Thomson 1990; Ziv, Shem-Tov et al. 1995).  The relative bioavailability 
is an estimate as the AUC for the oral dose is estimated from just three data points and 
the same animals were not used in the two studies.  The oral bioavailability of most 
antimicrobials is poor in the horse and highly dependent on the presence of feed in the 
intestines (Baggot 1992).  The bioavailability of erythromycin ranges from 13 – 26 % 
depending on the exact formulation studied (Lakritz, Wilson et al. 2000; Lakritz, Wilson 
et al. 2000) and azithromycin had an oral bioavailability of 39 or 56 % in two separate 
studies (Jacks, Giguere et al. 2001; Davis, Gardner et al. 2002).  The reasons for the low 
bioavailability of these antimicrobials, and especially the rough estimate of tilmicosin in 
the horse are not well understood (Baggot 1992).   
Foal feces contained extremely high concentrations of tilmicosin suggesting that 
the poor bioavailability is a result of poor absorption from the gastrointestinal tract 
rather than as a result of intestinal degradation or rapid hepatic excretion (first pass 
metabolism).  It is assumed that the presence of high concentrations of an antimicrobial 
in the intestinal lumen results in the disruption of the normal fecal flora demonstrated in 
our previous studies (Clark, Dowling et al. 2008(5)).  If this same effect is seen with 
other macrolide antimicrobials this may explain why the use of these products has been 
associated with diarrhea (Gustafsson, Baverud et al. 1997; Stratton-Phelps, Wilson et al. 
2000).  The high concentrations of antimicrobial in the feces may be enough to explain 
reports of diarrhea in the mares of treated foals, if the mares practice coprophagia with 
foal feces. 
Tilmicosin is easily administered to the foals at a dose of 40 mg/kg p.o. with no ill 
effects.  Oral dosing was used as opposed to an intra-gastric dosing to simulate the route 
of administration in a clinical case.  In addition repeated daily dosing by the intragastric 
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route is impractical, as is preventing feeding prior to drug administration.  An 
experimental model using analysis of tissue concentrations of tilmicosin was used in this 
and our previous study (Clark, Dowling et al. 2008(2)) for two reasons.  Firstly 
macrolides have an extremely high volume of distribution (Vd) (Prescott 2000) (Note: 
Vd was not calculated in this study as the dose was only administered by the oral route), 
consequently very little of the administered drug is present in the plasma.  Secondly, 
macrolides are known to accumulate preferentially in tissues and in WBCs, this is 
considered beneficial as the compounds are perceived to concentrate in the locale where 
they are most needed (Prescott 2000).  It can be argued that monitoring plasma 
concentrations and calculating plasma pharmacokinetics is of limited value as it does not 
describe the situation in the tissues where the drugs excerpt their beneficial effect.  This 
study focuses on the disposition of tilmicosin in body tissues where it accumulates rather 
than focusing on plasma concentrations.  This technique has been used in most food 
producing animals (Thompson and Lawrence 1994; Thomson, Darby et al. 1994).  
Researchers investigating other macrolides have measured plasma concentrations (Jacks, 
Giguere et al. 2002).  There has been some effort to investigate the deposition of the 
drug into other tissues by measuring concentrations in peripheral leucocytes, and cells 
recovered from BAL (Jacks, Giguere et al. 2001; Davis, Gardner et al. 2002).  How the 
concentration in these cells results to the concentration of the drug at the site of infection 
in the lung is not known.  Our studies are the first to directly measure tissue 
concentrations in the horse.  It is clear from our results that plasma concentrations of 
tilmicosin are of limited value in designing dose regimens for pneumonia.  The 
concentration of the drug found in the lung tissue was approximately 100 times greater 
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than that found in plasma and the MRT was longer for lung.  It was also apparent that 
the kinetics of tilmicosin in tissue is dependent on the tissue matrix of interest.   
Concentrations found in the BAL fluid are very low.  This is not surprising as 
tilmicosin does not appear to partition well into aqueous fluids (plasma, synovial fluid 
and CSF).  We had originally hoped to relate concentrations of tilmicosin in BAL to the 
concentrations of tilmicosin found in lung tissue.  Unfortunately at present the only way 
to determine the concentration of the drug in the lung is from post-mortem samples. 
The concentration of tilmicosin found in lung tissue is similar to those seen in 
other species where tilmicosin has been demonstrated to be effective: elk (9.2 µg/g @ 48 
h (Clark, Woodbury et al. 2004)), cattle (7.17 µg/g @ 24 h 
(http://www.fda.gov/cvm/efoi/section2/140929030392.html)), swine (2.59 µg/g @ 10 
days (Thomson, Darby et al. 1994)) , or mice (5.29 µg/g @ 2 h (Brown, Deleeuw et al. 
1995)).  However, measuring the concentration of tilmicosin in healthy lung tissue does 
not reflect the situation in an animal suffering from pneumonia (tilmicosin has been 
shown to accumulate in pneumonic lung (Modric, Webb et al. 1999) and does not reflect 
the local concentrations at the cellular level since tilmicosin has been shown to 
accumulate in WBCs (Scorneaux and Shryock 1999).  This is of particular importance 
with R. equi since the organism is able to survive and replicate within the lysosome of 
the macrophage (Wilkins 2004). 
 R. equi pneumonia is a condition that typically requires chronic therapy.  It is not 
uncommon for antimicrobial therapy to be used for 4 – 10 weeks (Wilkins 2004).  It is 
expected that during this period of therapy the macrolide will accumulate in body 
tissues.  Such accumulation should be beneficial providing it does not result in toxic 
effects and would contribute to the efficacy of treatment.  While it is possible to estimate 
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the amount of accumulation from a single dose it is obviously desirable that the 
concentrations achieved during chronic therapy be determined.  Consequently this study 
focused on long term administration of tilmicosin. 
The pharmacokinetics of oral tilmicosin in these foals differs markedly from our 
previous study (Clark, Dowling et al. 2008(2)).   It is important to recognize that there 
two parameters that have changed between these studies; the age of the foals, and the 
route of tilmicosin administration.  The tissue Cmax achieved with oral dosing of 40 
mg/kg once daily is approximately twice as high as that seen with a 10 mg/kg s.c. dose.  
However, the MRT is considerably shorter.  The injectable formulation had an MRT of 
approximately 27 hours in all tissues, whereas in this study the MRT ranges from 6.3 h 
in muscle to 8.8 h in lung.  The prolonged MRT with the injectable preparation is likely 
due to the slow rate of absorption from the injection site becoming the rate limiting step 
for elimination (so called “flip-flop” kinetics (Riviere 1999)).  The MRT following oral 
administration is likely to more accurately reflect the physiological rate at which the 
drug is cleared from the tissues. 
 The MIC90 for R. equi  (8 µg/mL) for tilmicosin was much higher than those 
reported for azithromycin, clarithromycin and erythromycin (1, 0.12 and <0.25 µg/mL 
respectively) (Jacks, Giguere et al. 2003).  It is tempting to link the low MIC for 
clarithromycin with the reported high efficacy in treatment described by Giguere et al. 
(Giguere, Jacks et al. 2004).  However, it is apparent that to date no controlled studies of 
the relative efficacy of the different macrolides have been conducted and that 
azithromycin appears to remain the most common choice of treatment among equine 
clinicians despite its high MIC (N. Cohen – Personal communication).  Although the 
MIC90 of tilmicosin for R. equi is higher than any of the other macrolides, this MIC90 is 
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similar to that reported for other respiratory pathogens (Histophilus somni 8 µg/mL, 
Mannheimia haemolytica 4 µg/mL, Pasteurella multocida 16 µg/mL) from cattle and 
sheep where the drug has a proven track record of very good efficacy (Prescott 2000). 
 The pharmacodynamics of the macrolide antimicrobials are not well understood.  
Their action is generally assumed to be concentration dependent and therefore the best 
predictor of efficacy should be the proportion of the dosing interval spent above the 
MIC.  The difficulty in making such a prediction in this case is that the concentration of 
the drug at the site of infection (the lysosome of the macrophage) remains unknown.  
The situation is further complicated by the fact that the MIC for an antimicrobial in vitro 
is unlikely to represent the effective concentration of the antimicrobial within the 
lysosome of the macrophage and does not take account of the possible positive and / or 
detrimental effects of the drug on the bactericidal actions of the cell.  Consequently it is 
not really possible to predict the efficacy of tilmicosin for the treatment of R. equi 
pneumonia.  Based upon the MRT of the oral dose in lung (8.8 h) compared to the MRT 
of the injectable dose in lung (28.3 h (Clark, Dowling et al. 2008(2))) and the fact that 
the injectable dose is effective for 72 hours  (package insert) an initial recommendation 
of once daily dosing would be appropriate. 
Tilmicosin has potential to be an effective treatment for R. equi pneumonia in 
foals based upon the pharmacokinetics, MIC and safety profile.  It also has the 
advantage of being a licensed veterinary pharmaceutical with no potential for human 
use.  Furthermore, tilmicosin is relatively inexpensive when compared to other modern 
macrolides costing less than $2/day (Canadian) to treat a 100kg foal compared to 
approximately $25 a day for azithromycin (based on costs from WCVM –VTH 
pharmacy). 
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Further studies are indicated to assess the clinical efficacy of tilmicosin in foals 
with R. equi pneumonia. 
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CHAPTER 6 
THE EFFECT OF TILMICOSIN ON THE FECAL FLORA OF 
RECENTLY WEANED FOALS 
Formatted for American Journal of Veterinary Research 
 
6.1.  Abstract 
Objective: 
To determine the effect of tilmicosin on the fecal flora of recently weaned foals. 
Animals or Sample Population: 
A group of 12 recently weaned (6 month old) foals purchased from a PMU ranch. 
Procedure: 
Foals were randomly allocated to receive tilmicosin at either 4 mg/kg po or 10 mg/kg sc.  
In phase one of the studies a single dose was administered.  In phase two the oral dose 
was administered daily and the injectable dose every 72 hours for a minimum of 2 
weeks. Foals were monitored throughout the study for any signs of ill health.  Feces 
were collected and analyzed using a quantitative culture technique to assess the impact 
of the antimicrobial on fecal flora.   
Results: 
By either route of administration, tilmicosin caused a transient reduction in fecal β-
hemolytic streptococci and a corresponding overgrowth in fecal coliforms, known 
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pathogens were not isolated.  Mild self limiting diarrhea was seen in one foal.  With 
chronic administration of tilmicosin the fecal flora appears to normalize within a week. 
Conclusions and Clinical Relevance: 
The effects of tilmicosin on the normal fecal flora were marked but the significance of 
the changes is not clear.  Had the animals been asymptomatic carriers of pathogenic 
Gram negative or tilmicosin resistant anaerobic bacteria, severe colitis may have 
occurred.  The technique used to quantify the changes in fecal flora has potential for use 
in better understanding the syndrome of antimicrobial associated diarrhea in the horse. 
 
6.2.  Introduction 
The macrolide antimicrobial tilmicosin is an efficacious treatment of bovine, ovine 
and porcine respiratory disease because of its antimicrobial spectrum, high volume of 
distribution and preferential accumulation in pulmonary tissue (Prescott 2000). It has a 
long half-life and can be administered subcutaneously or orally.  Its spectrum of activity 
includes most Gram-positive aerobes, Gram-negatives involved in respiratory disease 
(especially Pasteurella multocida, Mannheimia haemolytica and Histophilus somni) 
some anaerobes and Mycoplasma spp.(Prescott 2000). It is currently marketed in two 
forms: Micotil (Eli Lilly Canada Inc, Guelph, ON) is an injectable preparation licensed 
for the treatment of respiratory disease in sheep and cattle and is used extensively in 
North American feedlots; the product is also licensed in Italy for the treatment of rabbits. 
Pulmotil (Eli Lilly Canada Inc, Guelph, ON) is licensed as a feed additive for the 
prevention and control of respiratory disease in swine, this product is licensed for use in 
poultry in other parts of the world.  
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Macrolide antimicrobials have not been widely used in the horse.  Their main use 
has been in the treatment of R. equi infections in young foals (Dowling 2004).  The 
primary concern with their use is the potential for the development of antimicrobial 
associated diarrhea.  This syndrome has been investigated by researchers in Sweden who 
have implicated Clostridium difficile as a potential cause of the diarrhea (Baverud, 
Gustafsson et al. 1997; Baverud, Franklin et al. 1998).  Tilmicosin has the potential to be 
used in the treatment of R. equi infections and other severe equine pneumonias.  There is 
one report (Fenger 2000) published in 2000, describing an alternative injectable form of 
tilmicosin (IDEXX Pharmaceuticals, Durham, NC) used to successfully treat R. equi 
infection in two foals. A recent publication has described the pharmacokinetics of this 
product in foals (Womble, Giguere et al. 2006). 
We propose that tilmicosin has potential for use in equine veterinary medicine for 
three reasons.  Firstly, a retrospective analysis (Clark, Greenwood et al. 2008(1)) of 
1026 equine bacterial isolates collected over the past six years at the Western College of 
Veterinary Medicine (WCVM) has identified Streptococcus zooepidemicus as the most 
common bacterial species comprising 22% of all bacterial isolates. Of the 221 S. 
zooepidemicus species isolated from different sites of infection, 40% of them are from 
the respiratory tract. Although there are a wide variety of drugs to choose from; 
trimethoprim/sulfonamide (TMS) combinations are often chosen due to the ease of oral 
administration. However, only 55% of S. zooepidemicus isolates are reported as 
susceptible to TMS (using the CLSI standards which have not been validated for use in 
horses)(NCCLS 2002). Consequently, there is a need for a new, easily administered 
antibiotic for the treatment of equine respiratory disease. This need is particularly 
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relevant in equine feedlots, where respiratory disease is common and is typically treated 
with a variety of unlicensed antibiotics, especially long acting injectable preparations. 
Secondly, a great deal of recent research has been directed at a search for 
alternative treatments for R. equi infection in young foals. This is due to the 
development of antimicrobial resistance and the frequent dosing needed when 
erythromycin and rifampin are used. Currently, most interest has been focused on other 
macrolides or azolides such as azithromycin (Jacks, Giguere et al. 2001) or 
clarithromycin (Jacks, Giguere et al. 2002) even though neither drug is licensed for 
veterinary use and both are relatively expensive. Tilmicosin shares many of the 
pharmacokinetic and antimicrobial properties of these two drugs, is licensed for 
veterinary use and would be more economical for treatment.  
Thirdly, concern has been raised that the erythromycin / rifampicin combination in 
common usage may result in peracute colitis in the mare following ingestion of feces 
from the treated foals which contain high concentrations of erythromycin (Baverud, 
Franklin et al. 1998).  It is unknown if this effect is specific to this drug combination or 
is shared by all drugs of the macrolide class. 
The goal of this study was to assess the effect of tilmicosin on the fecal flora of a 
group of healthy weaned foals.  
 
6.3.  Materials and methods 
The use of horses in this research was approved by the University of 
Saskatchewan Animal Care Committee. 
 
6.3.1.  Study animals 
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 The study was conducted on 12 recently weaned cross-bred female foals 
acquired from a PMU ranch in Western Canada.  Foals were approximately 6 months 
old at the start of the study.  They represented various cross-breeds and their weight 
ranged from 130-245 kg.  Ten of the 12 foals were used in a separate study prior to 
being entered into this study and had received an ovariectomy conducted 
laproscopically. These foals did not receive any perioperative antibiotics in that study.  
A four week washout period was used to separate the two studies. 
 
6.3.2.  Phase 1 – single dose study 
 Foals were randomly allocated using a coin toss to receive either one dose of 10 
mg/kg tilmicosin (Micotil, Eli Lilly Canada Inc, Guelph, ON) subcutaneously (sc) at a 
single site in the side of the neck (label dose for cattle) or 4 mg/kg tilmicosin (Pulmotil, 
Eli Lilly Canada Inc, Guelph, ON) orally (po)(six animals per group).  Pulmotil was 
weighed out and placed in a catheter tip syringe. Before administration it was mixed 
with approximately 10mL corn syrup and 20 mL water to create a liquid paste that could 
be administered to the back of the mouth.  The choice of the 4 mg/kg body weight dose 
was based on a previous study (Buck and Thomson 1997); where horses receiving a 
dose which approximated to 4 mg/kg po had shown minimal reaction. 
 Individual fecal samples were collected per rectum for analysis immediately 
prior to tilmicosin administration and again 24, 48 and 72 hours post administration. A 
further sample was collected 7 days after tilmicosin administration. 
 
6.3.3.  Phase 2 - multiple dose study 
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 Following completion of the phase 1 study, all foals received a minimum of a 
two week washout period to eliminate previously administered drug.  All foals were then 
entered into the second phase of the study.  Foals remained allocated to the same 
treatment groups and received either 10 mg/kg tilmicosin sc every 72 hours (injections 
alternated between the left and right side of the neck) or 4 mg/kg tilmicosin PO every 24 
hours for 14 days. Since the oral dose was given daily and the injectable dose every 72 
hours, this amounted to approximately the same total dose over time via both routes. 
Individual fecal samples were again collected per rectum immediately prior to the 
first dose of tilmicosin and after 7 and 14 days of tilmicosin therapy. 
 
6.3.4. Fecal bacteriological analysis 
Fecal analysis was conducted in a semi-quantitative manner to determine the effect 
of tilmicosin on the number of bacteria isolated from the feces.  A 1 g portion of fresh 
feces was weighed out and diluted in 9 mL of sterile saline.  10-fold serial dilutions were 
conducted to produce dilutions from 10-1 to10-6.  A 0.1 mL aliquot of solution was 
pipetted onto agar plates and spread.  Six different culture methods were used; aerobic 
blood agar (Becton, Dickinson and Company, Sparks, MD), aerobic MacConkey 
(Becton, Dickinson and Company, Sparks, MD)(general culture), aerobic Hektoen, 
aerobic XL-T4 (selective and differential for Salmonella spp.), anaerobic blood agar with 
neomycin (for Clostridium perfringens) and anaerobic Clostridium difficile agar (CDSA- 
Becton, Dickinson and Company, Sparks, MD).  All plates were incubated at 37ºC for 
24 hours with the exception of the XL-T4 and CDSA which were incubated for 48 hours. 
Control colonies of Salmonella spp. were placed on MacConkey, Hektoen and XL-T4 
agar.  A control colony of Clostridium difficile was placed on the CDSA plate. Three 
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different plates were produced for each media using three sequential fecal dilutions.  The 
exact dilutions used for each media were based on either our preliminary studies (data 
not shown) or the culture results from the previous day. 
Bacteria were identified following standard biochemical procedures.  A simple 
count of each bacterial colony was made from one of the three plates per sample which 
was most easily read.  In the event that no bacterial colonies were found on the highest 
concentration plate, a simple mean was calculated between the presence of a single 
colony on the plate and zero.   
 
6.3.5.  Statistical analysis 
Statistical analysis was conducted using Statistix 8.0 (Analytical Software 
Tallahassee FL).  Non-parametric statistics were used due to the logarithmic distribution 
of the data.  Data was compared in a number of ways.  First a geometric mean was taken 
from the results of each horse across each day of the study to give an average bacterial 
count.   The two treatment groups were compared.  Second the fecal results from each 
group were compared on day zero and a day in the mid point of the study (Phase 1, day 
2, Phase 2, day 7). Analysis was conducted using the Wilcoxon rank sum test.  Finally 
the results from day zero were compared directly with the results from the mid point of 
the study using the Wilcoxon signed rank test.  In all cases significance was set at 
p≤0.05. 
 
6.4.  Results 
Tilmicosin was well tolerated at the doses used in this study. One foal developed 
mild diarrhea 24 hours after the first single dose of oral tilmicosin. The diarrhea was 
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mild, self limiting and lasted less than 6 hours; the foal showed no other clinical signs 
and required no treatment.  The foal remained in the study and was bright and alert with 
a good appetite throughout.  The fecal culture did not reveal any differences between 
this foal and the others in the study group and it was included in the results.  It did not 
develop diarrhea with subsequent doses of tilmicosin.  
 
6.4.1.  Fecal analysis 
Administration of tilmicosin by either route resulted in changes in fecal flora.  
There was minimal difference between the two treatment groups with respect to the 
changes in fecal flora, comparison of the mean fecal bacterial counts for each of the 
horses in phase 1 and phase 2 did not approach statistical significance.  The effects of a 
single dose of tilmicosin on the fecal counts of coliforms and β-hemolytic streptococci 
are shown in Figures 6.1 and 6.2.  Equine feces normally contain high levels of β-
hemolytic streptococci and lower numbers of coliforms.  Administration of a single dose 
of tilmicosin by either route resulted in a precipitous drop in the number of streptococci 
isolated from the feces and a corresponding overgrowth of fecal coliforms.  A 
comparison of the fecal bacterial counts from day 0 and day 2 gives results that are 
either significant or approach statistical significance (Table 6.1).  There was no change 
in the consistency of the feces, but the administration of tilmicosin was associated with a 
marked change in the odor of the feces which became much fouler smelling.  At no time 
during phase one of the studies was a clostridial organism or a Salmonella spp. isolated.   
The results of the fecal analysis from phase 2 of the studies are shown in Figures 
6.3 and 6.4.  In this part of the study, fecal samples were collected every 7 days; little or 
no effect on the fecal flora could be demonstrated following the administration of  
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Figure 6.1.  The effect of a single dose of tilmicosin (either 10 mg/kg sc or 4 mg/kg po) 
on fecal coliform counts 
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Figure 6.2.  The effect of a single dose of tilmicosin (either 10 mg/kg sc or 4 mg/kg po) 
on fecal β-hemolytic streptococcal counts. 
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Figure 6.3. The effect of repeated doses of tilmicosin (either 10 mg/kg sc q 72 hours or 4 
mg/kg po q 24 hours) on fecal coliform counts 
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Figure 6.4. The effect of repeated doses of tilmicosin (either 10 mg/kg sc q 72 hours or 4 
mg/kg po q 24 hours) on fecal β-hemolytic streptococcal counts. 
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Phase 1 
 
Phase 
2 
 
Dose of 
tilmicosin  
Fecal 
analysis  
Day 0  
CFU/g 
feces 
Day 2 
CFU/g 
feces 
p-value Day 0  
CFU/g 
feces 
Day 7 
CFU/g 
feces 
p-value 
β-
Streptococci 
2,230,000 500 0.036 349,000 2,050,000 0.29 10 mg/kg 
sc 
Coliforms 152,000 34,900,000 0.036 25,700 156,000 0.4 
β-
Streptococci 
48,000 500 0.063 1,180,000 381,000 0..67 4 mg/kg 
po 
Coliforms 254,000 6,820,000 0.059 32,700 36,200 0.83 
 
Table 6.1. Wilcoxon Signed Rank Test comparing fecal bacterial counts (geometric 
mean) on day zero and mid way through the study (Phase 1, day 2; Phase 2, day 7) 
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repeated doses of tilmicosin (Table 6.1). Once again, no clostridial organisms or 
Salmonella spp. were detected in any of the fecal samples cultured. 
 
6.5. Discussion  
The syndrome of antimicrobial associated diarrhea has been extensively described 
in the veterinary literature (Whitlock 1986; Jones 2004).  However, the majority of these 
reports have not described important data such as the etiological agent and in many 
cases there are other factors that may have had a significant bearing on the development 
of acute colitis besides the use of antimicrobials such as hospitalization, transport or 
surgery (Traub Dargatz, Garber et al. 2000).  There has been little directed research in 
this area. In the one controlled study that investigated antimicrobial associated diarrhea, 
(Wilson, MacFadden et al. 1996) the length of stay in the hospital was a far more 
significant predictor of developing diarrhea than the administration of antimicrobials.  
Notwithstanding, macrolide antibiotics have been frequently implicated as being a cause 
of diarrhea especially in association with Clostridium spp. (Prescott, Staempfli et al. 
1988) More recently, interest has been primarily focused on Clostridium difficile 
(Weese, Staempfli et al. 2001). 
Quantitative fecal bacteriology is a simple technique that can be used to 
investigate the effect of antimicrobials on the normal fecal flora.  However the technique 
has not been widely used.  It was first described by Andersson et al. in 1971 (Andersson, 
Ekman et al. 1971) when investigating the effects of oxytetracycline.  These authors 
demonstrated a rapid, marked increase in the number of fecal coliforms and an increase 
in the number of Cl. perfringens isolated following the administration of 
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oxytetracycline.  In one horse the changes in the fecal flora persisted.  In the other the 
fecal flora normalized with a week.   
The techniques was also used by White and Prior (White and Prior 1982) to 
investigate the effects of oxytetracycline and trimethoprim/sulphadiazine on fecal flora.  
Trimethoprim/sulphadiazine had relatively little effect on the fecal flora.  The effects of 
oxytetracycline were similar to those previously described with a marked increase in 
fecal coliforms.  The authors also demonstrated an increase in the number of fecal 
streptococci (type not specified) and Bacteroides spp.  The effects on the fecal flora 
were relatively transient.  Although the oxytetracycline continued to be administered the 
fecal flora returned to normal within approximately one week.  The technique used in 
this paper for quantitating the fecal bacterial population differs from those described 
previously in that we followed the general populations of β-hemolytic streptococci and 
coliform bacteria and specifically focused on identifying known equine enteric 
pathogens; Salmonella spp., Cl. difficile and Cl. perfringens. 
The normal fecal flora of the foals in this study consisted of predominately β-
hemolytic streptococci, enterococci and lower numbers of coliforms.  There were also 
occasional Bacillus spp. isolated (less than 10-2/g).  Clostridium spp. were not found as 
part of the normal flora.  In this respect, the normal feces are similar to those described 
by previous researchers(Andersson, Ekman et al. 1971; Wierup 1977; White and Prior 
1982). 
It is apparent that regardless of the route or dose, tilmicosin initially resulted in the 
same effect on the fecal flora.  In general, there appears to be a marked reduction in the 
normal aerobic Gram-positive flora and a corresponding over growth of aerobic Gram-
negative organisms. Such an effect is not entirely unexpected given the spectrum of 
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tilmicosin, which is mainly active against Gram positive aerobes (Prescott 2000).  
Unfortunately, this study had little power given the small number of research animals, 
the use of non-parametric statistics and the lack of a negative control.  Consequently, the 
results did not meet the criteria for statistical significance however, they did come very 
close.   
The best explanation for the minimal difference seen between the two treatment 
groups is that both orally and systemically administered tilmicosin exerts a direct effect 
on the intestinal flora. A systemically administered dose is excreted mainly by hepatic 
metabolism and is excreted in the bile (Prescott 2000) where it is presumed to retain its 
activity and is available to affect the intestinal flora.  The intestines are obviously 
directly exposed to the orally administered dose. 
It is surprising that the severe disruption of the fecal flora noticed in this study was 
not associated with clinical disease.  However, the normal fecal flora of the horse has not 
been widely studied and there is little with which to compare these findings.  This is also 
a relatively simple bacterial assay of feces.  The feces of the horse obviously contain 
many species of bacteria, particularly anaerobic bacteria; for the purposes of this study, 
we focused only on aerobic β-hemolytic streptococci, coliforms, and a detailed search 
for Salmonella spp, Cl. difficile and Cl. perfringens.  There might be other fecal bacterial 
species of clinical importance that we did not investigate.  The noticeable change in the 
smell of the feces post tilmicosin treatment suggests an increase in the number of 
anaerobic Gram negative bacteria; however the study of these bacteria was not included 
in the current design.  It is also likely that the aerobic / facultative fecal flora of the horse 
does not represent the bacterial flora present within the various sections of the colon 
where more important changes potentially resulting in disease are most likely to occur.  
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The fecal flora are however readily accessible and fecal culture is routinely used for the 
diagnosis of bacterial colitis. 
The foals in this study were from a single high health status herd.  At no point in 
the study was Salmonella spp., Cl. difficile or Cl. perfringens cultured. It is possible that 
none of these horses were carriers of these bacteria.  Had they been subclinically 
infected (particularly with tilmicosin resistant strains of clostridium) the disruption of 
the normal fecal flora may have allowed these potential pathogens to multiply within the 
intestines and reach concentrations which may have resulted in clinical disease. 
The effect of chronic antibiotic therapy is less clear.  It would seem logical to 
assume that administration of the tilmicosin initially resulted in a similar effect on the 
fecal flora.  However the fecal sample collected after 7 days of administration were 
indistinguishable from normal feces, implying that the fecal flora had normalized even 
in the face of continued tilmicosin therapy.  An effect that has been described previously 
(Andersson, Ekman et al. 1971; White and Prior 1982).  This may have been due to the 
rapid development of streptococcal resistance to tilmicosin. In this study, samples of 
bacteria were not collected to evaluate the MIC of tilmicosin before and after treatment 
so we are unable to determine if the effect is due to the rapid development of 
antimicrobial resistance.  Further studies are needed to address this issue and the effects 
of other antimicrobials on the fecal flora of horses. In particular quantitative study of 
Gram negative anaerobes should be included in similar studies. 
In conclusion, administration of a single dose of tilmicosin either orally (4 mg/kg) 
or by subcutaneous injection (10 mg/kg) results in a similar effect on the fecal flora; 
essentially there was a marked reduction in the normal β-hemolytic streptococci 
population and a corresponding overgrowth of coliforms.  The effect on the fecal flora 
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lasted approximately 1 week after a single dose.  The change in fecal flora was not 
associated with disease and no known pathogens were isolated from the fecal flora.  The 
effects of long term therapy were hard to assess due to the experimental design, 
essentially long term therapy was not found to cause any significant changes in the fecal 
flora after a week of therapy.  The techniques described in this paper for quantitative 
fecal bacteriological analysis may be of use in quantifying the effects of other antibiotics 
on fecal flora and in providing a greater understanding of the syndrome of antimicrobial 
associated diarrhea in the horse.   
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CHAPTER 7 
A COMPARISON OF THE EFFECTS OF ORAL TILMICOSIN AND 
INTRAMUSCULAR CEFTIOFUR ON THE FECAL FLORA OF ADULT 
HORSES. 
 
7.1.  Abstract 
Administration of ceftiofur and macrolide antimicrobials has been associated with 
the development of peracute diarrhea in horses.  We have previously demonstrated using 
a quantitative fecal bacterial assay that administration of tilmicosin results in significant 
disruption of the normal fecal flora of the weaned foal and that this disruption is not 
necessarily associated with the development of diarrhea.  Using a double-blinded study 
design the effects of ceftiofur (4.4 mg/kg im) and tilmicosin (4 mg/kg po) on the fecal 
flora of mature horses were compared.  The effects of tilmicosin were similar to those 
previously described with a reduction in the numbers of Gram positive aerobic bacteria 
and a corresponding significant overgrowth of Gram negative coliforms.  In contrast to 
our previous study large numbers of Cl. perfringens were also found in feces following 
tilmicosin administration.  Administration of ceftiofur was associated with a less 
dramatic change in the normal fecal flora.   
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It is concluded that the syndrome of antimicrobial associated diarrhea is complex 
and that different pathological processes may be associated with different classes of 
antimicrobials.  
 
7.2.  Introduction 
 Many antimicrobial drugs used in the horse have been reported to be associated 
with the development of severe diarrhea.  It is assumed that the antimicrobials 
selectively target a component of the normal fecal flora of the horse.  This provides a 
niche allowing the intestines to be colonized with pathogenic bacteria resistant to the 
antimicrobial.  An alternative theory is that the antimicrobials alter the fecal flora 
resulting in changes in fermentation of feed.  This alters the fatty acid profiles within the 
intestines favoring the growth of pathogenic bacteria (Jones 2004).  Unfortunately, most 
reports of antimicrobial associated diarrhea are either simple case reports or short case 
series; most do not include a bacterial etiology for the diarrhea.  There has been little in 
the way of controlled clinical studies to investigate the syndrome.   
 Some researchers over the years have attempted to document the effect of 
antimicrobial administration on fecal flora using quantitative microbiological 
techniques.  Andersson et al. (Andersson, Ekman et al. 1971) showed that 
oxytetracycline resulted in an overgrowth of fecal coliforms and Cl. perfringens.  White 
at al (White and Prior 1982) confirmed the effect of oxytetracycline and showed that 
trimethoprim/sulfadiazine had little effect on the fecal flora.  Both studies also showed 
that with continued use of the antimicrobials the fecal flora would eventually return to 
normal, typically within 1 week. 
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 In a recent study, (Clark, Dowling et al. 2008(2)) we demonstrated that 
tilmicosin (Pulmotil, Eli lily Canada Inc, Guelph, ON) may be orally administered to 
weaned foals without adverse clinical reactions at a dose of 4 mg/kg.  As part of this 
study the effect of the drug on the bacterial populations within the feces was 
determined.  Tilmicosin caused a transient, but marked change in the types of bacteria 
within the feces similar to that described for oxytetracycline (Andersson, Ekman et al. 
1971).  However at no time were organisms that have been previously associated with 
acute colitis isolated.  There was no severe disease and only one animal developed a 
transient diarrhea (less than 6 hours in duration).  
 Ceftiofur (Excenel, Pharmacia Animal Health, Orangeville, ON) is widely used 
in the equine industry.  Anecdotally, this drug has been associated with acute equine 
colitis.  A review of the literature reveals little in the way of documented episodes. 
Foreman (Foreman 1998), reported a small case series, unfortunately in these cases no 
bacteriology was conducted to confirm the cause of the diarrhea.  This is particularly 
important as the horses used in the study had been recently transported and had also 
undergone surgery, both known risk factors for the development of Salmonella colitis 
(Owen, Fullerton et al. 1983).  The Freedom of Information summary from the Center 
for Veterinary Medicine, FDA for the approval for ceftiofur use in horses reports that 
mild diarrhea and weight loss was seen in some horses receiving very high doses of 
ceftiofur (25 mg/lb iv)(http://www.fda.gov/cvm/FOI/1496.htm).  However, the adverse 
reactions were mild and were only seen in animals receiving doses above the 
recommended label dose. 
 The aim of this study was to compare the effects of these two antimicrobials on 
the fecal flora of healthy adult horses using quantitative bacteriological techniques. 
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7.3.  Materials and methods 
 The use of horses in this research was approved by the University of 
Saskatchewan Animal Care Committee. 
 Twelve healthy mares from the teaching herd of the Veterinary Teaching 
Hospital were randomly allocated using a coin toss to receive either an intra-muscular 
dose of 4.4 mg/kg ceftiofur (Plumb 2002) or oral 4 mg/kg tilmicosin (Clark, Dowling et 
al. 2008(2)) mixed with corn syrup and water.  The horses also received either an oral 
dose of water and syrup or an injection of saline respectively to control for the 
administration of the other drug and to blind the investigator as to the treatment.  The 
mares were monitored on a daily basis for any signs of ill health. 
7.3.1.  Fecal bacteriological analysis 
Fecal analysis was conducted in a quantitative manner in order to determine the 
effect of tilmicosin on the absolute number of bacteria isolated from the feces (Clark, 
Dowling et al. 2008(5)).  A 1g portion of fresh feces was weighed out and diluted in 9 
mL of sterile saline.  Serial dilutions were conducted by diluting 1:10 to produce 
dilutions as low as 10-6.  A 0.1 mL aliquot of solution was pipetted onto agar plates and 
spread.  Six different culture methods were used; aerobic blood agar (Becton, Dickinson 
and Company, Sparks, MD), aerobic MacConkey (Becton, Dickinson and Company, 
Sparks, MD), aerobic Hektoen, aerobic XL-T4, anaerobic blood agar with neomycin and 
anaerobic Clostridium difficile agar (CDSA- Becton, Dickinson and Company, Sparks, 
MD).  All plates were incubated at 37ºC for 24 hours with the exception of the XL-T4 
and CDSA which were incubated for 48 hours.  Control colonies of Salmonella spp. 
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were placed on MacConkey, Hektoen and XL-T4 agar.  A control colony of Clostridium 
difficile was placed on the CDSA plate. 
Three plates were produced from sequential fecal dilutions from each sample.  The 
exact dilutions used were based on either our preliminary studies (data not shown) or the 
culture results from the previous day. 
Bacteria were identified following standard procedures. When necessary, 
additional biochemical tests were used to identify specific colonies.  A simple count of 
each bacterial colony was made from one of the three plates per sample which was most 
easily read.  In the event that no bacterial colonies were found on the highest 
concentration plate, a simple mean was calculated between the presence of a single 
colony on the plate and zero.  Results are presented as a geometric mean calculated for 
each of the horses in that study group with error bars representing the range. 
7.3.2.  Statistical analysis 
Statistical analysis was conducted using Statistix 8.0 (Analytical Software 
Tallahassee FL).  Non-parametric statistics were used due to the logarithmic distribution 
of the data.  Data was compared in a number of ways.  First, a geometric mean was 
taken from the results of each horse across each day of the study to give an average 
bacterial count.   The two treatment groups were compared.  Second, the fecal results 
from each group were compared on day zero and day 2. Analysis was conducted using 
the Wilcoxon rank sum test.  Finally the results from day zero were compared directly 
with the results from day 2 of the study using the Wilcoxon signed rank test.  In all cases 
significance was set at p≤0.05. 
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7.4.  Results 
 The administration of both drugs was tolerated very well by all horses.  There 
were no signs of ill health in either group. One horse in the ceftiofur treatment group 
was removed from the study because it was not possible to safely collect feces from the 
rectum without restraint facilities. The fecal consistency of the two groups was 
indistinguishable; however it was apparent that the feces from the horses treated with 
tilmicosin had an unusual “sour” odor. 
The effects of the two antimicrobials on fecal flora are shown in Figures 7.1 and 
7.2.  The effects of tilmicosin on the fecal flora of the horses were similar to those 
previously reported (Clark, Dowling et al. 2008(5)).  There was a drop in the number of 
β-hemolytic streptococci which was not statistically significant and a corresponding 
overgrowth of fecal coliforms which approached significance (Table 7.1).  The fecal 
flora began to normalize by day 3 and was essentially back to normal by day 7.  
Administration of ceftiofur resulted in only minor change in the number of fecal 
streptococci.  However there was an increase in the number of fecal coliforms that 
approached statistical significance on day 2 of the study (Table 7.2).  Comparison of the 
results from the ceftiofur and tilmicosin treated horses on day 2 demonstrates a much 
greater number of coliforms in the feces of the tilmicosin treated group that approaches 
statistical significance (Table 7.3).   
Salmonella spp. and Clostridium difficile were not isolated from any of the fecal 
studies throughout the study.  A number of organisms resembling Salmonella spp. were 
identified but were later demonstrated to be either Citrobacter spp. or Morganella.   
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Figure 7.1.  The effect of a single dose of ceftiofur (4.4 mg/kg im) or tilmicosin (4 
mg/kg po) on the number of β-hemolytic streptococci isolated from equine feces. 
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Figure 7.2.  The effect of a single dose of ceftiofur (4.4 mg/kg im) or tilmicosin (4 
mg/kg po) on the number of coliform bacteria isolated from equine feces. 
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Treatment group (geometric mean bacterial 
colonies /g feces) 
 
Fecal 
analysis  
Ceftiofur       
4.4 mg/kg im 
Tilmicosin            
4 mg/kg po 
p-value 
Streptococci 1.06E+05 
 
3.57E+04 
 
0.3153 
Coliforms 2.58E+05 
 
7.13E+06 
 
0.0828 
 
Table 7.1.  Wilcoxon Rank Sum Test comparing average fecal bacterial counts 
(geometric mean) throughout the study  
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Treatment 
group 
Fecal 
analysis 
Day 0  
CFU/g 
feces 
Day 2 
CFU/g 
feces 
p-value 
Streptococci 1.35E+05
 
1.11E+04
 
1.0000 Tilmicosin      
4 mg/kg po 
Coliforms 2.80E+05
 
1.08E+08
 
0.0360 
Streptococci 4.86E+04
 
1.07E+05
 
0.4185 Ceftiofur       
4.4 mg/kg 
im Coliforms 9.59E+04
 
2.57E+06
 
0.0591 
 
Table 7.2.  Wilcoxon Signed Rank Test comparing fecal bacterial counts (geometric 
mean) on day zero and day 2. 
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Treatment group  
(fecal bacterial count /g 
feces) 
Day of 
study  
Fecal 
analysis  
Ceftiofur       
4.4 mg/kg im 
Tilmicosin       
4 mg/kg po 
p-value 
Streptococci 4.86E+04 
 
1.35E+05 
 
0.6451 
 
Day 0 
Coliforms 9.59E+04 
 
2.80E+05 
 
0.5209 
Streptococci 1.07E+05 
 
1.11E+04 
 
0.3889 Day 2 
Coliforms 2.57E+06 
 
1.08E+08 
 
0.0552 
 
 
Table 7.3.  Wilcoxon Rank Sum Test comparing fecal bacterial counts between 
treatment groups (geometric mean) on day zero and day 2 
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morganii.  Colonies growing on the CDSA initially looked like Clostridium difficile 
however these were later shown to be Enterobacter cloacae. 
 Three of the six horses treated with tilmicosin showed significant overgrowth of 
Clostridium perfringens in the feces on at least one day in the study (Figure 7.3).  Cl. 
perfringens was not isolated from the feces of any horse prior to entry into the study.  
The numbers of Cl. perfringens isolated were very high ranging from 20,000 per gram to 
2,000,000 per gram.  Overgrowth by Cl. perfringens always occurred 48 hours after 
tilmicosin administration and the presence of the Cl. perfringens was short lived lasting 
only 1 to 2 days.    This effect was not seen in the ceftiofur treated horses.  A Fisher’s 
exact test on the data gives a p value of 0.18. 
 
7.5. Discussion 
 
 The effect of tilmicosin on the feces was very similar to that described in 
recently weaned foals with a reduction in the number of β-hemolytic streptococci and an 
increase in the number coliforms isolated from the feces (Clark, Dowling et al. 2008(5)).  
However, a major difference was the isolation of Cl.  perfringens.  Whether Cl. 
perfringens is a normal component of the equine fecal flora has been the issue of some 
debate it would appear that it may be found in the feces of normal horses but typically in 
low numbers and in a low percentage of horses (15%) (Jones 2004).  In our previous 
study we did not isolate Cl. perfringens from any study horses (Clark, Dowling et al. 
2008(5)).  It was also not isolated from any horses on day 0 of this study.  Other 
researchers have suggested that normal horse feces should contain less than 100 Cl. 
perfringens CFUs/g feces  
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Figure 7.3.  The effect of a single dose of tilmicosin (4 mg/kg po) on the number of Cl. 
perfringens isolated from the feces of three horses. 
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(Wierup 1977; Wierup and DiPetro 1981). Cl.  perfringens has been associated with 
severe colitis in the horse.  Colitis is generally associated with the presence of particular 
toxigenic strains of Cl. perfringens.  These strains secrete toxins especially Cl. 
perfringens enterotoxin (CPE) produced by Cl. perfringens Type A. More recently there 
have been reports of colitis associated with an alternative strain of Cl. perfringens  
producing a β2-toxin (Jones 2004).  The presence of the toxin can be confirmed by PCR 
analysis or ELISA.  Such analysis was not conducted in this study as the animals did not 
show any signs of ill health.  Some researchers have previously suggested that colitis 
associated with Cl.  perfringens may be associated with high numbers of the organisms 
in the feces (Wierup 1977; Wierup and DiPetro 1981).  A cut off of more than 106 
CFUs/g has been suggested as being common in horses with disease, however this 
association has since been questioned (Weese, Staempfli et al. 2001).  As this study 
shows, high numbers of Cl. perfringens are not always associated with disease. The 
presence of an enterotoxin producing strain in sufficient numbers would appear to be 
necessary for disease.  It is assumed that the horses in this study were not carrying CPE 
strains of Cl. perfringens, nor were they exposed to toxigenic strains during the 
performance of the study.  One can assume that if they had been exposed to a CPE strain 
of Cl. perfringens while receiving tilmicosin; the bacteria may have colonized the 
intestines following the disruption of the normal fecal flora resulting in disease. 
 The reduction in aerobic Gram positive organisms (especially β-hemolytic 
streptococci) and the corresponding overgrowth of the Gram negative coliforms 
associated with tilmicosin administration was similar to that seen previously in foals 
(Clark, Dowling et al. 2008(5)).  This effect is not unexpected as the spectrum of activity 
of tilmicosin targets Gram positive organisms.  Tilmicosin is assumed to be present in 
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the intestines in high concentrations since it was administered orally and is poorly 
absorbed from the gastrointestinal tract (Clark, Dowling et al. 2008(2)).  The equine 
aerobic fecal flora consists predominately of Gram positive streptococci (Wierup 1977; 
Clark, Dowling et al. 2008(5)) and administration of tilmicosin would therefore be 
expected to dramatically alter the bacterial populations within the intestines. Although 
these changes in fecal flora were not associated with disease, the overgrowth of the 
coliform organism is of concern.  Had the animals in the study been subclinical carriers 
of Salmonella spp. (Traub Dargatz, Garber et al. 2000) then this disruption in fecal flora 
could have allowed the overgrowth of Salmonella spp. resulting in clinical disease. 
The effects of ceftiofur on the fecal flora were less dramatic with an increase in the 
number of fecal coliforms 2 days after administration.  The number of streptococci did 
not alter significantly and Cl. perfringens was not isolated from any of the samples. This 
is in contrast to the widely held belief that the use of ceftiofur is associated with the 
development of bacterial colitis.  The lack of effect on the flora is perhaps not that 
surprising when one considers the pharmacokinetics of ceftiofur.  The drug is 
administered parentrally and is highly protein bound with a relatively small volume of 
distribution.  Ceftiofur is rapidly excreted by the kidneys with a half-life of 2.49 (± 0.49) 
hours (Cervantes, Brown et al. 1993).  Consequently, it is anticipated that relatively little 
drug will actually make its way into the intestinal mucosa let alone the intestinal 
contents.   Ceftiofur is also a broad spectrum antimicrobial with activity against Gram 
positive and negative organisms as well as some activity against anaerobes (Prescott 
2000; Weese, Staempfli et al. 2000).  Ceftiofur would, therefore, be expected to have 
much less effect on the fecal flora than tilmicosin. 
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Our understanding of the importance of Cl. difficile as a cause of equine enteritis 
has been increasing (Weese, Staempfli et al. 2001).  Similar to Cl. perfringens, Cl. 
difficile can rarely be found in the feces of normal horses.  However, it is specifically the 
toxigenic strains producing the A and B toxins that are associated with enteritis.  We did 
not isolate Cl. difficile from any horses involved in this study, however Cl. difficile is 
very difficult to culture, particularly without using enrichment broth.  Clinical diagnosis 
of colitis due to Cl. difficile is commonly made using an ELISA for the toxins (Weese, 
Staempfli et al. 2000).  We did not perform a toxin assay as none of the horses 
developed diarrhea.  However, it seems that the association of Cl. difficile and equine 
enteritis does have some regional differences.  While toxigenic strains of Cl. difficile are 
commonly isolated in certain geographical areas we have rarely documented cases in 
Saskatchewan.  The reasons for this geographical association are not clear but may be 
related to factors such as climate and soil type.  Despite the fact that Cl. difficile was not 
isolated from horses in this study, the possibility that alterations in fecal flora seen with 
oral tilmicosin administration could predispose to overgrowth of Cl. difficile in the 
intestines cannot be discounted. 
This study consisted of the administration of a single dose of antimicrobial and, 
therefore, its application to a therapeutic course of treatment lasting several days may be 
questioned.  We have demonstrated in our previous study (Clark, Dowling et al. 
2008(5)) a finding reported by other researchers that when a course of antimicrobials are 
administered the fecal flora is initially disrupted  but that it returns to normal within 
approximately one week (Andersson, Ekman et al. 1971; White and Prior 1982).  In this 
study, we elected to follow the effects of a single dose before following the logical 
progression of documenting the effects of a course of antimicrobials. 
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This was also a small study and suffers from a lack of power due to the small 
number of subjects and the necessity of using non-parametric statistics.  Consequently, 
few of the results reach statistical significance.  However, it is apparent that many of the 
results come very close to the accepted significance level of 5%.  Given the great 
variability in the fecal culture results a much larger study is required to truly assess the 
significance of the results. 
It is surprising that the severe disruption of the fecal flora noticed in this study was 
not associated with clinical disease.  However, the normal fecal flora of the horse has not 
been widely studied and there is little with which to compare these findings.  This is also 
a relatively simple bacterial assay of feces.  The feces of the horse obviously contain 
many species of bacteria, particularly anaerobic bacteria.  For the purposes of this study, 
we focused only on β-hemolytic streptococci, coliforms, and a detailed search for 
Salmonella spp, Cl. difficile and Cl. perfringens.  There might be other fecal bacterial 
species of clinical importance that we did not investigate.  It is also likely that the fecal 
flora of the horse does not represent the bacterial flora present within the various 
sections of the colon where more important changes potentially resulting in disease are 
most likely to occur.  The fecal flora, is however, readily accessible and fecal culture is 
routinely used for the diagnosis of bacterial colitis. 
In conclusion, we have shown that a simple quantitative fecal bacteriological assay 
can give important information about the effect of antimicrobial administration on the 
normal fecal flora.  We have confirmed that oral tilmicosin reduces the number of β-
hemolytic streptococci isolated from the feces with a corresponding significant 
overgrowth in Gram negative coliforms.  In this population of horses we also 
documented the appearance of large numbers of Cl. perfringens following tilmicosin 
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administration.  Cl. difficile was not isolated at any time.  In contrast, ceftiofur had less 
effect on the fecal flora with only a transient slight increase in fecal coliforms.  While 
none of the animals developed clinical disease, it is apparent that tilmicosin or ceftiofur 
has the potential to allow the overgrowth of enteropathogenic bacteria especially 
Salmonella spp. Tilmicosin also has the potential to allow overgrowth of toxigenic 
strains of Cl. perfringens with the risk of developing acute enteritis.   
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CHAPTER 8 
THE EFFECT OF ORAL TILMICOSIN ON THE FECAL FLORA OF 
UNWEANED FOALS 
Formatted for American Journal of Veterinary Research 
 
8.1.  Abstract 
Objective: 
To determine the effect of oral tilmicosin on the bacterial fecal populations in unweaned 
foals 
Animals or Sample Population: 
A group of 8 unweaned foals and their mares purchased from a PMU ranch in western 
Canada 
Procedure: 
Phase 1.  Foals were randomly divided into four groups of two to receive a single dose 
of 10, 20 or 30 mg/kg tilmicosin po.  Two foals remained as negative controls.  Fecal 
samples were collected and analyzed in a quantitative microbiological manner to 
determine the changes in the bacterial populations over time. 
Phase 2.  Following a 2 week wash-out period the previously treated foals received a 
daily dose of 40 mg/kg tilmicosin for 2 weeks.  Changes in the fecal bacterial 
populations were again monitored. 
Results: 
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The fecal flora of unweaned foals differed from that of weaned foals and adults.  
Enterococcus spp. and coliforms with occasional Bacillus spp. were the predominate 
bacteria.  Β-hemolytic streptococci were rarely isolated.  Administration of a single dose 
of tilmicosin resulted in a decrease in the number of Bacillus spp, an increase in the 
number of coliforms and a marked increase in the number of Cl. perfringens.  No 
animals developed diarrhea. 
In phase 2 of the study chronic administration of tilmicosin at 40 mg/kg resulted in very 
little change in the fecal flora at day 6 or 13 of the study.  No diarrhea was noted. 
Conclusions and Clinical Relevance: 
The difference in the fecal flora of the unweaned foal may explain why administration of 
macrolide antimicrobials is tolerated better in foals than adult horses.  Tilmicosin 
resulted in changes in the fecal flora of the foals but these changes were less pronounced 
that those observed in our previous studies.  The effect on the fecal flora is most 
pronounced immediately after therapy is started.  The fecal flora is able to normalize in 
the face of continued therapy. 
If a foal receiving macrolide therapy were to develop diarrhea, it would be important to 
rule clostridial organisms as possible etiologic agents. 
 
8.2.  Introduction 
Tilmicosin is a macrolide antibiotic that was developed as a chemical modification 
of tylosin.  It is currently marketed as an injectable preparation (Micotil Eli Lilly Canada 
Inc, Guelph, ON) for use in cattle and sheep and a feed additive (Pulmotil Eli Lilly 
Canada Inc, Guelph, ON) for use in swine.  The injectable product is also licensed for 
use in rabbits in Italy and the feed premix is licensed for use in poultry in several parts 
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of the world.  Its use in the horse has been discouraged due to concerns about possible 
toxicity; especially cardiac toxicity (Prescott 2000)(US drug insert).  There is however 
one report (Fenger 2000) of the successful use of an alternative injectable preparation 
(IDEXX Pharmaceuticals, Durham, NC) of tilmicosin to treat Rhodococcus equi 
infection in two foals.  More recently, the pharmacokinetics of this preparation have 
been described (Womble, Giguere et al. 2006).  No serious toxic effects were described 
in either study.  We have previously demonstrated that tilmicosin may be administered 
to weaned foals either orally (4 mg/kg) or by subcutaneous injection (10 mg/kg).  Other 
than swelling at the site of injection, there were no signs of acute toxicity (Clark, 
Dowling et al. 2008(2)), however the fecal flora was disrupted (Clark, Dowling et al. 
2008(5)) leading to concerns about antimicrobial associated diarrhea (ADD).  The 
syndrome of AAD is poorly understood, but is generally assumed that the administration 
of antimicrobials results in a disruption the normal enteric bacterial flora which allows 
the overgrowth of pathogenic species resulting in clinical disease (Jones 2004).  We 
have previously shown that the administration of tilmicosin by either the oral or 
injectable route has a profound effect on the fecal flora of weaned foals.  The 
administration of tilmicosin resulted in a reduction of Gram positive bacteria and a 
corresponding overgrowth of gram negative bacteria.  Despite these marked changes, no 
significant pathogens were isolated and only one foal developed mild transient diarrhea 
(Clark, Dowling et al. 2008(5)).   
In a second study tilmicosin 4 mg/kg po was administered to adult horses (Clark, 
Dowling et al. 2008(6)).  The effects on the fecal flora were similar and no animals 
showed signs of clinical disease.  However, very high numbers of Cl. perfringens were 
cultured from the feces of half the horses treated with tilmicosin.  
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The aim of this study was to determine if tilmicosin could be used safely in 
unweaned foals.  In particular, we hypothesized that the milk diet of the foal would 
result in a different bacterial population when compared to the weaned foal.  
Specifically, the milk diet may be associated with a predominantly Gram negative fecal 
flora that would be more stable in the face of tilmicosin therapy. 
 
8.3.  Materials and methods 
The use of horses in this research was approved by the University of 
Saskatchewan Animal Care Committee. 
 
8.3.1.  Study animals 
 The study was conducted on 8 unweaned foals and their dams acquired from a 
Pregnant Mare’s Urine (PMU) ranch in Western Canada.  The foals were approximately 
6 weeks old at the start of the study.  They represented a number of cross-breeds of 
horse and their weight ranged from 86-160kg.  After transport to the Veterinary College, 
the foals were allowed a 2 week period to acclimatize to their new surroundings before 
the study commenced.  Mare and foals were housed in a research paddock at the 
University of Saskatchewan with free access to hay and water.  A supplemental oat 
ration was provided twice daily.  
 
8.3.2.  Phase 1 – single dose study 
 Foals were randomly allocated to receive 10, 20 or 30 mg/kg tilmicosin 
(Pulmotil, Elanco Animal Health, Eli Lilly Canada Inc, Guelph, ON) orally.  Two foals 
remained as controls throughout the study and did not receive any tilmicosin.  
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Tilmicosin was weighed out and placed in a catheter tip syringe.  Before administration, 
it was mixed with approximately 10mL molasses and 20 mL warm water to create a 
liquid paste that could be administered to the back of the mouth.  Control foals were 
dosed orally with a mixture of molasses and water.  The doses of tilmicosin were based 
on the fact that in our previous work a dose of 4 mg/kg did not result in any detectable 
concentrations of tilmicosin in plasma or tissue (Clark, Dowling et al. 2008(2)).  Other 
researchers have used oral tilmicosin in the treatment of calf respiratory disease at doses 
of 25 mg/kg (Fodor, Reeve-Johnson et al. 2000).  
 Mares and foals were moved into the veterinary clinic for the first 24 hours 
following the dose of tilmicosin to facilitate monitoring of clinical signs and blood 
collection for tilmicosin plasma analysis(Clark, Dowling et al. 2008(2)).  Foals were 
examined daily by an experienced veterinarian for any signs of ill health.  Unfortunately, 
the fractious nature of the foals precluded a detailed physical examination.  Particular 
attention was paid to demeanor, appetite and fecal quality.  Fecal samples were collected 
for analysis immediately prior to tilmicosin administration and again 24, 48 and 72 
hours post tilmicosin administration.  A further sample was collected 7 days after 
tilmicosin administration. 
 
8.3.3.  Phase 2 - multiple dose study 
 Following the completion of the phase 1 study, all foals had a minimum of a two 
week washout period.  All foals were then entered into the second phase of the study, the 
two control foals continued to receive only molasses.  Because preliminary analysis of 
plasma samples collected in phase 1 indicated that only trace concentrations of 
tilmicosin were detected in plasma in the foals receiving the 30 mg/kg dose, a dose of 40 
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mg/kg tilmicosin orally every 24 hours was used in phase 2.  Once again foals were 
examined daily for signs of ill health.  Fecal samples were again collected immediately 
prior to the first dose of tilmicosin and after 6 and 13 days of tilmicosin therapy. 
 
8.3.4.  Fecal bacteriological analysis 
Fecal analysis was conducted in a semi-quantitative manner in order to determine 
the effect of tilmicosin on the absolute number of bacteria isolated from the feces.  This 
technique has been described previously (Clark, Dowling et al. 2008(5)). 
 
8.3.5.  Statistical  analysis 
Statistical analysis was conducted using Statistix 8.0 (Analytical Software 
Tallahassee FL).  Non-parametric statistics were used due to the logarithmic distribution 
of the data.  Data was compared in a number of ways.  All 6 tilmicosin treated foals 
were considered a single group and compared with the 2 control animals.  First, a 
geometric mean was taken from the results of each horse across each day of the study to 
give an average bacterial count, and the treated foals were compared with the controls.  
Second, the fecal results from the treated and control groups were compared on day zero 
and a day in the mid point of the study (Phase 1, day 2, Phase 2, day 6). Analysis was 
conducted using the Wilcoxon rank sum test.  Finally, the results from day zero were 
compared directly with the results from the mid point of the study using the Wilcoxon 
signed rank test.   
In the event of known pathogens being isolated from the feces, the numbers of 
horses with the presence of the pathogen were compared using Fisher’s exact test.  In all 
cases, significance was set at p≤0.05. 
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8.4.  Results 
Mixing Pulmotil with molasses and water facilitated oral administration.  
However, as Pulmotil is not soluble, obstruction of the syringes was common.  This was 
easily prevented by removing the tips from the syringes. 
The foals appeared to systemically tolerate tilmicosin administration very well; no 
foals showed any signs of ill health relating to the administration of tilmicosin and there 
was no diarrhea.  However, a noticeable change in the odor of the feces was apparent 24 
hours after administration.  One foal developed a severe lameness in the right hind leg 
which was determined to be due to a septic epiphysitis (determined using radiological 
examination; the foal was euthanized on humane grounds and the diagnosis confirmed at 
post-mortem examination).  The foal was removed one week early during the phase 2 
study.  A second foal developed thrombophlebitis associated with the site of jugular 
catheter placement after the phase 1 study.  This foal was treated with ceftiofur (2 mg/kg 
im sid) for 17 days during the washout period.  Consequently, fecal analysis was not 
conducted on this foal in the phase 2 study as there was no way of determining the 
contribution of the ceftiofur to the effect on the fecal flora. 
 
8.4.1.  Fecal analysis 
The normal fecal flora of the unweaned foals consisted of Enterococcus spp, 
Bacillus spp., E.coli and Klebseilla spp.  β-hemolytic streptococci were rarely isolated.  
Administration of oral tilmicosin resulted in changes in fecal flora.  There was almost no 
difference between the three treatment groups in the phase 1 study with respect to the 
changes in fecal flora; consequently, their results were combined to simplify the 
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analysis.  The effects of a single dose of tilmicosin on the fecal counts of coliforms and 
Bacillus spp. are shown in Figures 8.1 and 8.2.  A comparison of the average fecal 
bacterial counts between the treated and control foals shows differences that very closely 
approach significance with treated foals showing increases in the number of coliforms 
and Cl. perfringens isolated and a reduction in the number of Bacillus spp. (Table 8.1).   
A comparison of the fecal bacteriology on day 0 reveals no statistical differences 
between the groups (data not shown), with the feces containing approximately the same 
numbers of Bacillus spp. and coliforms.  The feces from two of the foals in the treatment 
group also contained low numbers of Cl. perfringens. Administration of tilmicosin 
resulted in a rapid precipitous drop in the number of Bacillus spp. isolated from the feces 
and a corresponding over growth of fecal coliforms.  In addition to these changes, the 
administration of tilmicosin was also associated with marked rapid overgrowth by 
Clostridium perfringens (Figure 8.3).  A comparison of the fecal culture results on day 2  
of the study shows changes that are significant for Bacillus spp. and approach 
significance for Cl. perfringens and fecal coliforms (Table 8.2). When the results from 
the individual foals are compared before and 2 days post treatment, a significant 
difference is seen for all three bacteria (Table 8.3).  No difference was detected for the 
control foals (data not shown). Following a single dose of tilmicosin the fecal changes 
persisted several days but were almost normal by the seventh day after treatment.  Cl. 
difficile and Salmonella spp. were not isolated at any time in the study and there was no 
change in the consistency of the feces. 
The results of the fecal analysis from the phase 2 study (chronic administration) 
are shown in Figures 8.4 and 8.5.  In this case, fecal samples were collected on days 0, 6 
and 13.  At the beginning of the phase 2 the fecal flora was similar to that seen at the  
 193
Time (days)
76543210
C
ol
ifo
rm
s 
(/g
 fe
ce
s)
1.E9
1.E8
10,000,000
1,000,000
100,000
10,000
30
20
10
0
Dose (mg/kg)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1.  The effect of a single dose of oral tilmicosin (10-30 mg/kg) on the number 
of coliform bacteria isolated from the feces of healthy unweaned foals. 
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Figure 8.2.  The effect of a single dose of oral tilmicosin (10-30 mg/kg) on the number 
of Bacillus spp. bacteria isolated from the feces of healthy unweaned foals. 
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Average fecal bacterial counts 
throughout phase 1 (Geometric mean 
CFU  /g feces) 
Bacteria 
Tilmicosin 
treated foals 
Control foals 
Statistical 
significance (p) 
Coliforms 4 x 106 
 
4.2 x 105 
 
0.0668 
Bacillus spp 1.2 x 105 
 
1.4 x 106 
 
0.0651 
Cl. perfringens 3.5 x 104 
 
50 0.0651 
 
Table 8.1.  Comparison of the average fecal bacterial counts seen during phase 1 of the 
study comparing tilmicosin treated foals with controls 
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Figure 8.3.  The effect of a single dose of oral tilmicosin (10-30 mg/kg) on the number 
of Cl. perfringens bacteria isolated from the feces of healthy unweaned foals. 
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Average fecal bacterial counts on 
day 2 of phase 1 study (Geometric 
mean CFU  /g feces) 
Bacteria 
Tilmicosin 
treated foals 
Control foals 
Statistical 
significance (p) 
Coliforms 1 x 107 
 
1 x 106 
 
0.0651 
Bacillus spp 5000 
 
2449490 
 
0.0164 
Cl. perfringens 3.6x106 
 
50 0.0651 
 
 
Table 8.2.  Comparison of the fecal bacterial counts on Day 2 of the study comparing 
tilmicosin treated foals with controls. 
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Average fecal bacterial counts for 
foals treated with tilmicosin 
(Geometric mean CFU  /g feces) 
Bacteria 
Day 0 Day 2 
Statistical 
significance (p) 
Coliforms 5.8 x 105 
 
1 x 107 
 
0.0360 
Bacillus spp 8.8 x 105 
 
5000 
 
0.0360 
Cl. perfringens 224 
 
3.6x106 
 
0.0360 
 
Table 8.3.  Comparison of the fecal bacterial counts before treatment and two days after 
treatment with oral tilmicosin. 
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Figure 8.4.  The effect of daily oral tilmicosin (40 mg/kg) therapy on the number of 
coliform bacteria isolated from the feces of healthy unweaned foals.  
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Figure 8.5.  The effect of daily oral tilmicosin (40 mg/kg) therapy on the number of 
Bacillus spp. bacteria isolated from the feces of healthy unweaned foals. 
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beginning of phase 1.  The fecal samples collected on days 6 and 13 were not very 
different from those at the start of the study and no significant differences were found 
either between treatment and control foals or between fecal flora at the start of the study 
and on day 6.    One foal in the tilmicosin treated group had Cl. perfringens isolated 
from its feces on days 6 and 13 at 3000 and 11,000 CFU /g feces, respectively.  Cl. 
difficile and Salmonella spp. were not isolated at any time 
 
8.5.  Discussion 
The fecal flora of the unweaned foals differed from what we had seen previously 
in weaned foals and adult horses (Clark, Dowling et al. 2008(5)).  In both previous 
studies, the main type of bacteria isolated were the β-hemolytic streptococci.  Wierup 
(Wierup 1977) had also shown results in adult healthy horses similar to our own.  The 
difference is not unexpected as the foals in this study were unweaned and still receiving 
the majority of their nutrition through their mother’s milk.  This diet is obviously very 
different from that of the herbivorous weaned or adult animal, which would presumably 
influence the bacterial flora within the intestines. 
The technique of semi-quantitative fecal culture has been used by ourselves and 
several other researchers to investigate the disruption of normal fecal flora following 
antimicrobial administration (Andersson, Ekman et al. 1971; White and Prior 1982; 
Clark, Dowling et al. 2008(5)).  It is a simple technique that can give some basic 
information about the manner in which antimicrobials may precipitate bacterial colitis.  
The technique however has important limitations:  Firstly, the fecal flora is extremely 
complex, in this study we focused only on fecal coliforms and Bacillus spp. as they were 
the most common bacteria isolated using our assay.  We also focused our attention on 
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known pathogens such as Salmonella spp., Cl. perfringens and Cl. difficile.  It is 
anticipated that the effects of antimicrobial administration have much more wide 
reaching effects than are reported here, but this technique demonstrates that the normal 
flora is disrupted.  It is also highly unlikely that the fecal flora directly represents the 
bacterial flora found in other areas such as the cecum and colon.  However, feces are 
easily accessible and are routinely used in the diagnosis of bacterial diseases of the 
intestinal tract as a whole. 
Secondly, this study suffers from the small number of animals involved.  Since the 
main focus of the study was to determine the tissue disposition of tilmicosin in foals in a 
terminal study, the number of animals was kept to a minimum.  The low number of 
animals and the use of non-parametric statistics significantly reduce the power of the 
study.  However, many of the results are statistically significant.  A larger study would 
obviously be helpful. 
Despite the study limitations, the administration of tilmicosin had an effect on the 
fecal flora of the unweaned foals.  The effect was similar at all three doses used in the 
phase 1 study.  There was a reduction in the number of Bacillus spp. and an increase in 
the number of coliforms found in the feces.  The Bacillus spp. numbers reduced over a 
48 hour period, but the increase in coliforms was much more rapid occurring within 24 
hours.  The fecal flora had almost normalized by 7 days after tilmicosin administration.  
The significant overgrowth of the coliforms has the potential to be of clinical 
significance.  Salmonella spp. was not isolated from any of the foals in this study.  The 
foals came directly from a closed high health status herd and it is unlikely that they 
would have been exposed to Salmonella in their lifetime.  Had the foals been subclinical 
carriers of Salmonella spp. or another Gram negative pathogenic bacteria, it is possible 
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that the reduction in the normal gram positive fecal flora may have allowed overgrowth 
of the pathogen resulting in colitis and clinical disease.  This effect was similar to but 
less dramatic than that seen in the weaned horses in our previous studies (Clark, 
Dowling et al. 2008(5); Clark, Dowling et al. 2008(6)).  Study results demonstrate once 
again that disruption of the fecal flora cannot be simply equated with diarrhea. 
Two of the foals in the treatment group had low numbers of Cl. perfringens 
isolated from the feces before treatment with tilmicosin.  Following treatment, large 
numbers of Cl. perfringens were isolated from the feces of all treated foals.  Cl. 
perfringens has been recognized as an important enteric pathogen of foals (East, Savage 
et al. 1998).  Previous studies have demonstrated that disease is typically associated with 
large numbers of Cl. perfringens being isolated from the feces (<1000 CFU/ml) (Wierup 
and DiPetro 1981) and the presence of specific toxins especially Cl. perfringens 
Enterotoxin (CPE) (Weese, Staempfli et al. 2001) assays were not conducted in this 
study as none of the animals developed disease.  However, this raises the question that 
had the foals been exposed to toxigenic strains of Cl. perfringens there could have been 
overgrowth in the intestines resulting in severe clinical disease. 
Conditions that favor the growth of Cl perfringens may also be expected to favor 
the growth of Cl. difficile.  Cl. difficile was not isolated from any of the foals in this 
study, nor were we able to isolate it in any of our previous studies.  Cl. difficile is 
particularly hard to culture even when selective media are used (Weese, Staempfli et al. 
1999).  Like Cl. perfringens colitis due to Cl. difficile has been associated with specific 
toxigenic strains producing the A and B toxins. The diagnosis of clinical disease is most 
commonly made using assays which detect the presence of Cl. difficile toxins in the 
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feces (Weese, Staempfli et al. 1999).  Such assays were not conducted in this study as 
none of the animals showed clinical disease. 
It is notable that the fecal flora in this study demonstrates the same kind of 
robustness that was seen in our own and previous studies (Andersson, Ekman et al. 
1971; White and Prior 1982; Clark, Dowling et al. 2008(5)).  With chronic 
administration of an antimicrobial, the fecal flora appears to be able to recover and 
normalize within approximately one week even with the continued presence of the 
antimicrobial.  
In, conclusion it is apparent that the fecal flora of the unweaned foal differs from 
that which has been described previously (Clark, Dowling et al. 2008(5)).  The flora 
contains higher numbers of Gram negative coliforms and almost no β-hemolytic 
streptococci.  There are however, more Bacillus spp. seen than would be expected in the 
feces of an adult horses.  The fecal flora was altered by tilmicosin administration 
resulting in coliform overgrowth and the loss of the Bacillus spp population. Tilmicosin 
was also associated with overgrowth of Cl. perfringens.  The overgrowth of coliforms 
was less pronounced than that seen in the adult. 
While these results support the hypothesis that macrolide administration may be 
associated with colitis in foals and that the colitis may be due to Salmonella spp., Cl. 
perfringens, or Cl. difficile.  However, the normal fecal flora of the foal may be more 
resistant to the effects of the macrolide that that of a weaned or adult horse. 
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CHAPTER 9 
AN ASSESMENT OF THE SAFETY OF THE USE OF TILMICOSIN IN 
THE HORSE 
 
9.1.  Abstract 
Objective: 
To determine if tilmicosin can be used safely in the horse 
 Animals or Sample Population: 
A group of 12 recently weaned foals purchased from a PMU ranch. A second group of 8 
newborn foals. 
Procedure: 
Study 1.  12 weaned foals were randomly allocated to receive tilmicosin at either 4 
mg/kg po or 10 mg/kg sc.  In phase 1 of the study a single dose was administered.  In 
phase 2 the oral dose was given daily and the injectable dose every 72 hours for 2 
weeks.    
Study 2.  In phase 1, newborn foals were randomly allocated to receive a single dose of 
control (n=2), 10, 20 or 30 mg/kg tilmicosin p.o (n=2 per group). In phase 2, 5 foals 
received 40 mg/kg tilmicosin p.o. for 2 weeks, 2 foals remained as controls. 
Foals were monitored throughout the study for any signs of ill health.  At the conclusion 
of the study, all foals were euthanized and a full necropsy was conducted. 
Results: 
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With the exception of severe swelling at the site of injection minimal reaction to 
tilmicosin administration was noted.  Mild diarrhea was seen in only one foal.  Minimal 
findings were noted on necropsy. 
 Conclusions and Clinical Relevance: 
The injection site reactions will likely prevent the use of injectable tilmicosin in horses.   
 
9.2.  Introduction 
 Tilmicosin is a macrolide antibiotic formed from a chemical modification of 
tylosin.  It is currently marketed in two forms. Micotil (Provel, Eli Lilly Canada Inc. 
Guelph, ON) is an injectable preparation licensed for the treatment of respiratory disease 
in sheep and cattle and is used extensively in North American feedlots.  Pulmotil® 
(Elanco Animal Health, Eli Lilly Canada Inc. Guelph, ON) is licensed as a feed additive 
for the prevention and control of respiratory disease in swine. Tilmicosin has been tested 
and used in various other species including rabbits, and mice (Brown, Deleeuw et al. 
1995; McKay, Morck et al. 1996).  It is currently licensed for use in chickens and rabbits 
in Europe.  However, the limiting factor in its use in some species is cardiac toxicity 
(Fodor, Varga et al. 1993; Jordan, Byrd et al. 1993; Main, Means et al. 1996).  Toxicity 
is most marked with the injectable preparation and its use is discouraged in the horse 
(Prescott 2000), however there are no published data to support this view.  There is one 
published report (Fenger 2000), describing the use of an alternative injectable 
preparation (IDEXX Pharmaceuticals, Durham, NC)  to successfully treat R. equi 
infection in two foals. 
Tilmicosin is a particularly useful drug for the treatment of respiratory disease 
because of its high volume of distribution and preferential accumulation in pulmonary 
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tissue (Prescott 2000).  The drug has a long half-life and can be administered 
subcutaneously or orally.  It has a spectrum of activity that includes most Gram-positive 
aerobes, Gram negatives associated with pneumonia (M. haemolytica, P. multocida and 
H. somni), some anaerobes and Mycoplasma spp. (Prescott 2000). 
Tilmicosin has the potential for use in equine veterinary medicine in two distinct 
areas:  Firstly, a retrospective analysis of equine bacterial isolates from the past six years 
at the Western College of Veterinary Medicine (Clark, Greenwood et al. 2008(1)) 
confirmed that the most common bacterial isolate is Streptococcus zooepidemicus ; the 
majority of isolates were from the respiratory tract.  Although there are a wide variety of 
drugs to choose from, many of these horses are treated with procaine penicillin, ceftiofur 
or trimethoprim-sulfa (TMS) combinations.  Many practioners opt for the TMS 
combinations based on the ease of oral administration.  Our data indicates that 
unfortunately only 47% of S.  zooepidemicus isolates recovered from our facility were 
sensitive to TMS (Clark, Greenwood et al. 2008(1)). Consequently, there is a need for a 
new, easily administered antimicrobial for the treatment of equine respiratory disease.  
This is particularly true in the equine feedlots, where respiratory disease is common and 
is typically treated with a variety of antibiotics especially long acting injectable 
preparations.  Secondly, there has been a great deal of recent research looking at 
alternative treatments for R. equi infection in young foals.  Currently, most interest is 
focused on the use of either azithromycin (Jacks, Giguere et al. 2001; Davis, Gardner et 
al. 2002) or clarithromycin (Jacks, Giguere et al. 2002).  While neither drug is licensed 
for veterinary use and are expensive, tilmicosin shares many of the properties of these 
two drugs and is veterinary licensed product. 
The safety of a new drug being used in horses may be assessed in three ways:   
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1. Acute toxicity resulting in an acute illness syndrome. 
2. Changes in fecal flora resulting in the potential for gastrointestinal disease. 
3.  Sub-clinical toxicity which may only be apparent based on histopathological 
examination of tissues.   
Published data regarding the use of macrolide antimicrobials in the horse indicates 
that this class of antimicrobials may be particularly associated with disturbances of the 
normal colonic flora resulting in acute severe and occasional fatal colitis.  In many cases 
the etiology of the diarrhea is not described, however recent publications have 
demonstrated a role for Clostridium difficile(Gustafsson, Baverud et al. 1997). 
 
9.3.  Materials and methods 
This study was approved by the University of Saskatchewan’s Committee on 
Animal Care and Supply in accordance with the guidelines provided by the Canadian 
Council on Animal Care. 
 
9.3.1.  Study 1 
 Twelve recently weaned female foals acquired from a PMU ranch in Western 
Canada.  Foals were approximately 6 months old at the start of the study.  They 
represented various cross-breeds and their weight ranged from 130-245 kg.  Ten of the 
12 foals had had an ovarietomy conducted laproscopically in a separate study prior to 
being entered in the tilmicosin study.  A one month washout period was used to separate 
the two studies.   
 Foals were randomly allocated using a coin toss to receive either 10 mg/kg 
tilmicosin (Micotil) subcutaneously at a single site in the side of the neck, or 4 mg/kg 
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tilmicosin (Pulmotil) orally.  Pulmotil was weighed out and placed in a catheter tip 
syringe.  Before administration it was mixed with approximately 10mL corn syrup and 
20 mL water to create a liquid paste that could be administered to the back of the mouth.  
A previous study (Buck and Thomson 1997) had administered  a dose which 
approximated to 4 mg/kg with minimal reaction.  In addition, a daily oral dose of 4 
mg/kg and a 10 mg/kg injectable dose every 72 hours approximated to the same dose 
over time.  
 Foals were monitored daily by an experienced veterinarian (Clark) for any signs 
of ill health.  Unfortunately the fractious nature of the foals precluded a detailed physical 
examination.  Particular attention was paid to demeanor, appetite, fecal quality and signs 
of reaction to injection.   
 Following the completion of the phase 1 study, all foals had a minimum of a two 
week washout period.  Foals remained allocated to the same groups and received either 
10 mg/kg tilmicosin subcutaneously every 72 hours (injections alternated between the 
left and right side of the neck) or 4 mg/kg tilmicosin orally every 24 hours.  Foals were 
monitored daily for signs of ill health.  The study lasted 2 weeks and foals were then 
sequentially euthanized with intravenous pentobarbital (Euthanyl Forte Vetoquinol N-A 
Inc, Lavaltrie, QC).  A board certified veterinary pathologist (Allen) who was blinded to 
the treatment group conducted a full post-mortem on all foals.  Samples of liver, kidney 
and heart muscle (left ventricular free wall, intraventricular septum and atrial walls) 
were collected for histopathological examination.   
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9.3.2.  Study 2 
 Eight unweaned foals and their dams were acquired from a PMU ranch in 
Western Canada.  Foals were approximately 1 week old at the start of the study.  They 
represented various cross-breeds and their weight ranged from 86-160kg.  After 
transport to the veterinary college the foals were allowed a 2 week period to acclimatize 
to their new surroundings.  Mare and foals were housed in a research paddock at the 
University of Saskatchewan with free access to hay and water.  A supplemental oat 
ration was provided twice daily.  
 Foals were randomly allocated to receive 10, 20 or 30 mg/kg tilmicosin orally.  
Two foals remained as controls.  Tilmicosin was weighed out and placed in a catheter tip 
syringe, it was mixed with approximately 10mL molasses and 20 mL warm water to 
create a liquid paste that was administered to the back of the mouth.  Control foals were 
dosed orally with a mixture of molasses and water.  The doses of tilmicosin were based 
on the fact that in our previous work a dose of 4 mg/kg did not result in any detectable 
plasma or tissue concentrations of tilmicosin (Clark, Dowling et al. 2008(2)).  Other 
researchers have used oral tilmicosin in the treatment of calf respiratory disease at doses 
of 25 mg/kg (Fodor, Reeve-Johnson et al. 2000).  
 Foals were monitored daily by an experienced veterinarian (Clark) for any signs 
of ill health.  Unfortunately the fractious nature of the foals precluded a detailed physical 
examination.  Particular attention was paid to demeanor, appetite and fecal quality.   
 A two week washout period followed completion of the phase 1 study.  
Preliminary analysis of plasma samples collected in phase 1 indicated that trace 
concentrations of tilmicosin were detected in plasma in the foals receiving the 30 mg/kg 
dose.  A daily oral dose of 40 mg/kg tilmicosin was therefore used in phase 2.  Foals 
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were monitored daily for signs of ill health.  Foals were treated with tilmicosin for 2 
weeks and then sequentially euthanized with intravenous pentobarbital (Euthanyl Forte 
Vetoquinol N-A Inc, Lavaltrie, QC).  A full post-mortem examination was conducted as 
before.   
 
9.3.3.  Investigation of gastrointestinal disturbance. 
In either study if an animal were to develop diarrhea a determined effort should be 
made to confirm the etiology.  Fecal samples would be collected and submitted for 
routine culture.  In addition, anaerobic culture using blood neomycin agar would be used 
to identify Cl. perfringens, enrichment culture for Salmonella spp., selective culture for 
Cl. difficile and an ELISA for its toxins. 
 
9.3.4. Statistical analysis 
 Fisher’s exact test was used to compare groups of foals with respect to the 
presence of disease or lesions.  Statistical significance was set at p < 0.05. 
 
9.4.  Results 
9.4.1.  Study 1 
Foals systemically tolerated sc and oral tilmicosin administration well.  One foal 
developed mild diarrhea 24 hours after a single dose of oral tilmicosin.  The diarrhea 
was mild and self limiting, lasting 6 hours and requiring no treatment.  No pathogens 
were isolated from the foal’s feces.  No other foals showed any other signs of systemic 
ill health.  The occurrence of one case of mild diarrhea in one group was not clinically 
significant. 
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In all cases, there was significant swelling at the site of a tilmicosin injection.  The 
swelling developed rapidly (<12 hours) and was edematous.  Foals resented palpation of 
the area when swollen.  In the majority of cases, the swelling resolved uneventfully in 3 
– 5 days, but in two cases there was a residual effect: the skin overlying the injection site 
became necrotic (Figure 9.1) and in another case the hair overlying the injection site 
changed color (Figure 9.2). 
All foals that received injectable tilmicosin had variable degrees of inflammation 
and necrosis in the subcutaneous tissues of the neck and in some cases the superficial 
muscles associated with the injection site (Figure 9.3).  Four foals in each of the 
treatment groups showed signs of a moderate pathology in the liver, either a moderate, 
multifocal nonsuppurative hepatitis or a cholangiohepatitis.  Four of the foals receiving 
injectable tilmicosin showed signs of sub-acute multifocal lymphocytic myocarditis and 
myocardial necrosis.  Similar changes were seen in three of the foals receiving the oral 
dose.  There was no statistical difference in the distribution of the hepatic or cardiac 
lesions between the treatment groups. 
 
9.4.2.  Study 2 
The unweaned younger foals also tolerated oral tilmicosin very well.  One foal 
developed a fore limb lameness and swollen fetlock shortly after receiving the first dose 
of 20 mg/kg tilmicosin.  Arthrocentesis confirmed septic arthritis and the foal was 
euthanized.  One other foal developed thrombophlebitis at the jugular catheter site.  No 
other signs of ill health were recorded during either the phase 1 or phase 2 trial. 
The liver sections from each foal contained a few small and moderate widely 
scattered foci of lymphocytes and a few macrophages in the parenchyma.  One control  
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Figure 9.1.  Photograph showing superficial necrosis of the skin after a subcutaneous 
injection of Micotil. 
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Figure 9.2.  Photograph showing bleaching of the hair overlying an injection site for 
Micotil (large division on scale = 1cm). 
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Figure 9.3.  Cross-section through an injection site in the side of the neck demonstrating 
inflammation of the subcutaneous tissues with edema and an area of central focal 
necrosis in the superficial muscle (large division on scale = 1cm). 
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foal had several small foci of lymphocytes in the epicardium of the left free wall.  One 
treated foal had several foci of fibrosis in the left ventricular free wall; there were also 
moderate numbers of lymphocytes and mononuclear cells around one small artery in the 
septum and a moderate-sized cluster of lymphocytes in a section from the atrium.  The 
distribution of lesions between the treated and control animals was not significant. 
No significant lesions were found on either gross examination or histopathological 
examination of any of the tissue samples. 
 
9.5.  Discussion 
The injection site reaction to Micotil was not unexpected.  Swelling at the site of 
injection is typically observed in cattle (Product label)(Jordan, Byrd et al. 1993) and 
injection site lesions have been described in the literature, although these typically 
resolve within several months (Van Donkersgoed, Dubeski et al. 2000).  Horses 
typically react more overtly to injectable preparations than cattle (Dowling and Russell 
2000; Dowling 2001).   In addition the injection site reactions in the horse are described 
by Cochrane and Thomson (Cochrane and Thomson 1990).  
 The degree of swelling and problems associated with skin necrosis means that 
tilmicosin will not be accepted by the majority of horse owners.  The reason for the 
severe injection site reaction is not clear.  Micotil simply contains 300 mg/mL tilmicosin 
in 25% propylene glycol.  The pH of the solution is adjusted to 7.0 using phosphoric 
acid (package insert).  It is therefore unlikely that the irritation seen at the injection site 
is due to either the carrier or its pH, but instead to some direct action of the drug itself. 
The syndrome of antimicrobial associated diarrhea has been extensively described 
in the veterinary literature (Jones 2004).  However, the majority of reports are simply 
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case reports or case series in which the etiological agent is rarely isolated and in many 
cases there are other factors that may have a significant bearing on the development of 
acute colitis besides the use of antimicrobials.  There has been very little directed 
research in this area. In the one controlled study investigating antimicrobial associated 
diarrhea  (Wilson, MacFadden et al. 1996), the length of stay in hospital was a far more 
significant predictor of developing diarrhea than the administration of antimicrobials!  
Notwithstanding, macrolide antimicrobials have been especially implicated as being a 
cause of diarrhea especially in association with Clostridium spp. (Prescott, Staempfli et 
al. 1988).   More recently interest has been especially focused on Clostridium difficile 
(Weese, Staempfli et al. 2001).  Clinical gastrointestinal disease following 
administration of tilmicosin was not a feature of this study.  However the normal fecal 
flora of the study animals was dramatically altered by the administration of tilmicosin as 
been previously described (Clark, Dowling et al. 2008(5); Clark, Greenwood et al. 
2008(7)). 
Unlike other macrolides which have a good safety profile (Periti, Mazzei et al. 
1993), tilmicosin has been linked to acute cardiac toxicity.  The toxicity of tilmicosin 
has been extensively reviewed (Jordan, Byrd et al. 1993).  The oral median lethal dose 
(MLD) in fasted rats is 800-850 mg/kg.  In fed rats the oral MLD rose to 2250 mg/kg.  
The MLD following sc injection is 100 mg/kg in mice and 185-440 mg/kg in rats (range 
due to sex differences).  Toxicity typically manifests as acute death with in 2 hours of a 
dose and no specific lesions are found at post-mortem examination.  The nature of the 
effect of tilmicosin on the heart is not known.  The most detailed work on the 
cardiovascular effects of tilmicosin was conducted in dogs (Main, Means et al. 1996).  
Administration of intravenous tilmicosin to unrestrained dogs results in negative 
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ionotropic and chronotropic effects.  The effects are exacerbated by propanalol but 
dobutamine infusion attenuates some of the effects.   
Chronic dosing studies in a variety of species have demonstrated that oral toxicity 
is not a significant problem (Jordan, Byrd et al. 1993).  Rats treated daily with tilmicosin 
doses ranging from 50 – 600 mg/kg for 2 weeks did not show any overt signs of toxicity.  
There was a mild increase in serum AST and induction of hepatic microsomal enzymes 
but no evidence of tissue toxicity was found.  In a separate study oral doses ranging from 
25- 1000 mg/kg were administered daily to rats for 3 months.   Some deaths occurred at 
the higher doses along with non-specific changes such as decreased body and organ 
weights. 
Beagle studies used oral doses of 4 – 36 mg/kg bid for a year.  All dogs survived, 
but the animals receiving the higher doses showed some signs of cardiac toxicity.  
Tachycardia was seen as well as depression in the ST segment of the ECG.   These 
animals showed moderate cardiomegally at post-mortem examination but no 
histopathological changes were found. 
Toxicity studies in cattle have demonstrated a wide margin of safety when the 
drug is used in its licensed manner (10 mg/kg sc)(Jordan, Byrd et al. 1993).  Four doses 
of 150 mg/kg 3 days apart resulted in 50% mortality.  Deaths occurred acutely 
associated with tachycardia and changes in the ECG.  At necropsy small foci of 
myocardial necrosis were evident in the papillary muscles of the left ventricle.  The 
higher dose caused very severe reactions at the site of injection, characterized by severe 
edema and some necrosis of the underlying muscle.  The loss of plasma proteins into the 
site resulted in a measurable decrease in plasma total protein.  In a separate study doses 
ranging from 10 -50 mg/kg administered subcutaneously every 72 hours for 3 doses 
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resulted in no overt signs of toxicity.  However, at necropsy lesions were again found in 
the papillary muscles of the left ventricle. 
A dose of 5 mg/kg iv in feedlot cattle resulted in labored breathing and lethargy 
with a 50% mortality rate (Jordan, Byrd et al. 1993), no lesions were found at necropsy.  
In a pharmacokinetic study Ziv et al. (Ziv, Shem-Tov et al. 1995) administered a 10 
mg/kg iv bolus, or as a slow infusion over 20 minutes at 0.5 mg/kg/min.  The cow 
receiving the bolus developed ataxia, tachycardia, jugular pulses, hyperpnea and 
collapse although the animal recovered.  The cows receiving the infusion dose showed 
less pronounced signs.  The intravenous dosing resulted in plasma concentrations above 
1 µg/mL in contrast to the standard 10 mg/kg sc dose with a Cmax of 0.13 µg/ml. This 
implies that the toxic effects of tilmicosin are dependent on plasma concentrations and 
that the toxic concentrations are very hard to achieve with either oral administration or 
subcutaneous injection. 
Toxicity in non-target agricultural animals has been assessed in neonatal calves 
(Jordan, Byrd et al. 1993).  Doses of 5 or 10 mg/kg iv resulted in labored breathing and 
lethargy.  One calf receiving the 10 mg/kg iv dose died.  No lesions were found at 
necropsy.   
Pigs appear to be more susceptible to tilmicosin toxicity (Jordan, Byrd et al. 1993).  
Intra-muscular doses of 10 mg/kg resulted in recumbency and convulsions.  At the 
higher doses of 20 or 30 mg/kg there was ataxia, restlessness and labored breathing with 
75% mortality at 20 mg/kg and 100% mortality at 30 mg/kg.  There was severe reaction 
at the injection sites.  Oral dosing with medicated feed containing 5- 500 ppm for 6 
weeks caused no adverse reactions (tilmicosin has since been licensed for use in swine 
feed at 200 ppm for the treatment and prevention of respiratory disease in growing pigs). 
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Studies in sheep found the toxicity profile to very closely resemble that of cattle 
and the drug was licensed for use in sheep to treat respiratory disease (Modric, Webb et 
al. 1998). 
Jordan (Jordan, Byrd et al. 1993) reports that sc and im dose of >10 mg/kg resulted 
in toxic reactions in horses and goats and that both species exhibited adverse reactions to 
iv doses of less than 10 mg/kg.  The details of the horse studies are found in Cochrane 
and Thomson (Cochrane and Thomson 1990).  Horses received doses of 3, 10, 30 mg/kg 
sc, 2.5, 5, 7.5 mg/kg iv and 10 mg/kg im.  Horses were monitored for adverse reactions 
and plasma was collected to measure tilmicosin concentrations in the horses receiving 
the sc dose.  A detailed necropsy was conducted upon completion of the study. 
Intravenous doses of 2.5 or 5 mg/kg did not result in any adverse reactions.  A 
dose of 7.5 mg/kg resulted in signs of colic, convulsions and labored breathing.  The 
horse was recumbent within 15 minutes and died within 1 hour.  The intra muscular dose 
resulted in stiffness at the site of injection lasting 3 – 4 days.  The subcutaneous doses 
resulted in swelling and reaction at the injection site.  Subcutaneous tilmicosin was well 
tolerated at 3 or 10 mg/kg.  A dose of 30 mg/kg resulted in signs of toxicity during the 
following 24 hours (anorexia, labored respiration, recumbency, depression), horses then 
appeared normal.  One horse receiving this dose died 6 days post injection. 
The two horses that died during the study had lesions in the heart muscle similar to 
those described in cattle receiving high doses of tilmicosin (Jordan, Byrd et al. 1993).  
There were multiple foci in the left ventricle of subacute necrosis characterized by loss 
of sarcoplasm, minimal cellular infiltration and increased prominence of small blood 
vessels within the damaged areas.  Of the remaining horses in the study 2 had no cardiac 
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lesions, one had focal lymphoid cell infiltration and one had mild lesions similar to the 
two that died (this horse had received a sc dose of 30 mg/kg and an iv dose of 2.5 mg/kg. 
A second study fed horses diets containing 400, 1200 or 2000 ppm tilmicosin for 
14 days (approximating to a daily intake of 4 mg/kg, 12 mg/kg and 20 mg/kg 
tilmicosin)(Buck and Thomson 1997).  Horses receiving the 400 ppm showed minimal 
reaction with 2 out of 6 horses showing a slight decrease in feed intake during the 
treatment period.  The same two horses were recorded as showing signs of toxicity 
(lethargy, anorexia loose stool).  All of the horses receiving 1200 ppm had significantly 
reduced feed intake during the second week of tilmicosin administration.  All six horses 
were reported to show signs of toxicity, mainly lethargy, soft stool, signs of colic and 
anorexia.  The horses receiving 2000 ppm had highly variable feed intakes throughout 
the study.  Five of the six horses in this group showed similar signs to those in the other 
treatment groups and one horse was found dead on the eleventh day on feed (a post-
mortem examination was not conducted).  The “signs of toxicity” described by Buck and 
Thomson (Buck and Thomson 1997) all appear to be associated with the gastrointestinal 
tract (the lack of a post-mortem examination on the one dead horse is unfortunate as no 
signs of toxicity were reported before the death).  Based upon our previous work (Clark, 
Dowling et al. 2008(5); Clark, Greenwood et al. 2008(7)) it is known that administration 
of tilmicosin by any route has a significant effect on the fecal flora of the horse.  The 
clinical signs described by Buck and Thomson (Buck and Thomson 1997) (lack of 
appetite, soft feces, and lethargy) are consistent with disruption of normal fecal flora, 
rather than a direct toxicity. 
These studies suggest that tilmicosin differs from other macrolide antimicrobials 
in having a direct effect on the heart.  The effect appears to be dose dependent and 
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related to plasma concentrations of tilmicosin.  The high Vd of tilmicosin and its slow 
absorption after sc or oral dosing ensure that at label doses plasma concentrations are 
low (<1 µg/mL) consequently toxic effects are rare.  However, following overdose or 
intravenous administration concentrations may be much higher resulting in acute cardiac 
toxicity manifesting as ECG abnormalities, tachycardia and decreased cardiac output.  If 
the individual survives the acute toxicity it is likely that there will be focal areas of 
necrosis scattered throughout the myocardium especially the left ventricle in the region 
of the papillary muscles. 
In our studies the tilmicosin concentrations found in plasma were low.  Oral doses 
of 4 mg/kg did not result in detectable concentrations in plasma (Clark, Dowling et al. 
2008(2)) using an assay validated to a LOD of 24 ng/mL (Clark, Dowling et al. 
2008(3)).  A subcutaneous dose of 10 mg/kg resulted in a Cmax of 0.2 µg/mL (Clark, 
Dowling et al. 2008(2)).  Oral doses of 40 mg/kg sid resulted in a Cmax of approximately 
60 ng/mL.  These concentrations are much lower than those that have been described as 
being associated with cardiac toxicity (Cochrane and Thomson 1990; Ziv, Shem-Tov et 
al. 1995).  Consequently cardiac toxicity was not anticipated in this study. 
Interpretation of the histopathology results from study 1 is hampered by the lack of 
a negative control.  However, it should be noted that oral tilmicosin (4 mg/kg) did not 
result in detectable concentrations of tilmicosin from plasma or any tissues assayed.  
Consequently, the animals receiving oral tilmicosin are effectively acting as control 
animals.  Lesions were found in the liver and cardiac muscle from most of the animals 
enrolled in the study regardless of tilmicosin treatment.  The changes reported are mild 
and non-specific.  Liver damage is not a feature of toxicity studies in all species 
investigated and the cardiac lesions found in this study differed from those reported in 
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other tilmicosin studies using much higher doses (Cochrane and Thomson 1990; Jordan, 
Byrd et al. 1993).  The distribution of the lesions between the two treatment groups in 
this study argues against tilmicosin being the etiological agent. 
In study 2, occasional lesions were found in the liver and cardiac muscle of treated 
and control foals.  The lesions are again mild and non-specific and had no similarity to 
those described in previous toxicity studies (Cochrane and Thomson 1990; Jordan, Byrd 
et al. 1993). 
In conclusion, subcutaneous injection of tilmicosin results in a significant reaction 
at the site of injection that in severe cases may result in skin necrosis.  Administration of 
a single dose of tilmicosin either orally (4mg/kg) or by subcutaneous injection 
(10mg/kg) did not result in clinical gastrointestinal disease.  Mild histopathological 
lesions were found in cardiac and hepatic tissues, but were unlikely to be related to the 
administration of tilmicosin. 
 Oral doses of up to 40 mg/kg in unweaned foals were well tolerated; there were 
no clinical signs of disease or toxicity.  Mild inconsistent lesions were again identified at 
post-mortem examination that were unlikely caused by tilmicosin.  It is our conclusion 
that while tilmicosin may have the potential to cause severe cardiac toxicity, this toxicity 
is only seen with high plasma concentrations.  Such concentrations are unlikely to be 
achieved with oral dosing in the horse and therefore the risk of toxicity is low.  The 
potential remains that tilmicosin may be associated with acute colitis following 
disruption of the fecal flora of the horse resulting in the overgrowth of a pathogenic 
bacteria.  However, this did not occur in the animals in this study. 
Tilmicosin has the potential to be used for the treatment of respiratory disease 
(especially caused by R. equi) in young foals.  Further studies are required to 
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demonstrate the efficacy of such a treatment and to further quantify any risks associated 
with therapy.  
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CHAPTER 10 
DISCUSSION 
 
10.1. Introduction 
In this thesis I set out to investigate the use of a different antimicrobial (tilmicosin) 
in the horse.  I also wanted to address some of the deficiencies seen in previous studies 
and to determine if there was a better way to assess the use of a new antimicrobial in 
horses. 
With the exception of procaine penicillin G, ceftiofur, and trimethoprim/ 
sulphadiazine there are very few injectable antimicrobials licensed for use in the horse in 
Canada, and none take account of the fact that the horse is a food producing animal.  
There are also a number of products licensed for intra-uterine and topical use, as well as 
some “grandfathered”, rarely used oral products such as neomycin.  Most veterinarians 
use a much wider selection of antimicrobials with little thought to the fact that they are 
extra-label (oral TMS, gentamicin, amikacin, erythromycin, metronidazole etc).  The 
evidence supporting the extra-label use of most antimicrobials is not strong.  There are 
very few controlled clinical trials of antimicrobial use in horses.  Most experimental 
evidence for the rational use of antimicrobials is simply based on plasma 
pharmacokinetic results; typically using a single dose of the antimicrobial.  These trials 
are then coupled with in vitro estimations of susceptibility by calculating MICs using 
techniques and breakpoints that are not necessarily validated for horses (approved 
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breakpoints exist only for, ampicillin for equine streptococci, ceftiofur and gentamicin 
for equine Gram negative bacteria (NCCLS 1999)) and only the ceftiofur breakpoints 
have been validated through clinical trials (Papitch – personal communication). 
This approach to extra-label drug use has a number of deficiencies:   
Plasma concentrations rarely reflect the concentration of the antimicrobials in 
tissues where many drugs exert their action.   
The breakpoints and in vitro MICs quoted for a number of equine pathogens are 
not validated and, therefore, attempts to integrate an unsubstantiated target concentration 
with an inappropriate measure of the drug concentration are questionable.   
There is also the issue of using drugs with long elimination half-lives.  If the drug 
is dosed more frequently than 2 elimination half-lives there is the potential for 
significant accumulation in tissue to occur.  Single dose studies do not take account of 
this issue.  It is possible to use superposition to approximate the effect of multiple doses 
in a plasma study.  In a terminal study it is simpler to use multiple doses and measure the 
concentrations directly. 
In order to control the experimental parameters, oral medications are commonly 
administered to fasted subjects.  While this does remove a source of variability in the 
experimental study, it does not reflect the way in which the drug is likely to be used by 
veterinarians.  We know that many oral medications are poorly absorbed in horses 
(Baggot 1992), so it is important to take this into account in the evaluation of new 
antimicrobials. 
In Canada and in many other parts of the world the horse is used as a food animal.  
It is important that this be considered in the development of new antimicrobials for use 
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in horses as the potential exists that they may be used in horses destined for human 
consumption. 
Finally, very little attention has been paid to possible adverse reactions to the 
administered antimicrobial.  This is somewhat surprising given the apparent level of 
concern about AAD in horses. 
 
10.2.  Assay evaluation 
I have adapted and validated a HPLC assay for tilmicosin in a variety of equine 
tissues.  The assay is sensitive and specific.  Using the assay in our studies has shown 
that for a tilmicosin residue assay in equine tissues, kidney would be the target tissue to 
use.  
To effectively investigate the pharmacokinetics of tilmicosin in horses, it was 
necessary to develop and validate an analytical assay.  We were fortunate that we had 
access to the CFIA Center for Veterinary Drug Residues (CVDR) and their expertise 
with tilmicosin assays in different species.  We had worked together previously to 
develop a tilmicosin assay in elk tissues and, therefore, had some experience with the 
technique (Clark, Woodbury et al. 2004).  The assay was robust and required only a few 
minor changes in order to adapt it to a variety of equine tissues and plasma.  The biggest 
problem that we faced with the development and validation of the assay was the range of 
tilmicosin concentrations that we would have to deal with.  We had hoped to develop an 
assay for use in residue detection work with an LOD of <50 ng/g.  However, once we 
started to run tissues from treated animals, it was apparent that we had significantly 
underestimated the concentrations of tilmicosin that would be in tissues especially lung 
and kidney.  Concentrations were found to be in the 5 µg/g range, and since our initial 
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focus was to be on determining concentrations in tissue with respect to therapeutic 
efficacy, we elected to focus on the higher concentrations.  This was achieved by using a 
four point standard curve with high concentrations of tilmicosin (Table 3.1).  The LODs 
and LOQs for the assay were found to be 13 ng/mL, 43 ng/mL and 181 ng/g and 626 
ng/g for plasma and lung respectively. 
Each of the equine tissues had its own particular difficulties with respect to the 
tilmicosin assay; lung and muscle are both very difficult to homogenize; muscle due to 
its fibrous nature and lung because it has such a low density and is very “spongy”.  Liver 
homogenizes well but the fluid eluted from the SPE column can be difficult to work with 
as it occasionally contains large amounts of what appears to be “bile” like fluid.  Kidney 
is probably the easiest tissue to work with and coincidently it contains the highest 
concentrations of tilmicosin  
 
10.3.  Pharmacokinetic studies 
Based upon our MIC results and the concentrations of tilmicosin found in lung 
tissue it may be concluded that oral tilmicosin has potential to be effective as a treatment 
for R. equi pneumonia.  The use of injectable tilmicosin, however, should be avoided 
because of the severity of the injection site reactions. 
The first animal study was initially designed as a simple comparative 
pharmacokinetic study.  Weaned foals were used to represent young animals recently 
weaned and moved to a feedlot.  The number of animals in the study was kept low 
because it was a terminal study.  The comparative nature of the study worked well for 
the pharmacokinetic analysis but had serious deficiencies for the additional studies of 
adverse reactions where the lack of a control causes problems in the interpretation of the 
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data.  In hindsight, this is an obvious deficiency in the experimental design that should 
have been addressed. 
The pharmacokinetics of injectable tilmicosin (Micotil) in horses are essentially 
the same as those described in other species (Thompson and Lawrence 1994; Modric, 
Webb et al. 1998; Clark, Woodbury et al. 2004) and similar to those previously 
described in the horse (Cochrane and Thomson 1990).  An oral dose of 4 mg/kg did not 
result in detectable tilmicosin concentrations in plasma or tissues. 
The low dose of oral tilmicosin used was based upon the previous study of (Buck 
and Thomson 1997) who used a compounded feed with 400 ppm tilmicosin.  Oral doses 
higher than 400 ppm resulted in reduced feed intake and signs of “toxicity”.  Assuming a 
feed intake of 2-3%, body weight this approximates to 4 mg/kg, hence our cautious first 
dose.  This is a low dose of an oral macrolide for a horse (compared to other macrolides 
which have been used in this species) but it is equivalent to that which results in 
therapeutic effects in pigs (Thomson, Darby et al. 1994).  Much higher doses (25 mg/kg) 
have also been used therapeutically in calves  (Fodor, Reeve-Johnson et al. 2000).  
Given the concerns about the potential for toxicity, we decided to start with a low dose 
which eventually proved to be too low to result in detectable concentrations in any tissue 
or plasma.  In retrospect, this was fortuitous; since no drug apparently entered the body 
(or the concentrations in the tissues were below the LOD of the assay), it provided a 
control group for the histopathological study with which to compare the animals 
receiving the injectable dose.   
The injectable form of tilmicosin produced ideal pharmacokinetics and would have 
been a useful preparation had it not been for the severity of the injection site lesions.  
The local reaction was extremely severe and appears to be a direct toxic effect of the 
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tilmicosin possibly acting as a direct tissue irritant since the formulation of Micotil is 
fairly innocuous.  Not only does this effect prevent the use of tilmicosin in this form but 
it almost certainly has an effect on the absorption of tilmicosin from the injection site 
and may contribute to the highly unusual lack of a single defined Cmax.  The 
inflammation and increased blood flow may initially result in increased absorption.  
However, the large amounts of fluid that are released into the tissues almost certainly 
will dilute the drug removing the concentration gradient that is required for absorption 
therefore reducing the rate of absorption.  It seems likely based upon the work of other 
researchers that this inflammation and delayed absorption from the injection site is 
actually beneficial as “flip-flop kinetics” means that delayed absorption will actually 
decrease the apparent elimination rate from the plasma and tissues.  This means that if 
tilmicosin is reformulated as an injectable or used orally the extremely long half-lives 
reported for Micotil in other species will not be repeated and some of the advantages of 
the product will be lost. 
Unfortunately, as a simple solution tilmicosin will never be used in its injectable 
form.  The pharmacokinetics of an alternative injectable formulation have been recently 
described (Womble, Giguere et al. 2006).  Comparison of the two studies reveals that the 
Cmax in lung tissue are very similar1.9 µg/g vs. 2.8 µg/g in our study.  However, 
Womble et al. report a much longer MRT of 323 hours vs. the MRT of 28.3 hours 
obtained in our study.  Part of the explanation of these differences may be the difference 
in tilmicosin formulation with delayed absorption from the injection site in the Womble 
et al. study.  Another possibility may be that in their study tilmicosin concentrations 
were measured for up to 288 hours; consequently, their estimates of MRT are likely to 
 232
be more accurate given the importance of estimating the AUC and AUMC in the 
calculation of MRT. 
All pharmacokinetic analysis in this thesis was conducted using non-
compartmental pharmacokinetic analysis.  This approach was specifically chosen for 2 
reasons.  Firstly, the plasma kinetics of tilmicosin following Micotil injection were 
extremely complex.  There was no obvious Cmax, in fact, there appeared to be three 
distinct peak maxima.  Such a data set cannot be easily modeled using a model that 
assumes a single distinct peak.  Secondly, classical pharmacokinetic analysis assumes a 
compartmental model and models the concentrations on drug in the central compartment 
with the assumption that drug is being absorbed and eliminated from this central 
compartment with a reversible drug “sink” into one or more deeper compartments.  
When dealing with a drug where tissue concentrations are greater than plasma 
concentrations you are by definition in a “deep” compartment where the assumptions of 
a standard pharmacokinetic model are no longer valid.  Since a non-compartmental 
model makes no such assumptions, it can be used.  Consequently, the Tmax and Cmax are 
simply read from the data and the elimination phase of the data is described by the MRT 
(Riviere 1999). 
Our second study investigated the pharmacokinetics of much higher doses of oral 
tilmicosin in unweaned foals.  We elected to use the younger foals in this study for two 
main reasons.  Firstly, we were concerned that the severe disruption of the fecal flora 
following tilmicosin administration in the adult would prevent any routine use of the 
product in such animals.  We hypothesized that the fecal flora of the foals would be 
different from the adults due to their milk diet and that this may protect foals from the 
adverse effects of macrolides; this would allow macrolides to be used with relative 
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safety in young foals.  Secondly, there are a number of published studies looking for 
alternatives to the use of erythromycin for the treatment of R. equi pneumonia in foals.  
Tilmicosin has a number of characteristics that would make it an ideal candidate for 
further investigation.   
Our results demonstrate that a very high dose of oral tilmicosin is required to 
produce plasma concentrations which are similar to those seen with the injection of a 
therapeutic dose in other species.  The 40 mg/kg dose is also higher than used for the 
other macrolides in foals but is similar to that having therapeutic success in pneumonic 
calves (25 mg/kg)(Fodor, Reeve-Johnson et al. 2000).  The bioavailability of tilmicosin 
in foals is certainly very low at 11% which is lower than but similar to most other 
macrolides studied in horses.  Similar to all other species the plasma concentrations do 
not reflect tissue concentrations.  The concentrations of tilmicosin achieved in lung with 
oral dosing are quite high at 4 µg/g.  This is higher than those seen with the injectable 
preparation and reported by Womble et al. (Womble, Giguere et al. 2006), although the 
MRT is reduced which is not surprising given that the slow absorption from the injection 
site is no longer an issue. 
In most food producing animals it has become the standard to analyze the 
pharmacokinetics of macrolide antimicrobials using tissue concentrations especially 
lung concentrations.  Such an approach has not been previously described in the horse.  
Our results have shown that tilmicosin certainly concentrates in lung tissue; however, 
the clinical relevance of this finding is not clear.  More recently other researchers (Jacks, 
Giguere et al. 2001; Womble, Giguere et al. 2006) have attempted to use other matrices 
such as PELF.  These have the advantage of being repeatable samples and avoid the 
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necessity of performing terminal studies.  However, the significance of either tissue 
concentrations or PELF concentrations has not been determined. 
The MIC for R. equi isolates determined in our study was lower than that reported 
by Womble et al.(Womble, Giguere et al. 2006)  the reason for this difference is not 
clear.  A possible explanation may be the geographical difference in which the R. equi 
isolates were acquired. 
 
10.4. Antimicrobial associated diarrhea 
The results of this study demonstrate for the first time that tilmicosin, a typical 
macrolide antimicrobial has a profound effect on the normal fecal flora of the horse and 
that disruption of the fecal flora is not always associated with colitis.  The effect in the 
adult horse can be summarized as elimination of the β-hemolytic streptococci population 
and overgrowth of the Enterobacteriacae.  In certain cases this may also be associated 
with overgrowth of Cl. perfringens.  One interesting factor that has become evident from 
our results and review of the literature is that once disrupted the change in the fecal flora 
is fairly consistent.  It is also worth noting that TMS (which seems to be rarely 
associated with AAD) did not cause such a disruption (White and Prior 1982), and 
ceftiofur which is anecdotally linked to AAD also caused much less disruption of the 
fecal flora as compared to tilmicosin.  One of the most interesting findings was the 
confirmation of our hypothesis that foals have a different fecal flora from adults.  Until 
the significance of the effects of tilmicosin on fecal flora in horses is better understood it 
is prudent to recommend against the use of this product in adult horses.  Consequently, it 
should not be used in feedlot horses.  
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Our assessment of the fecal flora of adult horses was similar to that previously 
described (Andersson, Ekman et al. 1971; Wierup 1977).  Unlike other species where 
Gram negative organisms predominate, the major components of the fecal flora in horses 
are Gram positive organisms, most notably β-hemolytic streptococci and Enterococcus 
spp.  (Note:  In the studies described here the Enterococcus spp. numbers are not 
reported as they were simply too high to quantify on most days of the studies typically 
108 /g feces). It is not surprising that when a drug with a predominately Gram positive 
spectrum of activity and low oral bioavailability is administered orally it should be noted 
to have a profound effect on the fecal flora.  Certainly, tilmicosin concentrations in 
tissue following oral administration are extremely high.  It must be assumed that 
elimination of the streptococci either opens a niche which can be exploited by the other 
bacteria or that the presence of the streptococci in the colon suppresses the growth of the 
other pathogenic bacteria. 
Although this technique is very simple and it can be argued that the fecal flora 
does not represent colonic flora, I believe that this technique could be a very powerful 
tool for the investigation of AAD in the horse.  Fecal bacteriology is routinely used for 
diagnosis of acute colitis, so the use of fecal bacteriology is well accepted as a 
diagnostic tool.  Although there are a number of newer techniques being used to 
investigate the fecal flora using advanced techniques such as PCR, this technique has the 
advantages that it is simple and easy to use.  It also gives absolute numbers of bacteria 
present in contrast to amplification techniques that obviously prevent such analysis. 
It is interesting that the bacterial species that overgrew following tilmicosin 
administration in these studies are either associated with per acute colitis in the horse or 
are closely related to species associated with acute colitis.  This is especially true of Cl. 
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perfringens and the Enterobacteriacae (although Salmonella was not isolated in these 
studies).  It would seem likely that conditions favoring the over growth of Cl. 
perfringens would also favor the overgrowth of Cl. difficile.  We did not see any severe 
diarrhea in any of the subject animals and only saw one case of mild self limiting 
diarrhea.  This demonstrates that disruption of the fecal flora and colitis are two separate 
entities, although it is assumed that one predisposes to the other.  One potential problem 
with our study is that the clinical impression that acute colitis in our geographical area is 
relatively rare and that when such animals are treated we rarely find an etiological agent.  
We do typically find an overgrowth of Cl. perfringens in clinical cases of equine colitis 
but have only occasionally confirmed toxigenic strains.   
  Salmonellosis is also extremely rare in any species seen at WCVM and we have 
only isolated Cl. difficile on two occasions. The reason for this geographical association 
with colitis is not known.  We do have very cold winters here and the summers tend to 
be very dry, which may influence the survival of these pathogens in the environment.  
Since the diseases are rare, we must assume that none of the horses in our studies were 
sub-clinical carriers of the pathogens.  Had they been carriers we remain concerned that 
they could easily have developed potentially fatal disease.  The two groups of foals were 
perhaps unlikely to be carriers of disease; they were stable healthy groups which were 
transported directly from a PMU ranch.  In contrast, the group of adult horses used in the 
ceftiofur/tilmicosin comparative study was a very mixed group mainly acquired through 
a local auction and under normal circumstances this would be the sort of group in which 
one would expect to find such carrier animals.  The only real difference in the fecal flora 
of the two groups was that the mixed group carried Cl. perfringens in their feces. 
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This begs the question whether Saskatchewan is a good place to study AAD?  
Certainly, Saskatchewan has the advantage that overt disease can be avoided and that 
this avoids treatment cost and the associated animal welfare problems.  It allows us to 
investigate disruption of fecal flora without these other confounding factors.  However, 
it is hard to investigate a disease in an area where the disease occurs infrequently. 
Oxytetracycline and tilmicosin seem to have essentially the same effect on the 
fecal flora, that is the removal of the β-hemolytic streptococci and the overgrowth of 
coliforms and Cl. perfringens (Andersson, Ekman et al. 1971; White and Prior 1982).  
Strangely enough this same effect is seen in cases of naturally occurring colitis (Wierup 
1977).  This begs the question as to whether these changes seen in the fecal flora are the 
potential cause of the colitis or are in fact simply an effect of disruption of the fecal flora 
in the more inaccessible areas of the equine intestines.  
Another interesting finding which has been seen in the work of previous 
researchers but not commented upon (Andersson, Ekman et al. 1971; White and Prior 
1982), is that with continued use of an antimicrobial the fecal flora is able to normalize.  
Why this should occur is not known.  It is tempting to speculate that this is due to the 
development of antimicrobial resistance.  This would seem unlikely as resistance to 
tilmicosin, a 16 membered lactone structure, is rare (Giguere 2006).  Unfortunately, an 
error in our first study meant that S. zooepidemicus isolates were not preserved for 
susceptibility testing.  We had hoped to rectify this situation in the second study but S. 
zooepidemicus was not found as part of the fecal flora in the unweaned foals.  It would 
also have been beneficial to have collected more fecal samples during the two week 
repeated dosing study.  This was not done at the time due to budget and resource 
restraints. 
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The technique described in this thesis is inexpensive and simple to perform.  The 
technique could form the basis of a simple screening test to determine which 
antimicrobials are truly associated with a significant risk of acute colitis in the horse. 
One of the most interesting findings was the confirmation of our hypothesis that 
foals have a different fecal flora from adults.  This is not really surprising since the diet 
is so completely different.  However, the nature of these differences may be very 
important when it comes to potential adverse reactions to antimicrobials.  The 
predominately Gram negative nature of the fecal flora should protect them from the 
effects of an antimicrobial that mainly targets Gram positive organisms.  However, there 
was still a marked overgrowth of Cl. perfringens which indicates that there is still the 
potential for AAD in foals and the potential for overgrowth of Cl. difficile, if present.  
The magnitude of the reduction in risk of diarrhea in the foal is not known. 
It should be noted that tilmicosin is now licensed for use in rabbits in Italy.  The 
significance of this is that the rabbit is a hindgut fermenter and highly susceptible to 
AAD; they are often considered to be “little horses” in this respect.  The fact that 
tilmicosin has managed to pass through all the regulatory steps and has been considered 
acceptable for use in this species is surprising.  Unfortunately, the data from the 
licensing studies is not available in the public domain. 
 
10.5. Toxicity 
Tilmicosin has a bad reputation for cardiac toxicity (Prescott 2000).  Our studies 
failed to demonstrate any clinically significant cardiac effects.  Although, tilmicosin has 
a direct effect on the heart, like most other toxic effects it is dose dependent.  Because 
the drug is slowly absorbed from the SC injection site or the intestines and rapidly 
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partitions into tissues, the plasma concentrations of tilmicosin remain very low.  
Consequently, the probability of seeing toxic effects would be anticipated to be low.  If 
the drug were administered by an alternative route such as IV or at higher doses toxic 
effects may be likely.  It should be noted that following SC administration or oral 
administration serious adverse reactions were not described (Cochrane and Thomson 
1990; Buck and Thomson 1997).  The adverse reactions associated with administration 
of tilmicosin in feed were probably due to a combination of the adverse taste of the 
product and potential disruption of fecal flora.  Since post-mortems were not conducted 
in that study the true nature of the effect is not known (Buck and Thomson 1997).  It 
would appear that the potential for toxicity following tilmicosin administration in the 
horse has been over emphasized and that the risk in this species is similar to that 
described in other species such as cattle, sheep and pigs in which the drug is licensed. 
Our studies support this view.  Unfortunately, our first study suffered from the 
lack of true negative controls.  However, the fact that the low oral dose was not absorbed 
and no concentrations above the detection level of the assay were detected means that 
this group can act as a form of control.  In both studies mild histopathological lesions 
were found in the heart and liver.  These findings were not statistically significant and 
were classed as mild.  Their clinical relevance is unknown but they were not the same as 
those associated with administration of massive doses of tilmicosin and severe toxicity 
(Jordan, Byrd et al. 1993). 
 
10.5.  Ideas for future research 
The most obvious extension of this research is a clinical trial to evaluate the 
efficacy of tilmicosin against R. equi.  This would have to be a randomized controlled 
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clinical trial in which the control group is treated with azithromycin (the recommended 
standard drug for treatment in southern US, Cohen –personal communication).  This 
study would be very useful for a number of reasons.  Firstly, there have been no 
prospective studies of treatment for R. equi since the mid 80s (Hillidge 1986) and no 
true clinical trials have been conducted.  Secondly, this study could investigate adverse 
effects in the foals and their dams when treated with a macrolide antimicrobial.  This 
could be achieved through routine fecal culture and detailed investigation of any 
observed adverse effects. 
Another opportunity for investigation is the newly developed macrolide 
tulathromycin.  This compound bears many similarities to tilmicosin.  Two important 
differences are that tulathromycin is very unstable within the intestines and can only be 
administered parentrally (Evans 2005).  This means that foals would have to be injected 
intramuscularly with the potential for severe injection site reactions.  The fact that the 
drug is rapidly degraded in the intestines may be beneficial as this drug may be less 
likely to alter fecal flora and therefore be associated with AAD.  Tulathromycin 
concentrates in lung tissue at much higher concentrations and persists much longer than 
tilmicosin (Evans 2005).  Therefore, this drug has potential for the treatment of R. equi.  
An investigation of the pharmacokinetics in foals, coupled with detailed investigation of 
potential adverse effects as documented in this thesis is warranted. 
AAD is a significant problem in equine medicine.  It is also of major concern in 
human medicine.  The techniques used in this thesis to investigate the effects of 
antimicrobials on fecal flora should be used to investigate a wide range of antimicrobials 
in order to develop a ranked list of the relative safety of antimicrobials with respect to 
AAD.  Such information would be vital to allowing clinicians to make informed choices 
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about potential adverse reactions to antimicrobials when treating a clinical case.  This 
would allow an informed cost/benefit analysis to weigh the benefits of treatment with 
the likelihood of an animal developing an adverse reaction. 
The lack of labeled antimicrobial products for the treatment of respiratory disease 
in feedlot horses is a significant problem for the industry.  Dowling had previously 
investigated a number of long acting products to determine their plasma 
pharmacokinetics in horses (Dowling and Russell 2000; Dowling 2001).  The results of 
the tissue disposition studies reported for tilmicosin residues are the first of their kind to 
be reported in equine tissues.  Given the size of the industry and the significance of drug 
residues in meat for the export industry, further studies are required to provide the 
additional data required to estimate appropriate withdrawal intervals for the products 
that are already in widespread use. 
Finally this thesis has demonstrated that it is inappropriate to use serum/plasma 
concentrations of antimicrobials such as macrolides and in particular tilmicosin with its 
high volume of distribution to predict the tissue pharmacokinetic parameters.  A new 
approach is needed to accurately predict drug distribution in the body.  Pharmacokinetic 
studies are a vital component of assessing drug action.  Without them it is not possible to 
estimate doses, withdrawal intervals or the potential effects of disease on drug 
elimination.   However, we must start to identify appropriate tissue/fluid/cell samples 
which are related to the site of action and measure/estimate drug concentrations at these 
sites.  Ideally, this would be a repeatable sample which would allow the same animal to 
be sampled on multiple occasions with a minimally invasive technique.  Another 
possibility would be to try and develop effective physiologically based pharmacokinetic 
(PBPK) models to describe drug distribution in the body based upon blood flow and 
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tissue mass which could be used to minimize the number of animals required in terminal 
studies (Riviere 1999). This would be a major research undertaking and ideally should 
be coupled with an investigation of the pharmacodynamics of the macrolides such that a 
truly appropriate model of the most effective dosing regimen can be developed. 
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